A Modular Phase II, Ope n-label, Multicentre 
Study to Assess AZD4573 Effic acy and 
Safety as Monotherapy or in Combination 
with Anti-c ancer Agents in Patients with 
Relapsed/Ref ractory Peripheral T- cell 
Lymphoma or classical  Hodgkin Lymphom a
ClinicalTrials.gov  Identifier: [STUDY_ID_REMOVED] 
Clinical Study Protocol: version 2.0, dated 09 Sep 2021 Clinical Study Protocol -2.0
AZD4573 -D8231C00001[COMPANY_008]
CONFIDENTIAL AND  PROPRIETARY AZDoc0189620
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 1of 148 AZDoc0189620Clinical Study Protocol 
Study Intervention AZD4573
Study Code D8231C00001
Version 2.0
Date 09Sep2021
A Modular Phase II, Open -label, Multicentre Study to Assess 
AZD4573 Efficacy and Safety as Monotherapy or in Combination
with Anti -cancer Agents in Patients with Relapsed/ Refractory 
Peripheral T -cell L ymphoma or classical Hodgk in Lymphom a
Sponsor  Name: [CONTACT_122655]: [COMPANY_008] AB, [ADDRESS_137743] number: 2021 -002570 -54
IND number: [ADDRESS_137744] procedures. The Clinical Study Protocol is publicly registered and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy on Bioethics and in 
compliance wi th prevailing laws and regulat ions.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 2of 148 AZDoc0189620Protocol  Number: D8231C0 0001
Amendment Number: 1
Study  Intervent ion:AZD4573
Study  Phase: Phase II
Short Title: AZD4573 asMonotherapy  or in Combinat ionwith Anti-cancer Agents in 
Patients wi th r/r PTCL  or r/r cHL 
Study Physician Name [CONTACT_9352] [CONTACT_122578] S UMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
Version 2.0, Amendment 1 09-Sep-2021
Version 1.0 25-Jun-2021
The Protocol Amendment Summary  of Changes table is provided below for the current 
amendment.
Version 2.0, Amendment 1 (09September 2021 )
Overall Rationale for the Amendment:
This protocol amendment incorporates changes requested by  [CONTACT_122579] n 1.0 of the protocol.
The Clinical Study  Protocol  (CSP), Version 1.0, dated 25June 2021, was updated with the 
following changes:
Section # and Name [CONTACT_122656].Correction of typographical error 
in EudraCT number .
IND number added.
Section 1.1 Synopsis Text related to o bjective response 
rate removed from primary  and 
secondary efficacy objectives in 
the Core Objectives table to align 
with Table 3, Section 3 
(Objectives and Endpoints) , and 
Section [IP_ADDRESS].2 (Secondary 
Efficacy Endpoints) and due to a 
typographical erro r in secondary  Typographical erro r in secondary  
objectives (“by [CONTACT_122580] n of 
objective response rate”) .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 3of 148 AZDoc0189620Section # and Name [CONTACT_122657] (objective response 
rate not evaluated). 
Section 5.1 Inclusion Criteria Inclusion criteria in Module 1 
(Section 10 .5.1) have been 
moved to the Core protocol 
(Section 5.1).Updated in line with response to 
FDA request.
Section 5.2 Exclusion Criteria Exclusion criteria from Module 1 
(Section 10.5.2) have been 
moved to the Core protocol 
(Section 5.2).Updated in line with response to 
FDA request.
Section 7.[ADDRESS_137745].
Section 10.1.2 Schedule of 
Activities, footnote c; Section 
[IP_ADDRESS] Clinical Safety Laboratory 
AssessmentsFootnote was updated and 
Section [IP_ADDRESS] amended for 
clarificatio n of the h aematologic 
and chemistry criteria required to 
initiate each cycle of therapy.Clarification as per FDA request.
Section 10.4.1 Module 1 Design: 
AZD4573 monotherapyInclusion of a requirement for 
pooled safety monitoring 
assessments to be conducted at 
3-monthly intervals.Amended in line with response to 
FDA request .
Section 10.5.[ADDRESS_137746].
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 4of 148 AZDoc0189620Section # and Name [CONTACT_19523] 10.6.1 Dose Modification Update of Grade 3 or 4 
non-haematological toxicities 
Table 11to add the guidance of 
one dose level reduction in order 
to resume AZD4573 dosing after 
resolution of a Grade 4 
non-haematologic al(excluding 
liver and TLS) AEto Grade 1,
and guidance on discontinuation 
following a third occurrence.Amended in line with response to 
FDA request.
In addit ion, minor formatting and editorial changes were made throughout the CSP.
Clinical Study Protocol -2.[ADDRESS_137747] ivities....................................................................................... 14
2 INTRODUCTION ............................................................................................ 15
2.1 Study  Rati onale ................................................................................................ 15
2.2 Background ...................................................................................................... 17
2.3 Benefit/Risk Assessment ................................................................................... 19
2.3.1 Risk Assessment ............................................................................................... 19
2.3.2 Benefit Assessment ........................................................................................... 22
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... 22
2.3.4 Benefit/Risk Pertaining to AZD4573 Study  Conduct During the COVID -19 
Pandemic .......................................................................................................... 23
3 OBJECTIVES AND ENDPO INTS ................................................................... 25
4 STUD Y DESIGN ............................................................................................. 26
4.1 Overall Design .................................................................................................. 26
4.1.1 Modular Protocol Structure ............................................................................... 27
4.1.2 Module Naming Convent ions........................................................................... 28
4.1.3 Regulatory  Amendment for Addit ional Modul es............................................... 28
[IP_ADDRESS] Europe and Rest of W orld................................................................................. 29
[IP_ADDRESS] [LOCATION_002] of America .................................................................................. [ADDRESS_137748] yle Considerat ions................................................................................... 39
5.4 Screen Failures ................................................................................................. 39
Clinica l Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 6of 148 AZDoc01896206 STUDY  INTER VENTION ............................................................................... 40
6.1 Study  Intervent ion(s) Administered ................................................................... 40
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 40
6.3 Measures to Minimise Bias: Rando misat ion and Blinding ................................. 40
6.4 Study  Intervent ion Compliance ......................................................................... 41
6.5 Concomitant Therapy ........................................................................................ 41
6.6 Dose Modificat ion............................................................................................ 43
6.7 Intervention after the End of the Study .............................................................. 43
7 DISCONTINUA TION OF STUDY  INTER VENTION AND PARTICIPANT 
DISCONTINUA TION/WITH DRA WAL........................................................... [ADDRESS_137749] .................................................................... 51
8.3.7 Potenti al Hy’s Law Cases ................................................................................. 52
8.3.8 Disease Progressi on and Disease Under Study .................................................. 52
8.3.9 Reporting of Serious Adverse Events ................................................................ 52
8.3.10 Pregnancy ......................................................................................................... 53
[IP_ADDRESS] Maternal Exposure ............................................................................................ 53
[IP_ADDRESS] Paternal  Exposure ............................................................................................. 54
8.3.1 1 New Cancers ..................................................................................................... 54
8.3.12 Deaths .............................................................................................................. 55
8.3.13 Medicat ion Error ............................................................................................... 55
8.4 Overdo se.......................................................................................................... 56
8.5 Hum an Bi ological  Samples ............................................................................... 56
8.5.1 Pharmacokinet ics.............................................................................................. 57
8.5.2 Pharmacodynamics ........................................................................................... 57
8.5.3 Immunogenicit y Assessments ........................................................................... 57
8.6 ............................................................. 57
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 7of 148 AZDoc01896208.7 Optional Genomics Ini tiative Sample ................................................................ 57
8.8 Health Economics ............................................................................................. 58
9 STATISTICA L CONSIDERA TIONS ................................................................ 58
9.1 Statistical Hypotheses ....................................................................................... 58
9.2 Sample Si ze Determinat ion............................................................................... 58
9.3 Popul ations for Analyses ................................................................................... 58
9.4 Statistical Analyses ........................................................................................... 58
9.4.1 General Considerations ..................................................................................... 58
9.4.2 Efficacy Analyses ............................................................................................. 59
9.4.3 Safety Analyses ................................................................................................ 59
9.4.4 Pharmacokinet ic Analyses ................................................................................ 60
9.4.5 Pharmacodynamics  Analyses ........................................... 60
9.5 Interim Analyses ............................................................................................... 60
9.6 Data Mon itoring Committee ............................................................................. 60
10 MODULE 1 ...................................................................................................... 61
10.1 Summary  –Modul e 1........................................................................................ [ADDRESS_137750] ivities....................................................................................... 62
10.2 Introduction –Module [ADDRESS_137751] ives and Endpo ints –Modul e 1............................................................... 67
10.4 Study  Design –Modul e 1.................................................................................. 68
10.4.1 Module 1 Design: AZD4573 monotherapy ........................................................ 69
10.4.2 Justification for Dose ........................................................................................ 71
10.4.3 End of Module Definit ion................................................................................. 72
10.4.4 Safety Review Co mmit tee................................................................................. 72
10.5 Study  Popul ation –Modul e 1............................................................................ 73
10.6 Study  Intervent ion –Modul e 1.......................................................................... 73
10.6.1 Dose Modificat ion............................................................................................ 74
10.6.2 Prevent ion and T oxicity Management of Risks for AZD4573 Monotherapy ......78
[IP_ADDRESS] Tumour Lysis Syndrome (TLS) ......................................................................... 79
[IP_ADDRESS] Transaminases Increase With or Without Concomitant Bilirubin Increase and 
the Risk of Liver Injury ..................................................................................... 82
[IP_ADDRESS] Diarrhoea .......................................................................................................... 83
[IP_ADDRESS] Nausea and V omiting........................................................................................ 84
[IP_ADDRESS] Neutropenia and Febrile Neutropenia ................................................................ 84
[IP_ADDRESS] Infection/Bone Marrow Toxicity with Peripheral  Effect/L ympho id Tissue 
Hypocellularit y................................................................................................. 85
[IP_ADDRESS] Pancreat ic and Cortical Adrenal Injury  (as well as Surveillance for Renal, 
Thymus, and Spleen T oxicity)........................................................................... 85
[IP_ADDRESS] Drug -Drug Interactions ..................................................................................... 85
[IP_ADDRESS] Myocardial  Ischaemia and Heart Rate Increase ................................................. [ADDRESS_137752] OF FIGURES
Figure 1 AZD4573 Modular Phase II CSP in r/r PTCL and r/r cHL ....................... [ADDRESS_137753] ic T-cell Lympho ma 
Patient-derived Xenograft Model (DFTL -[ZIP_CODE]; n = 5) ........................... 17
Figure 5 Module 1 Schema: AZD4573 Monotherapy  in Participants with r/r 
PTCL and r/r HL ..................................................................................... [ADDRESS_137754] OF TABLES
Table 1 Module 1: Planned Response -evaluable Parti cipant Popul ation................ [ADDRESS_137755] ion...................................................... 33
Table 7 Prohibited Conco mitant Therapi [INVESTIGATOR_014]........................................................... 42
Table 8 Permi tted Concomitant Therapi[INVESTIGATOR_014] (Condit ional)...................................... [ADDRESS_137756] ivities: Module 1 (AZD4573 Monotherapy ).................... 62
Table 10 Module 1: Planned Response -Evaluable Participant Populat ion............... [ADDRESS_137757] Resul ts............................................................................ 76
Table 13 Mandatory  TLS Prophylaxis Guidance (in Addit ion to Insti tutional 
Guidance) ................................................................................................ 80
Table 14 The Lugano Response Criteria ................................................................. 88
Table 15 Radiologic Scans and PET Scans for Tumour Assessments ...................... 91
Table 16 Laboratory  Safety Variables ..................................................................... 98
Table 17 Exploratory  Who le Blood Analyses Samples (All Participants) .............. 102
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 10of 148 AZDoc0189620Table 18  Sam pling Schedule (All Participants) ............ 108
Table 19 Sample Si ze: Modul e 1.......................................................................... [ADDRESS_137758] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons....................... 116
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ...................................................................... 121
Appendix C Handling of Human Bio logical  Samples ................................................ 126
Appendix D Optional Genomics Ini tiative Sample ..................................................... 128
Appendix E Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ......................................................................... 131
Appendix F Abbreviat ions........................................................................................ 137
Appendix G Cairo-Bishop Tum our Ly sis Syndrom e Definit ion and Grading Criteria 
(Howard Modificat ion).......................................................................... [ADDRESS_137759] ion. 
Figure 1 AZD4573 Modular Phase IICSPin r/r PTCL and r/r cHL
aAdditional AZD4573 combination modules in r/r PTCL or r/r cHL may be added pending new pre -clinical/clinical data. Combination risk assessment for 
PTCL and cHL to be performed when their respective clinical monotherapy profiles are understood.
Abbreviatio ns: AE, adverse events; cHL, classical Hodgkin Lymphoma ; CSP, clinical study protocol; CTCAE , Common Terminology Criteria for Adverse 
Events ;ECG, electrocardiogram ; ECOG, Eastern Cooperative Oncology Group; lab , clinical laboratory results ; NK PTCL , natural killer /peripheral T -cell 
lymphoma ; r/r, relapsed /refractory .

Clinical Study Protocol -2.[ADDRESS_137760] ive protocol section.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 15of 1482 INTRODUCTION
AZD4573 is a potent, selective inhibitor of CDK9 that is being developed as a m onotherapy  
and/or combinat ion therapy  for the treatm ent of several haematol ogical malignancies, 
including r/r PTCL  and r/r cHL.
2.1 Study Rationale
This is a modular, Phase II, mult icentre , open label study  of AZD4573 administered 
intravenously as mo notherapy  or in co mbination wit h other anti -cancer agents, to pa rticipant s 
with r/r PTCL  or r/r cHL.
As a CDK9 inhibitor, treatm ent wi th AZD4573 leads to rapid deplet ion of short lived gene 
transcri pts, including MCL1and BFL1which are commo nly overexpressed by  [CONTACT_122581] a 
survival mechanism .AZD4573 induces apoptosis in cancer cells that are dependent on either
MCL1 ,BFL1 or both proteins for survival (Cidado et al  2020 ). 
Haematological malignancies exhibit a high frequency of MCL1 dependence, which is 
consist ent with known lineage expressio n and dependency patterns of Bcl2family 
anti-apoptoti c proteins during haematopoiesis. Whereas CDK9 and MCL1 inhibitors exhibit 
similar preclinical act ivity profiles across l eukaemias and myelo ma, a number of lympho ma 
models which are insensit ive to MCL1 inhibit ion are sensit ive to acute CDK9 inhibit ion. This 
is due to addit ional dependence on, and AZD4573 -mediated m odulati on of , BFL1 in 
lympho mas ( Boiko et al 2020 ). BCL2A1, the gene encoding BFL1, is a target of NF -κB 
signalling, which is frequent ly dysregulated in many lympho mas, including PTCL  and cHL. 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_137761] of AZD4573 on OSin Angioimmunoblastic T-cell Lymphoma 
Patient -derived Xenograft Model (DFTL -[ZIP_CODE]; n = 5)
Abbreviations: n, number; OS, overall survival .
Source: Cidado et al 2020
Module 1 of this study explores AZD4573 monotherapy  in these patient popul ations; i f 
monotherapy treatm entshows ant i-tumour efficacy in r/r PTCL  or r/r cHL, AZD4573 may be 
investigated in co mbination wit h other anti -cancer agents for greater efficacy . In thi s case, 
combinat ion therapy  modules will be added to the study  viaa protocol  amendment.
The overarching primary  hypothesis for this study  is: AZD4573 will demo nstrate anti -tumour 
efficacy , as m onotherapy  or in co mbinat ion with other anti -cancer agents, in p articipant s with 
eitherr/r PTCL  or r/r cHL. 
2.2 Background
Peripheral T-cell lymphom as represent a sm all heterogeneous subgroup of non -Hodgkin 
lympho mas ( Swedl ow et al  2017 ). Approximately  [ZIP_CODE] new cases of non -Hodgkin 
lympho ma are diagnosed annually in the [LOCATION_002] (Cancer Stat Facts: Non -Hodgkin 
Lympho ma)and 123000 cases annually in Europe ( GLOBOCAN 2020 ).Less than 10% of 
these cases are PTCL  (Armitage et al  2004 ). There are > 20 subt ypes of PTCL  and the m ain 
subtypes are: PTCL  not otherwi se specified (~30%), angio immunoblast ic T-cell lympho ma 
(AITL; 15 %to 30%), anaplastic large cell lymphoma (ALCL; ~ 15%), and natural  killer T -cell 
lympho ma (NKTCL ;~10% ;Fiore et al  2020 ). Notably , the incidence of PTCL  and proporti on 
of subty pes differ across global r egions. Of 240000 cases of non -Hodgkin lympho mas 
diagnosed annually in Asia (GLOBOCAN 2020 ),15%to30% are classified as PTCL .Hence, 
in contrast to the US and Europe ,NKT CLis the major PTCL  subty pe in Asia ( Park and Ko 
2014 ).
Most PTCL  patients progress after receiving first line chemotherapy -based protocol s, wi th or 
without auto -HSCT . Currently , 3drugs are approved (as accelerated approvals) by [CONTACT_122582] -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 18of 148for use in all subt ypes of r/r PTCL: pralatrexate (a novel ant ifolate agent ); romidepsin ;and
belinostat (histone deacetylase inhibitors ). Of these, pralatrexate and romidepsin are also 
approved in Japan (along with several other therapi[INVESTIGATOR_122542] o f single -arm trial 
data); and none are approved in the EU. None of these drugs provide a cure and the ORR is 
only 25% to 30% ( Zain 2019 ). In addi tion, the ant i-CD30 ant ibody-drug conjugate BV is 
approved for relapsed ALCL or CD30+ PTCL  in the [LOCATION_002], EU ,and Japan ,based on 
an ORR of 86%. Pati ents wi th r/r PTCL, including patients with ALCL  relapsing after BV , 
have limit ed treatm ent opti ons and poor outcom es underscor ing the high unmet medical need 
in these pat ient populat ions.
Classical  Hodgkin L ympho ma (cHL) is a unique ha ematopoi etic neopl asm characteri sed by 
[CONTACT_122583]. Approximately 9000 new cases of HL  present each year in the 
US, ~[ZIP_CODE] in Europe, and ~[ZIP_CODE] in Asia (GLOBOCAN 2020 ). In HL  the cure rate is high, 
which is reflected by  a 5-year OSafter ini tial diagnosis of 80% to 90% ( Cancer Stat Facts: 
Hodgkin L ympho ma.). Histori cally ,treatm ent has been based on chemotherapy  and 
radiotherapy  in first line and adding auto -HSCT in second line treatment. In recent years, BV 
and the ant i-PD1 check point inhibito rs nivo lumab and pembrolizumab have been introduced 
as new approved treatments for cHL in the US (nivolumab under accelerated approval), EU, 
and Japan . Although these novel treatments have demonstrated high response rates , the 
majorit y of r/r cHL patients do not achieve durable remissio n and go on to develop 
progressive disease ,highlight ingthe continuing need for additional treatments in this pat ient 
popul ation(Connors et al 202 0; Chen et al  2016 ;Chen et al  2019 ; Kuruvilla et al 2021 ). 
AZD4573 (formerly  known as AZ13810325) is a potent and select ive inhibitor of CDK9 with 
nano molar potency against the enzyme (IC50 < 4nM) and excellent select ivity over other 
CDK family  members. AZD4573 decreases pSer2RNAP2 levels (the phosphorylat ion levels 
of Ser2 found in the carboxyl -terminus domain of RNA  polymeras e II [RNAP2]). This 
decrease in pSer2RNAP2 is linked to preferential reduction of labile proteins like the B cl2 
family ant i-apoptoti cs M CL1 and B FL1 as well as other well -known oncoproteins like M yc, 
which leads to rapid induction of apoptosis in a broad r ange of human cancer cell lines 
derived fro m haematological malignancies (Cidado et al  2020 , Boi ko et al  2020 ). 
In a first time in human study  (Study  D8230C00001), the safet y and tol erabilit y of AZD4573 
monotherapy  have been dem onstrated in B cell non -Hodgkin lympho ma at the established 
RP2D of [ADDRESS_137762] ivity was reported in DLBCL  patients. No pati ents wi th PTCL  or cHL  were 
enrolled in the study .
A detailed descript ion of the chemistry , pharmaco logy, efficacy , and safet y of AZD4573 is 
provi ded in the IB.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 19of 1482.3 Benefit/Risk Assessment
More detailed informat ion about the known and anticipated benefits and potenti al risks of
AZD4573 may be found in the IBand the relevant modules .
Refer to individual study  modules for the benefit/risk assessment of other anti -cancer agents in 
combinat ion with AZD4573.
2.3.1 Risk Assessment
The safet y and tol erabilit y of AZD4573 monotherapy at the established lympho ma RP2D 
(12mg 1QW  including int ra-participant ram p-up) have already  been dem onstra ted in the first 
time in human study  (Study  D8230C00001).
Based on nonclinical toxico logy findings and clinical experience to date, including experience 
from other medicinal products in the same class, the fo llowing have been assessed as risks for 
AZD4573:
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 20of 148Table2 Risk Assessment
Potential risk of clinical 
significanceSummary of data/rationale for 
riskMitigation strategy
Important identified risks:
• TLS
• Transaminases increase
• Bilirubin increase with 
transaminase (ALT or AST 
or both ALT and AST) 
increase
• Diarrhoea
• Nausea
• Vomiting
• Neutropenia (includes 
neutrophil count decreased)
• Febrile neutropenia
Important potential risks:
• Gastro -intestinal toxicity
• Infection/ bone marrow 
toxicity with peripheral 
effect/ly mphoid tissue 
hypocellularity
• Liver injury
• Neutropenic sepsis
Potential risks for AZD4573 
include:
• Pancreatic injury
• Cortical adrenal injury
• Drug -drug interactions
• Myocardial ischaemia
• Heart rate increaseRisks identified based on 
nonclinical and clinical data 
availabl e to date.These risks are monitored via 
routine pharmacovigilance 
activities and standard treatment 
practices. Further details of these 
risks can be found in the 
AZD4573 IB.
Risk minimisation activities are 
reflected in the study protocol 
specific inclus ion and exclusion 
criteria, alongside the safety 
monitoring strategy ( Section 8), 
dose modification guidance 
(Section 6.6), toxicity management 
guidelines (per module) ,and 
concomitant medication guidance 
(Section 6.5).
Additionally, enrolled pa rticipant s 
will have been screened for 
adequate bone marrow function 
prior to commencing AZD4573 as 
per the exclusion criteria in the 
protocol.
Abbreviations: ALT, alanine aminotransferase ; AST, aspartate aminotransferase; TLS, tumour lysis syndrome .
For a com plete characterisat ion for each ri sk please refer to the IBfor AZD4573. 
In general, the protocol includes measures such as frequent monitoring of blood counts and 
serum  chemistry , along wi th other addi tional monitoring. A urine dip stick test will be also be 
perform ed, where a posi tive test will trigger urine microanalysis for the presence o f casts (red 
cell and protein casts). For a summary o f management for each risk, including dose 
modifications, see Secti on 6.6and the Dose Modificat ion sect ion of the relevant module. 
In addit ion to these risks, embry o-foetal and reproductive toxici ty is Missing information in 
relation to AZD4573.
Clinical Study Protocol -2.[ADDRESS_137763] practises. This guarantees that 
[COMPANY_008] ’s safet y reporti ng obligat ions to Regulatory  Authorities, invest igators ,and Ethics 
Committees are met and optimal risk management of participants is maintained. These 
procedures have been developed to b e consistent wit h “ICH E2A  Clinical  Safety  Data 
Management: Definit ions and standards for reporting ”, which provides guidance to support 
that seri ous unexpected adverse drug reactions information must be provided as early  as early 
as possible, but no later than 7 days (fatal/life threating event) or otherwi se [ADDRESS_137764] inal (nausea, 
vomiting, and diarrhoea), haematological (neutropenia, febrile neut ropeni a,and 
thrombocy topenia), hepat ic (transaminase increase with or without conco mitant bilirubin 
increase) and TLS. These toxicit ies are m anageable wi th appropri ate prophylaxis and 
treatm ent, and by  [CONTACT_2715] m odificat ion.
Regarding the hepatic toxicit y events, it has been observed that whilst the biochemical 
changes of increased transaminase with conco mitant elevat ion in bilirubin seen in so me 
participants coul d be classified as Hy ’s law by  [CONTACT_122584], they  do not follow a pattern 
that is consist ent wi th true Hy ’s law predictive of severe hepat ic injury (see theAZD4573 IB). 
The events are rapi[INVESTIGATOR_122543] . Repeated dosing with AZD4573 fo llowing these events does not lead to 
adverse clinical sequelae or consistent increase in severit y of events.
The safet y and tol erabilit y of AZD4573 monotherapy at the established lympho ma RP2D 
(12mg 1QW including intra -participant dose ramp -
up) have already  been dem onstrated in the 
first time in human study  (Study  D8230C00001) . 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 22of 1482.3.2 Benefit Assess ment
AZD4573 hasthe potenti al to provi de clinical benefit in terms of anti- tumour efficacy , as 
monotherapy  and in combinat ion with other anti -cancer treatm ents, in participant s with
relapsed/refractory PTCL  or cHL.
Nonclinical studies support the hy pothesis that inhibiting CDK9 may be a valid target for the 
treatm ent of haematol ogical malignancies including lympho mas (Secti on 2.1). Furtherm ore, 
preliminary ant i-tumour acti vity has been observed with AZD4573 as monotherapy in 
participants wi th relapsed or refractory  haematol ogical malignancies in the ongoing FIH, 
Phase I dose escal ation study  (Study  D8230C00001). Best object ive responses included 1 CR, 
1 PR, and 4 SD in 17 dosed participants with DLBCL . Signs of clinical activit y werealso
observed in participants with other haematological malignancies, such as CLL, AML, and 
MM.
In patients wi th r/r PTCL  who have limited treatment options andpatients withr/r cHL  who 
have exhausted standard of care and not achieved remissio n, the potential clinical  benefi ts 
with AZD4573 warrant investigat ion, as current preclinical data suggest that AZD4573 is an 
attractive invest igational drug for these diseases.
Please refer to the individual study  modules for the benefit/risk assessments for each 
combinat ion treatment.
2.3.3 Overall Benefit: Risk Conclusion
The safet y and tolerabilit y of AZD4573 monotherapy  (RP2D 12 m g 1QW  including 
intra-participant dose ramp -up) have al ready been demonstrated in lympho ma patients in the 
first time in human study  (Study  D8230C00001).
Furtherm ore, t aking into account the measures taken to minimise risk to particip ants in th e 
current study, including specific monitoring and dose modificat ion criteria specified in the 
protocol  for cases of transaminase +/- bilirubin increase, the safet yrisks identified in 
associ ation with AZD4573 are j ustified by [CONTACT_122585] m ay be afforded to 
participants wi th r/r PTCL  or r/r cHL.
The benefit -risk assessment for AZD4573 in co mbinat ion with other anti -cancer therapi[INVESTIGATOR_122544] r addi tion by  [CONTACT_122586].
Please seeSection 2.3.4 for the benefit/risk assessment pertaining to the conduct of this study  
during the COVID -19 pandemic.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 23of 1482.3.4 Benefit/Risk Pertaining to AZD4573 Study Conduct During the 
COVID-[ADDRESS_137765] an increased risk of exposure to SARS- CoV-2 due to frequent hospi[INVESTIGATOR_122545]. A retrospective cohort study  of 28 SARS -CoV-2 
(COVID -19)- infected cancer pati ents from [ADDRESS_137766] 
of patients (28.6%; N = 8) were suspected to have acquired the infect ion by [CONTACT_2360][INVESTIGATOR_307] -
associ ated transmissio n (Yu et al  2020 , Zhang et al 2020 ). Patients with cancer may have a 
higher ri sk of devel opi[INVESTIGATOR_35910] -19 than individuals without cancer but current evidence 
appears insufficient to support a conclusive association between cance r in general and 
COVID -19 (Kumar et al 2019, Xia et al  2020 ).
This Phase II study  will enrol participant s with r/r PTCL  and r/r cHL. Participant s in this study  
will receive AZD4573, which leads to inhibit ion of CDK9. In Module 1, they  will not be 
receiving chemotherapy , radi cal radi otherapy , immunotherapy ,or other continuing antibody  
treatm ents for cancer as part of the treatment strategy . Overall , the study  treatm ent and 
procedures received during the course of this study are considered to have low risk for 
increasing suscept ibilit y to COVID -[ADDRESS_137767] ive of the participat ion in a study . Therefore, it is ant icipated that overall, 
participat ion in this clinical study should not significant ly incre ase this population ’s risk of 
exposure to COVID -[ADDRESS_137768] participants in the study , but there may  be increased ri sk to 
participant s by [CONTACT_122587] -CoV-2 due to study  visits. However, this risk is offset by 
[CONTACT_122588] s may receive in the form o f an extended period of PFS.
In accordance with EMA  and FDA  guidelines ( EMA- CTFG -EC 202 1, FDA  2020 ), a risk 
assessment will be conducted in co llaboration with invest igators for each site and participant
prior to si te ini tiation/participant enrolment and on an ongoing basis throughout the study to 
assess whether addit ional measures may be necessary  to ensure participant safet y and data 
validit y. Measures may  include postponement of study  start on a gl obal, country , or si te level 
or suspensio n of recruit ment of participant s in l ocati ons wi th an increased ri sk of COVID -19-
related disruption.
If there is a need to reconsent study  participant s for the implementation o f new urgent changes 
in study  conduct, addi tional guidance on alternat ive means o f obtaining reconsent to avoid 
unnecessary  study  visits is provi ded as Appendix H 1(as a supplement to the standard consent 
procedures in Appendix A 3). Any deviati ons to the protocol  necessary to safeguard 
participant safet y or data validit y as a resul t of COVID -19-related disruption will be recorded 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 24of 148and any  perm anent changes requiring an amendment to the protocol will be communicated to 
Regulatory  Authorit ies and IRBs/ IECs in line wit h relevant l ocal guidance and procedures.
Clinic al Study  Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 27of 148Further m odules may  be added via protocol amendment. Study  inform ation applicable to all 
participants in thi s study  is described in the core section sof this protocol; the rationale for 
each studytreatm ent and cohort , and specific study informat ion and assessments will be 
described in each separate module. This study is planned to take place in approximately 
30centres across 10 countries. 
Module 1 will assess the efficacy , safet y, tolerabilit y,and PK of AZD4573 as a monotherapy 
in r/r PTCL  and r/rcHL popul ationsand explore pharmacodynamics in these disease subtypes. 
If AZD4573 monotherapy is found to have promising anti -tumour efficacy in Module 1, an 
AZD4573 monotherapy  Phase II expansio n may be added via a substant ial protocol
amendment . Additional m odules may also be added via substant ial protocol  amendments to 
assess AZD4573 in co mbination wit h other ant i-cancer agents in r/r PTCL  or r/r cHL based on 
emerging preclinical and clinical dat a and study  rationale.
Future m odules may  include an ini tial combinat ion dose confirmat ion phase, dependent on the 
AZD4573 combinat ion partner being evaluated . The planned intra -participant dose escalat ion, 
the cohort escalat ion scheme, and the dosing schedul e may  be amended in light of emerging 
PK, safet y, pharmacodynamic data and available efficacy data, which will be reviewed on an 
ongoing basis throughout the stud y.
A study -specific SRC will provide ongo ing safet y surveillance of the study , with 
regul arly scheduled reviews of safet y, PK, and other relevant data (see study  design 
section of the relevant module ).
The end o f module is defined as the last scheduled visit or contact [CONTACT_122589] (Sect ion 4.4).
The end o f the study  is defin ed as the l ast visi t of the last participant undergo ing the 
study , or as the l ast scheduled procedure shown in the relevant module ’s SoA  for the 
last parti cipant in the study  globally(Sect ion 4.4).
4.1.[ADDRESS_137769] ives, rationale, core inclusio n and exclusio n criteria, 
safet y assessments, and AE reporting can be found in th iscore protocol module(ie,Secti ons1
to 9).
The starting dose/schedule of AZD4573 in further combinat ion modules will not exceed the 
equivalent m aximum  dose of AZD4573 found to be tol erated in the monotherapy  Modul e 1or 
from other studies in the clinical programme at that point.
Study  drug-specific information including doses and just ifications, toxicit y manage ment, dose 
Clinical Study Protocol -2.[ADDRESS_137770] of 1initial module (Modul e 1)evaluating the efficacy , safety , and 
tolerabilit y of AZD4573 as monotherapy in participant s who have eitherr/r PTCL  or r/r cHL. 
Addit ional modules m ay be added by [CONTACT_122590]4573 in 
combinat ion with other anti -cancer agents in the r/r PTCL  or r/r cHL  populat ion.
Table4 Module Naming Conventions
Module Tumo ur type Intervention
Module 1 –Monotherapy r/r PTCL
r/r cHLAZD4573
Naming convention for potential combination therapy modulesa
Module X –AZD4573 + [combination treatment] r/r PTCL AZD4573 + 
[combination treatment]
Module Y –AZD4573 + [combination treatment] r/r cHL AZD4573 + 
[combination treatment]
aAnticipated combination treatment modules will be numbered per the order added to the study protoco l
(Module 1, Module 2, Module 3, ect) . The order of addition of the combination treatment modules is to be 
determined based on clinical and nonclinical data.
Abbreviations: cHL ,classical Hodgkin Lymphoma; PTCL ,peripheral T -cell lymphoma ; r/r, relapsed/refractory .
4.1.3 Regulatory Amendment for Additional Modules
New m odules may  be added in the future to assess treatment combinat ions in either r/r PTCL  
or r/r cHL. Up to 5addit ional co mbination modules may be added .The combinat ion partners
may include, but are not limited to ,the following opti ons: romidepsin, belinostat, pralatrexate, 
anti-PD1, and BV .
To support amendment of the protocol for addit ional modules /cohorts, [COMPANY_008] will 
provi de a summary  of all nonclinical and clinical data to support the cohort expansio n or any  
new proposed combination treatm entand dosing schedule; this will include updating the 
following:
Study  objectives
Background informat ion provi ding rati onale for the proposed patient populat ion(s) and 
the proposed treatment plan(s)
Study  eligibilit y criteria
A detailed description o f the proposed study  treatment plans
A revised schedule o f participant assessments
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 29of 148A summary  of safet y data from  the com pleted or ongoing cohort(s)/modules(s) and the 
proposed toxicit y management plans for anyproposed new co mbinat ion.
A descript ion of any  dose m odificat ions and the data (clinical safet y informat ion, clinical 
PKdata, and nonclinical data) that support the safety  of the proposed dose modifications 
for the regimen in question .
A clearly  stated sam ple size and j ustificat ion for the proposed sample size based on the 
objectives for that specific cohort/module .
A detailed description o f the method and performance characterist ics of any  test that will 
be used to ident ify the pat ient populat ion to be enrolled in the cohort/modul e, if the 
popul ation will be selected based on a diagnost ic assay .
[IP_ADDRESS] Europe and Rest of World
[COMPANY_008] will provide a substant ial amendment for review and approval.
[IP_ADDRESS] [LOCATION_002] of America
[COMPANY_008] will provide an amendment to the FDA  [ADDRESS_137771] udy Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The gui dance given below supersedes instructions provided elsewhere in this CSP and should 
be implemented only during cases of civil crisis, natural disaster, or public healt h crisis (eg, 
during quarant ines and result ing site closures, regional travel restrict ions, and considerat ions if 
site personnel or study  partici pants beco me infected with SARS -CoV-[ADDRESS_137772] ion) which would prevent the conduct of s tudy-related activit ies at study  sites, thereby 
[CONTACT_122591] f or the participant’sabilit y to conduct the study . The 
investigator or designee should contact [CONTACT_122592] d be imple mented. 
To ensure continuit y of the clinical study  during a civil  crisis, natural  disaster, or public healt h 
crisis, changes m ay be implemented to ensure the safet y of study  participants , maintain 
compliance wi th GCP, and minimi se risks to study  integri ty. 
Where allowable by  [CONTACT_122593], ethi cs commi ttees, heal thcare provi der gui delines 
(eg, hospi[INVESTIGATOR_13338]) or local government, these changes may include the fo llowing opti ons: 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 30of 148Obtaining reconsent for the mit igation procedures (note, in the case of verbal reconsent,
the ICF should be signed at the participant’s next contact [CONTACT_72953]).
Rescreening: Addit ional rescreening for screen failure and to confirm eligibilit y to 
participate in the clinical study  can be performed in previously screened parti cipants. The 
investigator should confirm this wit h the designated study  physician. 
Hom e or Rem ote vi sit: Perf ormed by  a site qualified HCP or HCP provided by  a TPV.
Telemedicine visit: Remote contact [CONTACT_122594], virtual or video visit s, and m obile heal th devices. 
At-home IP administration: Performed by a site qualified HCP, HCP provided by a TPV, 
or by  [CONTACT_122595]’s caregiver, if possible and appro priate for the 
therapy . Addi tional information related to the visit can be obtained via telemedicine. 
For further details on study  conduct during civil crisis, natural disaster, or public health crisis, 
refer to Appendix H. 
4.2 Scientific Rationale for Study Design
This is a modular, Phase II, multicentre, open -label, dose confirmat ion and expansio n study  
primarily designed to establish the efficacy of AZD4573, administered as monotherapy or 
combinat ion therapy , to parti cipants wi theitherr/r PTCL  or r/r cHL. The study will also 
confirm the safet yprofile and PKofthe module-defined A ZD4573 monotherapy  or
combinat ion therapy in these popul ations, and explore potential bio logical  activi ty by 
[CONTACT_122596]-tumour efficacy .Modul e 1 
will assess the efficacy of AZD4573 as a monotherapy in r/r PTCL  and r/rcHL populations.
If AZD4573 monotherapy is found to have promising anti -tumour efficacy in Module 1,an 
AZD4573 monotherapy  Phase II expansio n may be added via a substant ial protocol
amendment . Addit ional m odules may  also be added via substant ial protocol  amendments to 
assess AZD4573 in co mbination wit h other ant i-cancer agents in r/r PTCL  or r/r cHL based on 
emerging preclinical and clinical data and study  rationale. Future m odules may include an 
initial combinat ion dose confirmat ion phase, dependent on the AZD4573 combina tion partner
being evaluated . The planned intra -participant dose escalat ion, the cohort escalat ion scheme, 
and the dosing schedule may  be amended in light of emerging PK, safet y, and 
pharmacodynamic and available efficacy data, which will be reviewed on an ongoing basis 
throughout the study . 
The results from this study  will form  the basis for decisio ns for future studi es.Biological 
samples will be co llected in order to establish an archive and allo w future m eta-analysis o f 
data deri ved from  a number of st udies with AZD4573.
CCI
Clinical Study Protocol -2.[ADDRESS_137773] participant enrolled in 
the module; see the rel evant m odule for more informat ion.
The results from each module will be reported to Regulatory  Authorit ies wit hin [ADDRESS_137774] ion are for the core study  design and apply to 
all modules of the study . Addit ional, m odule-specific cri teria and considerations a re listed in 
the study  popul ation secti on of  the rel evant m odule.
5.1 Inclusion Criteria
The below are the core inclusio n criteria for all m odules of  the study; all part icipants m ust 
meet the criteria described in the relevant module in addit ion to those descr ibed below . Where 
module-specific criteria are more stringent than core study  criteria, the m odule-specific 
criteria take precedent. 
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Informed Consent
1Capabl e of giving signed informed consent as described in Appendix Awhich incl udes 
compliance wi th the requi rements and restri ctions listed in the ICF and in this protocol .
2Provisio n of signed and dated, written informed consent prior to any mandatory  
study -specific procedures, sampling, and analyses. 
Clinical Study Pr otocol -2.[ADDRESS_137775] 18 y ears of age inclusive at the time of signing the informed 
consent.
Type of Participant and Disease Characteristics
5Parti cipants who are diagnosed with one of the fo llowing, as defined by [CONTACT_122597] h 
Organisat ion:
(a)Peripheral  T-cell Lympho ma
(b)Classical  Hodgkin Lympho ma
6Eastern Cooperative Oncology  Group perform ance status of ≤ 2.
7Must have received at least [ADDRESS_137776] d ocum ented relapsed or refractory  active disease requiring treatment ,defined as:
(a)Recurrence of disease after response to prior line(s) of therapy , or
(b)Progressive disease after complet ion of or on the treatment regimen preceding entry  
into the study , or
(c)Disease which did not achieve an object ive response (CR or PR).
8Prior lines of therapy :
(a)PTCL: Participants must have failed at least 1 prior therapy  for the treatm ent of 
PTCL.
(i)Non NK -PTCL: Prior t herapy must have included an alkylat ing agent and/or 
anthracycline. In addit ion, ALCL participants must have received BV as part of 
prior therapy .
(ii)NKTCL: Prior treatment must have included asparaginase and/or a plat inum 
agent .
(b)cHL: Parti cipants m ust have f ailed at l east 2 pri or therapi[INVESTIGATOR_122546] 
(including BV and ant i-PD1) except where unable to receive BV or anti -PD1 due to 
neuropathy  or autoimmune disease.
9Presence ofat least 1 radiographically measurable, FDG -avid lympho madisease l esion
>1.5cm (according to theLugano criteria [Cheson et al 2014 ]).
10Uric acid level < ULN at screening. If hyperuricaemia is present at scr eening, SoC 
therapy  shoul d be administered (including IV fluid and rasburicase or allopurino l) to 
reduce the uric acid levels to < ULN before the start of study  intervent ion.
11Willing and able to participate in all required evaluations and procedures in thi s study  
protocol  including receiving IV administration of study  drug and being admitted, if
requi red, for at l east [ADDRESS_137777] be confirmed to be available at 
screening . 
13Adequate haematologic function at screening ( Table 5).
(a)No growth factor support within 14 days prior to the date of the screening laboratory  
assessment .
(b)No transfusio ns wit hin 7 days prior to the date of the screening lab assessment.
Table5 Criteria for  Adequate Haematological Function
Category Parameter Value
Haematologic Haemoglobin ≥ 8.0g/dL
Absolute neutrophil count ≥ 1000 cells/mm3 (1.0 × 109/L)
Platelet count ≥ [ZIP_CODE] cells/mm 3 (75 × 109/L) 
without bone marrow involvement
≥[ZIP_CODE] cells/mm3(50× 109/L) 
with bone marrow involvement
14Adequate organ funct ion at screening as defined below in Table 6.
Note that 1 rescreen is permitted for participants if required ,in line with Section 5.4. 
Table6 Criteria for  Adequate Organ Function
Category Parameter Value
Hepatic Bilirubin ≤ 1.5 × ULN in the absence of 
Gilbert’s syndromea
≤ 3× ULN if the participant has 
Gilbert’s syndromea
Alanine transaminase and 
aspartate transaminase≤ 3× ULN
Renal Calculated creatinine clearance by 
[CONTACT_122598] 
[(140-Age) • Mass (kg)/(72 • 
creatinine mg/dL) • multiply by 
0.85 if female])≥ 60 mL/minute
Coagulation INR < 1.5 × ULN
Pancreatic Lipase ≤ 3× ULN and no ongoing
pancreatitis
Amylase ≤ 3× ULN and no ongoing 
pancreatitis
Cardiac LVEF as assessed by 
[CONTACT_122599]≥ 40%
aGilbert’s syndrome = ratio between total and direct bilirubin > 5.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 34of 148bAppropriate correction to be used, if a MUGA is performed.
Abbreviations: INR ,International Normalised Ratio; LVEF ,left ventricular ejection fraction; MUGA , multi-
gated acquisition scan; ULN ,upper limit of normal.
15PTCL Only: All part icipants wi th PTCL m ust be willing and able to provide mandatory  
baseline bone marrow aspi[INVESTIGATOR_6706]/or biopsy no older than [ADDRESS_137778]-treatm ent bone m arrow bi opsy  when requi red to confirm response.
Reproduction
16Contraceptive use by [CONTACT_122600] d be consistent wi th local regulat ions regarding 
the methods of contraception for those participat ing in clinical studies.
(a)Male participants :
(i)Male parti cipants must be willing to use barrier contraception (ie, condoms) for 
the duration of the study  plus a further [ADDRESS_137779] ive 
methods of contraception (defined below) for the duration of the study and for a 
washout period of 4 months after discont inuing AZD4573 .
(ii)Male parti cipants shoul d refrain from  donating sperm  from the start of dosing 
until 4 months after discont inuing AZD4573. If male participants wish to father 
children, they  shoul d be advised to arrange for freezing of sperm samples before 
the start of receiving AZD4573.
(b)Female participants :
(i)Female participants must be either women not of childbearing potential (defined 
below) , or m ust use one highly effective for m of birth control  (defined below )
from3 months pri or to enrolment ( the participant should have been stable on 
their chosen method of birth control for a minimum o f 3 months before entering 
the study ), throughout the study ,and until7months after last d ose of study  
intervent ion.
(ii)All WOCBP must have a negat ive serum pregnancy test result at Visit 1.
(iii)Female participants must not donate, or retrieve fo r thei r own use, ova from the 
time of start of dosing and throughout the study  treatm ent peri od, and for at least 
7 months after the final study  drug administrati on.
Women not of childbearing potential are defined as women who are either 
perm anent ly sterilised (hysterectomy, bilateral oophorectomy , or bilateral  
salpi[INVESTIGATOR_1656] ), or who are postm enopausal . Women w ill be considered 
postm enopausal if they  have been amenorrhoeic for [ADDRESS_137780] 
dose of study  drug without an alternat ive medical cause. The fo llowing age -
specific requirements apply :
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 35of 148Women <[ADDRESS_137781] 
been amenorrhoeic for 12 months or more fo llowing cessat ion of exogenous 
horm onal treatm ent and follicle stimulat ing horm one levels in the 
postm enopausal range.
Women ≥[ADDRESS_137782] 
been amenorrhoei c for 12 months or m ore following cessat ion of all 
exogenous hormonal treatment.
(iv)Women of childbearing potential must use one highly effect ive form of bi rth 
control . A highly  effect ive method of contraception is defined as one that can 
achieve a failure r ate of l ess than 1% per y ear when used consistently and 
correctly . Women of childbearing potential who are sexually act ive wit h a non -
sterilised male partner must agree to use [ADDRESS_137783] inence 
(calendar, symptotherm al, post -ovulation methods), withdr awal (coitus 
interruptus), spermicides only, and lactational amenorrhoea method are not 
acceptable methods of contraception. Female condom and male condo m shoul d 
not be used together. 
(v)Highly effect ive birth control methods include: sexual abst inence (note that 
periodic abst inence methods are not acceptable methods of contraception [eg, 
calendar, ovul ation, symptothermal, post -ovulation methods, declarat ion of 
abstinence for the duration of exposure to IMP, and withdrawal)], a 
vasectomised partner, Implanon ®, bilateral  tubal  occl usion, intrauterine 
device/levonorgestrel intrauterine system, Depo -Provera™ injections, oral 
contraceptive, and Evra Patch™, Xulane™, or NuvaRing®. 
Genomics Initiative Research Study (Optional):
17For inclusio n in the opti onal Geno mics Init iative component of the study, participants 
must fulfil the fo llowing addi tional criteria:
(a)Provisio n of signed and dated written Optional Genet ic Research Informat ion 
inform ed consent pri or to collect ion of samples for optional genet ic researc h that 
supports Genomic Init iative. If a participant declines to participate in the genet ic 
component of the study , there will be no penalt y or loss of benefi t to the parti cipant. 
The parti cipant will not be excluded fro m other aspects of the study  describ ed in this 
protocol , so l ong as they  consented to the m ain study .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 36of 148Bone Marrow Aspi[INVESTIGATOR_337] / Tumour Biopsy at Progression (Optional) :
18For inclusio n in the opti onal bone marrow aspi [INVESTIGATOR_337]/tum our bi opsy  com ponent of the 
study , parti cipants m ust fulfil  the following addi tional cri teria:
(a)Provisio n of signed, written, and dated informed consent for a bone marrow aspi[INVESTIGATOR_122547]. If a parti cipant declines to participate in the 
bone marrow aspi[INVESTIGATOR_337]/tumour biopsy  com ponent of the study , there will be no penalt y 
or loss of benefit to the participant. The participant will not be excluded from other 
aspects of the study  described in this protocol, so long as they  consented to the main 
study . 
(b)Having an accessible tumour/lymphadenopath y and a stabl e clinical  condi tion that 
will allow the participant to tol erate the procedure, if deemed safe and feasible by [CONTACT_1275].
5.2 Exclusion Criteria
The below are the core exclusio n criteria for all modul es of  the study; all part icipants m ust
meet the criteria described in the relevant module in addit ion to those described below . Where 
module-specific criteria are more stringent than core study  criteria, the m odule-specific 
criteria take precedent. 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Type of Participant and Disease Characteristics
1PTCL only : Presence of bulky disease (defined as largest lympho ma lesio n ≥10 cm ) or a 
LDH value > [ADDRESS_137784].
2PTCL only: Diagnosis of any o f the following:
(a)Lymphoblast ic/pre cursor T -cell lympho ma or leukaemia
(b)T-cell prolymphocyt ic leukaemia
(c)T-cell large granular lymphocy tic leukaemia
(d)Cutaneous T -cell lympho ma (eg, primary cutaneous ty pe ALCL, mycosis 
fungo ide/Sezary syndrome).
Medical Conditions
3With the exception o f alopecia and neuropathy , presence of any unreso lved 
non-haematological toxicit ies from prior therapy  greater than CTCAE Grade [ADDRESS_137785] 
compressi on.
5 H istory of prior non -haematological malignancy except for the fo llowing:
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 37of 148(a)Malignancy  treated wi th curative intent and with no evidence of act ive disease 
present for more than 1year prior to screening and felt to be at low risk for 
recurrence by [CONTACT_122601]. 
(b)Adequately treated lent igo m aligna m elano ma without current evidence of disease or 
adequately  controlled non -melano matous skin cancer.
(c)Adequately treated carcinoma in situ without current evidence of disease.
6As judged by  [CONTACT_3170], any  evidence of: 
(a)Severe or uncontrolled systemic disease (eg, severe hepat ic impairment, interstit ial 
lung disease [bilateral, diffuse, parenchymal lung disease]).
(b)Current unstable or unco mpensated respi[INVESTIGATOR_122548].
(c)Uncontrolled hypertensio n.
(d)Uncontrolled active systemic fungal, bacterial, viral, or other infect ion (defined as 
exhibit ing ongoing signs/symptoms related to the infect ion and wit hout 
improvement, despi[INVESTIGATOR_122549]) .
(e)IV anti -infect ive treatment within 1week before first dose of study  drug.
7Known history  of infect ion with HIV.
8Serol ogic status reflect ing act ive hepatit is B or C infect ion:
(a)Parti cipants who are hepati tis B core antibody  (anti -HBc) posi tive and who are 
surface ant igen negat ive will need to have a negat ive PCR result before enrolment. 
Those who are hepatit is B surface antigen posit ive or hepatit is B PCR -positive will 
be exclude d.
(b)Parti cipants who are hepati tis C antibody  posi tive will need to have a negat ive PCR 
resul t before enrolment. Those who are hepatit is C PCR -positive will be excluded.
9Any of the fo llowing cardi ac cri teria:
(a)Resting QT interval corrected using Fridericia’s formula (QTcF) ≥ 470 msec 
obtained fro m a single ECG.
(b)Any clinically  important abnorm alities in rhy thm (except for parti cipants wi th a 
pacemaker in place), conduction or morpho logy of resting ECG (e.g., complete left 
bundle branch block, third degree hear t block).
(c)Any factors that increase the risk o f QTc prol ongati on or risk of arrhy thmic events 
such as heart failure, congenital lo ng QT syndrome, family history  of long QT 
syndro me or unexplained sudden death under [ADDRESS_137786] dose :
(a)Coronary  artery  by[CONTACT_122602] -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 38of 148(b)Angioplasty
(c)Vascular stent: 
(i) A participant who has hada cardi ac stent or arterial stent implanted within [ADDRESS_137787] dose, is not eligible for the study .
(ii)Aparticipant who has hada venous stent implanted within [ADDRESS_137788] 
dose,is eligible for the study .
(d)Myocardial  infarct ion
(e)Angina pectori s
(f)CHF ([LOCATION_001] Heart Associat ion Class ≥ 2)
(g)Ventricular arrhy thmias requi ring continuous therapy
(h)Atrial fibrillat ion, which is judged as uncontrolled by [CONTACT_1963]
(i)Haem orrhagic or thromboti c stroke, i ncluding transient i schemic attacks or any  other 
CNS bleeding .
Prior/Concomitant Therapy
12Treatment with any o f the following:
(a)Received major surgery  (as defined by [CONTACT_3170]) or immunotherapy  
(specifically immune checkpo int inhibitors )within 28 days.
(b)Rece ived cy totoxic chem otherapy, standard ant i-lympho ma therapy ,or radi ation 
therapy  within [ADDRESS_137789] dose of study  treatm ent. 
(c)Received adoptive cellular therapy  such as autol ogous or donor NK cell or 
T lymphocy te infusi ons [eg, CAR -T cells]) within 90 day s.
(d)Received an investigational drug within [ADDRESS_137790] scheduled dose or not 
recovered fro m associated toxicit ies.
(e)Parti cipants who have previously received an autologous SCT are excluded if less 
than [ADDRESS_137791] scheduled dose.
(f)Parti cipants wi th a history  of allogeneic SCT are excluded UNLESS the following 
eligibilit y criteria are met: 
(i) Transplant was > [ADDRESS_137792] scheduled dose
(ii)Parti cipant has no history  of liver GVHD
(iii)Parti cipant has no active GVHD
(iv)Participant has not taken immunosuppressive medications for at least [ADDRESS_137793] scheduled dose ;low-dose steroids ( ≤ 10 mg of prednisone or 
equivalent per day ) are permitted as therapy for comorbid condit ions other than 
GVHD.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 39of 14813Requi res ongoing immunosuppressive therapy , including systemic (eg, intravenous or 
oral) corti costeroi ds for treatm ent of  lympho id cancer or other condit ions. 
Note: Participants may  use topi [INVESTIGATOR_122550] -dose steroids 
(≤ 10 mg of p redniso ne or equivalent per day ) as therapy for comorbid condit ions, but use 
of corticosteroi ds as therapy  for lymphoi d cancer is not permitted . Short courses of 
steroi ds before study  entry  are all owed. During study  parti cipat ion, parti cipants m ay 
receive systemic corti costeroi ds as needed for treatment -emergent com orbid condi tions.
14Receipt of live, attenuated vaccine within [ADDRESS_137794] dose of study 
treatm ent(s).
Prior/Concurrent Clinical Study Experience
15Parti cipation in another clinical stud y with an IPadministered in the last [ADDRESS_137795].
Other Exclusions
17Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
staff and/or staff at the study  site).
18Judgment by  [CONTACT_122603] d not parti cipate in the study  if the 
participant is unlikely to comply wit h study  procedures, restrict ions and requirements.
19Previous enrolment in th epresent study . 
20For wom en only -current ly pregnant (confirmed wit h posi tive pregnancy test) or 
breast feeding.
5.3 Lifestyle Considerations
There are n odietary /activityrestri ctions for this study .For restri ctions around reproduction
and contracepti on, refer to the inclusio ncriteria (Secti on5.1).
5.4 Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but 
are not subsequent ly entered in the study . A minimal set of screen failure informat ion is 
requi red to ensure transparent reporting of screen failure participant s to m eet the CONSOR T 
publishing requirem ents and to respond to queries fro m regulatory  authori ties. Minimal 
inform ation includes demography , screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen fail ure) m ay be
rescreened. Only 1rescreening is allowed in the study . Rescreened participant s shoul d be 
assigned the same participant number as for the initial screening.
Clinical Study Protocol -2.[ADDRESS_137796] igational intervent ion(s), m arketed product(s) or 
placebo intended to be administered to or medical device(s) utilised by a study  participant
according to the study  protocol .
6.1 Study Intervention(s) Administered
Please refer to the relevant module for inform ation on study  interventi on(s).
6.2 Preparation/Handling/Storage/Accountability
1The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2Only participants enro lled in the study  may receive study  intervent ion and only author ised 
site staff may supply or administer study  intervent ion. All study  intervent ion must be 
stored in a secure, environmentally controlled, and mo nitored (m anual or autom ated) area 
in accordance wit h the labelled storage condit ions with access limited to the invest igator 
and author ised site staff.
3The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie,recei pt, reconciliat ion, and final disposit ion records).
4Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provided in the Pharm acy Manual .
5The study  personnel at the investigational site will account for all study  intervent ion
dispensed and where appropriate , for all destructi on of  study  intervent ionor delivery of 
intervent ionto sponsor for destruction . Unused study intervent ionshoul d be destroy ed 
according to local guidelines, and the certificate of delivery/ destructi on shoul d be signed. 
Destruction should not take place until approved by [CONTACT_122604]. All study  supplies and associated documentation wil l be regularly reviewed 
and verified by  [CONTACT_122605].
6.3 Measures to Minim iseBias: Randomi sation and Blinding
This is an open -label study . Each potenti al parti cipant is assigned a unique participant 
enrolment number . If a parti cipant w ithdraws fro m the study , then the enrolment number 
cannot be reused. Study  intervent ion will be dispensed at the study  visit s summarised in the 
relevant m odule. Returned study  intervent ion should not be re-dispensed to the participants.
If an unscheduled a ssessment is performed, and the participant has not progressed, every  
attem pt shoul d be made to perform the subsequent assessments at their scheduled visit s. This 
schedule is to be fo llowed to minimi se any  unintenti onal bias caused by  [CONTACT_122606] e parti cipants 
Clinical Study Protocol -2.[ADDRESS_137797] the 30 days before starting IP, as well as all conco mitant 
treatm ents given during the study  (including over -the-counter or pre script ion medicines, 
vitamins, and/or herbal supplements )must be recorded in the eCRF along with:
Reason for use /indicat ion
Dates of administration including start and end dates
Dosage information including dose and frequency
The Study  Physician shoul d be contact[CONTACT_17064] .
Participants m ust abstain from  taking prescript ion or non -prescri ption drugs (including 
vitamins and di etary  or herbal  supplements) wi thin 7 days (or 14 day s if the drug is a potenti al 
enzyme inducer) or 5 half-lives (whichever is longer) before the start of study  intervent ion 
until completion of the fo llow-up visit, unless, in the opi[INVESTIGATOR_1649] o f the invest igator and sponsor, 
the medicat ion wil l not interfere with the study .
Given the proposed clinical dosing regimen of AZD4573, a nIV infusio n over 2 hours (once 
weekly), and the observed short half- life o f approximately  [ADDRESS_137798] igator in consultat ion with theStudy  
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C [ZIP_CODE]
CONFIDENTIAL AND PROPRIETARY 42of 148Physician if required .
Table 7 Prohibited Concomitant Therapi[INVESTIGATOR_122551]/class of drug Usage
Any other investigational therapy (including 
anticancer therapy ,other than those under 
investigation in this study .)Should not be given concomitantly while the 
participant is on study  intervention .
Any concurrent chemotherapy, radiotherapy, 
immunotherapy, or biologic or hormonal therapy for 
cancer treatment other than those under investigation 
in this study .Should not be given concomitantly while the 
participant is on study  intervention. (Concurrent use 
of hormones for non -cancer -related conditions 
[eg,insulin for diabetes and hormone replacement 
therapy ] is acceptable. Local treatment of isolated 
lesions, e xcluding target lesions, for palliative intent is 
acceptable [eg, by [CONTACT_72971]] .)
Live attenuated vaccines Should not be given through [ADDRESS_137799] 
dose of investigational products .
Immunosuppressive medications such as
methotrexate, azathioprine, and tumour necrosis 
factor -α blockers . Should not be given concomitantly or used for 
premedication .
Table8 Permitted Concomitant Therapi[INVESTIGATOR_014] (Conditional)
Supportive medication/class of drug Usage
Premedication for prophylaxis of diarrhoea, nausea, 
vomiting, TLS ,and infection .Permitted as per protocol and as deemed required by 
[CONTACT_093] .
Blood transfusions During the study, blood and platelet transfusions are 
allowed as clinically indicated at any time during the 
study and can be given as per local institutional 
guidelines.
G-CSF G-CSF should not be used prophylactically from 
Cycle 1, Day  1 but can be started when medically 
indicated.
Corticosteroids At study  entry , participants m ay be using topi[INVESTIGATOR_122552] -dose steroids (≤ 10 mg 
of prednisone or equivalent per day) as therapy for 
comorbid conditions, but use of corticosteroids as 
therapy  for ly mphoid cancer is not permitted. 
Doses of systemic corticoste roid > 10 mg/day may be 
used during the study if clinically indicated (eg, for 
treatment of an AE/SAE), but the dose must be 
tapered back down to no greater than 10 mg/day upon 
resolution of the event, to avoid chronic use.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 43of 148Table8 Permitted Concomitant Therapi[INVESTIGATOR_014] (Conditional)
Supportive medication/class of drug Usage
Concomitant drugs that have the potential to prolong 
QTcConcomitant drugs that have the potential to prolong 
QTc should not be used around the time of the 
scheduled ECG assessments during this study.
Strong CYP3A4 inducers/inhibitors It is recommended that treatment with strong 
CYP3A4 inducers is avoided, unless it is deemed 
clinically warranted in the opi[INVESTIGATOR_871]. 
If potent CYP3A4 inhibitors are administered, it is 
recommended to avoid administering them on the 
same day as AZD4573 administration where possible. 
Altern atively, such inhibitors should be administered 
[ADDRESS_137800] supportive care (including recombinant growth 
factor support, bisphosphonates, antibiotics, 
nutritio nal suppo rt, correction of metabolic disorders, 
optimal symptom control, and pain management 
[including palliative radiotherapy to non -target 
lesions, etc] .)Should be used, when necessary, after discussion 
with the st udy physician and in accordance with local 
institutional guidelines.
Inactivated viruses, such as those in the influenza 
vaccine and COVID -[ADDRESS_137801] dose of IP, or during Cycle 
1, to avoid biases in the interpretation of safety data 
due to the potential overlap of vaccine -related AEs 
with IP AEs. 
Abbreviations: AE, adverse event; ECG, electrocardiogram; G -CSF, granulocyte colony stimulating factor; IP, 
investigational product; SAE, severe adverse event; TLS, tumour lysis syndrome.
6.6 Dose Modification
If, in the opi[INVESTIGATOR_3078] n of the inv estigator, a participant experiences a clinically significant and/or 
unacceptable adverse react ion, then the dose m ay be tem porarily  or perm anently hal ted or 
reduced. 
Supportive therapy  will be administered as required. Relevant reporting and discussion w ith 
the Study  Physician will take pl ace before resumptio n of dosing.
See the relevant module for detail on dose modification.
6.[ADDRESS_137802] dose of the 
intervent ion therapy .
In the event that a roll -over or safet y extensio n study  is available at the time of the final DCO 
and database cl osure, participant s current ly receiving treatment with study  intervent ionmay 
be transit ioned to such a study , and the current study  woul d reach i ts end. The roll -over or 
safet y extensi on study  woul d ensure treatm ent continuat ion with visits and assessments per its 
protocol . Any participant who would be proposed to move to such a study  woul d be asked to 
sign a new ICF .
7 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL
7.1 Discontinuation of Study Intervention
It may be necessary for a participant to permanent ly discont inue (definit ive discontinuation) 
study  interventi on. If  study  intervent ion is permanent ly discont inued, the participant will
remain in the study  to be evaluated for safet yand efficacy during the 30-dayfollow-up peri od 
(Secti on 8.2.1 ),or until docum ented di sease progressio n during the l ong term  follow-up 
period (Section 8.2.2 ). See the SoA  for data to be collected at the time of discont inuat ion of 
study  interventi on and fo llow-up and for any  further evaluat ions that need to be completed.
Note that discontinuation fro m study  intervent ionis NOT the same as a wi thdrawal  from the 
study .
The participant shoul d continue attending subsequent study  visits and data collect ion shoul d 
continue according to the study  protocol . If the participant does not agree to continue 
in-person study  visit s, a m odified foll ow-up m ust be arranged to ensure the collect ion of 
endpo ints and safet y information. This could be a telephone contact [CONTACT_122607]-up visit , a contact [CONTACT_29881] a rel ative or treating physician, or informat ion from medical 
records. The approach taken should be recorded in the medical records. A participant who 
agrees to m odified fo llow-up is not consi dered to have wit hdrawn consent or to have 
withdrawn from  the study .
Participantsmay be discont inued fro m study  intervent ionin the fo llowing si tuations:
Object ive disease progression assessed by [CONTACT_53953]
Adverse event as defined in Sect ion
 8.3
Parti cipant or invest igator decisio n. The participant is at any  time free to discont inue 
treatm ent, wi thout prej udice to further treatmen t
Pregnancy (See Secti on8.3.10 )
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 45of 148Non-compliance wi th the CSP ( invest igator or participant )
Parti cipant incorrectly init iated on study  treatm ent
When the reason does not impact safet y, the Study Physician together wi th the 
investi gator will consider the risk/benefit to the participant of stoppi[INVESTIGATOR_122553].
The Study  Physician is responsible for ensuring all such contacts are appropriately 
docum ented.
Unexpected, significant ,or unacceptable risk to the participant senrolled in the study .
Sponsor terminat ion of study for reasons includ ingbut not limited to unfavourable
risk/benefit or change in drug development plan .
See the SoA for the relevant module for data to be collected at the time of intervent ion 
discontinuat ion and fo llow-up and for any  further evaluat ions that need to be completed.
Restarti ng of study  intervent ionmay only occur in line with the dose modificat ion and 
discontinuat ion guidelines described in the relevant module. Participants who have had 
investigat ive treatment discont inued for safet y reasons m ay not be restarted on this treatment 
during the study .
7.1.[ADDRESS_137803] one of the 
following events occurs:
Fatal  event deemed rel ated to study  therapy  by [CONTACT_122608] n with the 
SRC (probable or certain causalit y based on WHO -UMC after full et iological work -up). 
This will also result in a comprehensive re view o f safet y.
Confirmed true Hy’s law event as assessed by [CONTACT_122608] n with the 
SRC.
A CTCAE grade 4 or higher TLS event that is not reversible within 48 hours as assessed 
by [CONTACT_122608] n with the SRC.
Unexpected and li fe-threatening non -haematol ogicalevent deem ed rel ated to study  
therapy  by [CONTACT_122608] n with the SRC.
Sponsor decisio n that study  partici pants are pl aced at undue safet y risk.
Sponsor decisio n to di scont inue the development of the study tr eatment in the proposed 
indicat ions.
If, on an ongoing basis, > 25% of participants experience any AEs related to study 
intervent ion that result in discont inuat ion of study  treatm ent, the study  data will be evaluated 
by [CONTACT_12217]. Enrolment may be paused u ntil the safet y data revi ew by [CONTACT_122609].
Clinical Study Protocol -2.[ADDRESS_137804].
A participant may withdraw from  the study  at any  time at hi s/her own request, or may  be 
withdrawn at any  time at the di screti on of  the investi gator for safet y, behavioural, 
compliance, or administrative reasons. This is expected to be unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  [CONTACT_122610]-up opti ons (eg, telephone contact, a contact [CONTACT_4490] a 
relative or treating physician, or information fro m medical records).
If the participant withdraws cons ent for discl osure of  future inform ation, the sponsor may  
retain and cont inue to use any data collected before such a withdrawal o f consent.
If a participant withdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried out in line with what was stated in the informed consent and local regulat ion The 
investigator must document the decisio n on use of exist ing samples in the site study  
records and inform the Global Study  Team .
Parti cipants that are wi thdrawn fro m the study  but are evaluable per the definit ion in the 
Popul ations for Analyses sect ion of t he relevant module will not be replaced. Any part icipant 
that is withdrawn and is not evaluable will be replaced to ensure a minimum number of 
evaluable part icipants.
In addit ion, parti cipants willbe wit hdrawn fro m the study  in the event that the sponsor
terminates this study .
7.[ADDRESS_137805] be taken ifa participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_78778] m issed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and asc ertain whether or not the participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to f ollow up, the invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and ,
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 47of 148if necessary ,a certified letter to the participant ’s last known mailing address or local 
equivalent m ethods). These contact [CONTACT_13140] ’s 
medical record .
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix A.
8 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing are summar ised in the SoA for the relevant module .
Protocol waiver s or exem ptions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al 
participant s meet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all partici pants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg,blood 
count) and obtained before signing of the ICF may be util ised for screening or baseline 
purposes provided the p rocedures m et the protocol -specified criteria and were performed 
within the t ime frame defined in the SoA .
The m aximum  amount of  blood collected from  each participant over the duration of the 
study , including any  extra assessments that may be required, is not anticipated to exceed
436.5mL in Cycle 1 (cy cle durati on of  5 weeks) and 124mL in each subsequent cy cle 
(cycle durati on of  3 weeks) . Repeat or unscheduled samples may be taken for safet y 
reasons or for technical issues with the samples .
All efficacy assessments should cont inue unt il progressio n, including when a participant’s 
study  treatm ent has been stopped. 
8.1 Efficacy Assessments
Efficacy assessments are detailed in the relevant module.
8.2 Safety Assessments
Planned time po ints for all saf ety assessments are provided in the relevant m odule.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 48of 1488.2.1 30-D ay Follow -up Visit
A follow-up visit will  be perf ormed 30 (± 7) days from  the time that all study  interventi on is
perm anent ly discont inued (see the SoA  for the rel evant m odule). Tumour assessments 
(including PET -CT) will be repeated at this visit if they  have not been performed within 
9weeks if the participant discont inued before W eek 26, or [ADDRESS_137806]. Participants will be followed for 
survival by  [CONTACT_122611]  3 months. During this period, 
inform ation will be co llected in the eCRF on survival status and any new ant icancer therapi[INVESTIGATOR_014], 
and on any SAEs considered related to study  drug(s) or study  procedures.
8.[ADDRESS_137807] ion.
The definit ions of an AE andanSAE can be found in Appendix B.
Adverse events will be reported by  [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally author ised representative) . 
The invest igator and any design ees are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE .
All AEs (including SAEs) must be entered into the Clinical Database which will be used to 
generate the CSR . SAEs are also to be entered into the Global Patient Safet y database which is 
used for expedited and periodic regulatory  safet y reporting and safet y surveillance act ivities. 
Regular reconciliat ion of SAEs between these 2 databases will be conducted by  [CONTACT_122612] a peri odic basis. 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 49of 1488.3.1 Time Period and Frequency for Collecting AE and SAE Information
Adverse events and SAEs will be collected from time of signature [CONTACT_48028], throughout the 
treatm ent peri od and including the follow -up period of 30 days (± 7 day s)after last dose of 
study  interventi on.
A formal assessment of AEs will occur at the visits marked in the SoA  of the relevant module, 
but AEs reported at any  time during the study  must al so be recorded i n the eCRF.
If the invest igator becomes aware of a SAEwith a suspected causal relat ionship to the IMP(s)
that occurs after the end of the clinical trialin astudy participant , the invest igator shall, 
without undue del ay, report the SAE to the sponsor .
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unreso lved at the participant ’s last assessment in the study  are fo llowed up 
by [CONTACT_24549], but without further recording in the 
eCRF. [COMPANY_008] retains the right to request additional information for any  participant with 
ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
After the init ial AE/SAE report, the Investigator is required to proactively fo llow each 
participant at subsequent visits/contacts. All SAEs and non -serious AEs will be fo llowed unt il
resol ution, stabili sation, the event is otherwise explained, or the participant is lost to foll ow-
up.
Adverse event variables
The fo llowing variables will be collected for each AE:
AE (verbat im)
The capture of diagnoses is preferred over all associated signs and symptoms. For 
example: laboratory  TLS, clinical TLS, cytokine rel ease syndrom e. Provisional 
diagnoses (eg, PHL) must be updated as soon as possible.
The date when the AE started and stopped
When the onset of an AE in relat ion to dosing is rapid, for example TLS, it is
important to record the exact time of the start of infusion dosing and the time of 
AE onset in addit ion to the dates.
CTCAE grade/changes in CTCAE grade
For TLS events: Adverse events of TLS shall be graded according to CTCAE. The AE 
verbat im shall discriminate between laboratory  and clinical  TLS. In addi tion, TLS events 
will be graded according to Howard modification of the Cairo -Bishop grading system 
(see Appendix G) on the TLS monitoring eCRF form.
Whether the AE is serious or not
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 50of 148Invest igator causalit y rating against the IP(s) (y es or no)
Action taken with IP(s)in response to the AE (for example: no action, dose reduced, 
treatm ent tem porarily stopped, treatment permanent ly discont inued) .
Outcom eof the event
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
The date of start of first signs and symptoms should be captured together with the 
date the event became serious. 
Date invest igator became aware of SAE
Reason AEisclassified as serious
Date of hospi[INVESTIGATOR_72913]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed(yes/no)
Causalit y assessment in relat ion to Study  procedure(s)
Causalit y assessment to other medicat ion
8.3.[ADDRESS_137808] igator should assess causal relationship between IPand each Adverse Event, and
answer ‘yes’ or ‘no’ to the question ‘Do y ou consider that there is a reasonable possibilit y that 
the event may have been caused by [CONTACT_33249]?’
For SAEs, causal relat ionship shoul dalso be assessed for other medicat ion and study  
procedures .Note that for SAE s that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
A guide to the interpretation of the causalit y question is found in Appendix Bto the CSP.
8.3.4 Adverse Events Based on S
igns and Symptoms
All AEs spontaneously reported by [CONTACT_122613]: ‘Have y ou had any heal th probl ems since the previo us visi t/you were 
last asked? ’, or revealed by [CONTACT_122614]. When 
collect ing AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms . However, if a diagnosis is known and there are other signs or symptoms 
Clinical Study Protocol -2.[ADDRESS_137809] igator (which may include but not 
limited to considerat ion as to whether treatment or non- planned visits were required or other 
action was taken wit h the study  treatm ent, eg,dose adjust ment or drug interruption).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated labora tory resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting invest igator
uses the clinical, rather than the laboratory  term  (eg,anaemia versus low haemoglo bin value) . 
In the absence of clinical signs or symptoms, c linically relevant deteriorations in non -
mandated parameters should be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless unequivocally 
related to the DUS .
8.3.[ADDRESS_137810] ive of seriousness criteria or causalit y:
Neutropenia, including Febrile n eutropeni a, Neutropeni c sepsis, Neutrophil count 
decrease
Thrombocy topeni a, including Platel et count decrease
Hepatotoxicit y, including PHL , Drug -induced liver injury, Bilirubin increase wit h 
transaminase (ALT or AST, or both ALT and AST) increase
Pyrexia
TLS
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 52of 148Myocardial  ischaemia
8.3.7 Potential Hy’s Law Cases
Cases where a participant shows elevations in liver transaminases and bilirubin levels require 
further evaluat ion. Occurrences of AST and/or ALT ≥ 3 × ULN together with total bilirubin 
≥2 × ULN must be r eported as SAEs due to medical significance. The PHL  page of the 
eCRF  form must also be completed without delay . The verbatim of 'Potential Hy's Law' 
is a pr ovisional diagnosis and must be updated as soon as possible. All PHL  cases must 
be reported by [CONTACT_122615] a S[LOCATION_003]R in an expedited manner  (even 
befor e all other  possible causes of liver  injury have been excluded). Please r efer to 
Appendix Efor mor e details.
For all PHL  events, expedited safety  reporting is required. The investigator must inform the 
sponsor as soon as more informat ion is available on the event.
Please refer to the toxicit y management and dose modification guidance in the relevant 
module. Di scussio ns regarding treatm ent discont inuation due to increased liver transaminases 
and/or bilirubin increases should be documented. All PHL  cases shoul d be cap tured in the 
study  PHL  logby [CONTACT_122616] .
8.3.8 Disease Progression and Disease Under Study
Disease progressi on can be considered as a worsening of a participant ’s condi tion attri butable 
to the di sease for which the treatm ent is being studied. It may be an increase in the severit y of 
the DUS and/or increases in the symptoms of the disease. The development of new , or 
progression of exist ing, metastasis to the primary cancer under study should be considered as 
disease progressi on and not an AE. Events, which are unequivocally due to disease 
progression, should not be reported as an AE during the study .
Symptom s of DUS are those which might be expected to occur as a direct result of r/r PTCL  
or r/r cHL . Events which are unequivocally due to DUS shoul d not be reported as an AE 
during the study  unless they  meet SAE cri teria or lead to discont inuat ion of the study  
treatm ent.Death clearly result ing fro m disease progressio n should not be reported as an SAE.
8.3.[ADDRESS_137811] to be reported, whether or not considered causally related to the IP, the study  
procedure(s) or other medicat ion. All SAEs will be recorded in the eCRF .
If any SAE occurs in the course of the study , then investi gators or other si te personnel inform 
the approp riate [COMPANY_008] representatives within one day  ie, immediately but no later  than 
[ADDRESS_137812] igators or other site personnel indicate an AE is serious in the eCRF , an 
autom ated em ail alert is sent to the designated [COMPANY_008] representative.
If the eCRF system  is not available, then the investi gator or other study  site staff reports a 
SAE to the appropriate [COMPANY_008] representative by  [CONTACT_122617] m ethod .
The [COMPANY_008] representative will advise the investigator/study site staff how to proceed. 
For further guidance on the definit ion of a SAE, see Appendix Bof the CSP.
The reference document for definit ion of expectedness/listedness is the IB for the AZD4573. 
8.3.10 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except for if 
the pregnancy  is discovered before the s tudy participant has received any  study  interventi on.
If a pregnancy  is reported, the investigator should inform [COMPANY_008] wit hin 24 hours of 
learning of the pregnancy .
Abnorm al pregnancy outcom es (eg, spontaneous abortion, foetal death, stillbirth, cong enital 
anomalies, ectopi c pregnancy ) are considered SAEs.
[IP_ADDRESS] Maternal Exposure
If a participant beco mes pregnant du ring the course of the study , IPshould be discontinued 
immediately .
Pregnancy itself is not regarded as an AEunless there is a suspi[INVESTIGATOR_24510] n that the IPunder study 
may have interfered with the effect iveness of a contraceptive medicat ion.Elective abortions 
without com plicat ions shoul d not be handled as AEs. The outcome o f all pregnancies 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 54of 148(spontaneous miscarriage, e lective terminat ion, ectopic pregnancy , norm al birth,or congenital 
anomaly/birth defect ) shoul d be fo llowed up and docum ented even if the participant was 
discontinued fro m the study .
Congenital a nomalies/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. 
If any pregnancy  occurs in a female participant during exposure to IPor in the [ADDRESS_137813] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Pati ent Safet y data entry  site within 1 or  
5 calendar  days for SAEs (see Section 8.3.9 ) and within 30 days for all ot her pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy and the paper -based 
PREGOUT module is used to report the outcome of the pregnancy .
[IP_ADDRESS] Paternal Exposure 
Male parti cipants shoul d refrain from  fathering a child or donating sperm during the study  and 
for [ADDRESS_137814] dose (see Inclusio n Cri teria Sect ion 5.1).
Pregnancy of a participant ’s partner i s not considered to be an AE. However, any concept ion 
occurring from the date of dosing unt il 4 months after discont inuation o f dosing should be 
reported to [COMPANY_008] and fo llowed up for i ts outcom e. The outcom e of all pregnancies 
(spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy , norm al birth,or congenital 
anomaly), occurring fro m the date of the first dose unt il [ADDRESS_137815] be obtained before the Pregnancy  Report Form  is completed. 
If a pregnancy  occurs in a parti cipant ’s partner wi thin the t imeframe specified above, then 
investigators or other site personnel wi ll inform  the appropri ate sponsor representative 
immediately , or no l ater than [ADDRESS_137816] been identified after the participant ’s 
inclusio n in this study . They  do not include metastases of the original cancer.
8.3.[ADDRESS_137817] be 
reported as fo llows:
Death cl early  resul ting fro m disease progression should be reported to the study 
monitor/physician at the next monitoring visit and should be documented in the relevant
eCRF module.It should not be reported as an SAE.
Where death is not due (or not clearly  due) to progressio n of the DUS , the AE causing the 
death m ust be reported as an SAE within 24 hours. It should also be documented in the 
eCRF. The report should contain a comment regarding the co -involvement of disease 
progression , if appropri ate, and shoul d assi gn single maincause of death together wi th 
anycontributory  causes. Autopsie s shoul d be requested if available.
Death wi th an unknown cause should always be reported as an SAE , but every  effort 
shoul d be made to establish a cause of death . It shoul d also be documented in the eCRF. 
A postm ortem  may be helpful  in the assessment of the cause of death, and if performed, a 
copy  of the postm ortem  resul ts(with translat ion of important parts into English) shoul d 
be forwarded to [COMPANY_008] Patient Safet y or its representative within the usual t ime 
frames.
Deaths that occur after the treatment peri od during the survival fo llow-up peri od shoul d 
be reported on the survival log on the eCRF. If the death occurred as a result of an event 
that started after the defined fo llow-up peri od and the event is considered by [CONTACT_122618] a late -onset toxi city to study intervent ion, then it should also be 
reported as an SAE. 
8.3.[ADDRESS_137818] igator to ensure tha t all 
relevant informat ion is completed wi thin 1 (Initial Fatal /Life -Threatening or follow up 
Fatal /Life -Threatening) or 5(other serious init ial and fo llow up) calendar  days if there is an 
SAE associated with the medicat ion error (see Sectio n8.3.9 ) and within 30 days for all other 
medicat ion errors.
The definit ion of a Medicat ion Error can be found in Appendix B 4.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 56of 1488.4 Overdose
Overdose informat ion for AZD4573 is below; refer to relevant module for information on 
overdose for combinat ion therapi[INVESTIGATOR_014].
For thi s study , any  dose of AZD4573 greater than the dose intended to be delivered will be 
considered an overdose.
All overdoses should be recorded as follows:
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module
If an overdose on an [COMPANY_008] study drug occurs in the course of the study , the invest igator 
or other si te personnel inform appropriate [COMPANY_008] representatives immediately , but no 
later  than [ADDRESS_137819] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Pati ent Safet y data entry  site within 1 or 
5 calendar  days for overdoses as sociated wi th an SAE (see Section8.3.9 ) and within [ADDRESS_137820] confident iality. For further details on Handling o fHum an Bi ological 
Samplessee Appendix C.
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the issue of the CSR in 
line with consent and local requirement s, after which they  will be destroyed /repatri ated. 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 57of 148Pharmacokinet ic samples will be disposed of after the Bioanalyt ical Report finali sation or 
6months after issuance of the draft Bioanalyt ical Report (whichever is earlier), unless 
consente d for future analyses.
Pharmacokinet ic samples may be disposed of or anonymised by [CONTACT_76435]. Addit ional 
analyses may be conducted on the anonym ised, pool ed PKsamples to further 
evaluate and validate the analyt ical method. Any  resul ts from such analyses may be 
reported separately  from the CSR.
Remaining ADA sample aliquots will be retained at [COMPANY_008] or its designee for a 
maximum o f 15 years following issue of the CSR. Addit ional use includes but is not 
limited to further characteri sation of  any ADAs, confirmat ion and/or requalificat ion of the 
assay as well as addit ional assay devel opment work. The results from future analysis will 
not be repo rted in the CSR .
8.5.[ADDRESS_137821] deviat ion, median, 
minimum, and maximum. Geometric mean and coefficient of variat ion may be presented as 
applicable. Categorical variables will be summari sed by  [CONTACT_122619] . Unless otherwise stated, percentages will be calculated from the populat ion 
total, by [CONTACT_89799] t imepoint as appropriate . Time t o event variables will be presented 
using the KMmethodology where appropri ate, including median t ime calculated fro m the KM
curves. SAS® versio n 9.4 (as a minimum) will be used for analyses presented in the CSR.
Depending on the extent of any impact, summ aries of data relat ing to participants diagnosed 
with COVID -19, and impact of COVID -[ADDRESS_137822] (in particular missed visits, 
delayed or di scontinued study  treatm ent, and other protocol deviat ions) may be generated. 
More details will be provided in the SAP .
Refer to the relevant Module for details on analyses and cut -off triggers.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 59of 1489.4.2 Efficacy Analyse s
Analysis of Primary Endpoint (Efficacy)
The primary  object ive of this study  is to assess the efficacy o f the module-defined study  
treatm ent in participants wi th r/r PTCL or r/r cHL. Endpoints for this object ive are specific to 
each m odule.
For informat ion on efficacy analyses and endpo ints, refer to the relevant module.
9.4.[ADDRESS_137823] ings and 
summaries will be created using the safet y analysis set.
Adverse events will be listed individually  by [CONTACT_122620]. The number of 
participants experiencing each AE will be summarised by [CONTACT_122621], 
MedDRA  preferred term ,and CTCAE grade (in line wit h NCI CTCAE V ersion 5.0).TLS will 
be graded by [CONTACT_122622] ’s modificati on of  Cairo -Bishop grading 
(Appendix G;Howard et al  2011). The number and percentage of parti cipants experi encing 
each AE, and the number and percentage of participants with AEs in different categories 
(eg,causally related and CTCAE Grade ≥3) will be summarised by [CONTACT_9084], and even ts in each 
category  will be further summarised by [CONTACT_122623]. 
SAEs will be summarised separately if a sufficient number occur .
Adverse event summary tables will include only treatment -emergent AEs. Adverse events will 
be defined as treatment -emergent if they have an onset or worsen (by [CONTACT_122624] a 
change in intensit y/severit y), during the study  treatment until the follow-up peri od (as defined 
in the individual study  Modules), but prior to subsequent cancer therapy . AEs occurring 
outsi de of thisperiod will  be listed but not summarised. 
During the evaluat ion of the AE data, an [COMPANY_008] medically qualified expert w ill review 
the list of AEs that were not reported as SAEs and AEs leading to discont inuat ion of study  
treatm ent. Based on the expert ’s judgement, AEs of part icular clinical importance may , after 
consultation wit h the Gl obal Safety  Physician, be considered OAEs and reported as such in 
the CSR. A similar review of laboratory  values, vit al signs, ECGs ,and other safet y 
assessments will be performed for identificat ion of OAEs.
Examples of these could be marked haematological and other laboratory  abnorm alities, and 
certain events that lead to intervent ion (other than those already classified as serious) , dose 
reducti on, or si gnificant addi tional treatm ent.Duration of exposure will be summarised.
Clinical Study Protocol -2.[ADDRESS_137824] ive for the 
study .
The endpo ints for these analyses are plasma concentrations and derived PK parameters for 
AZD4573 summarised by [CONTACT_122625] . Plasma/serum concentrati ons and 
derived PK parameters for other ant i-cancer agents may besummarised by  [CONTACT_9084] f or the PK 
analysis set , as applicable .
For details on PKanalyses , please refer tothe separate Bioanalyt ical Report.
9.4.[ADDRESS_137825] ives for 
this study . 
For details on pharmacodynamic analyse s  analyses refer the relevant 
module. 
9.5 Interim Analyses 
See relevant module for information on planned interim analyses.
9.6 Data Monitoring Committee
There will be noformaldata monitoring co mmittee for this study . See rel evant m odule for 
inform ation regarding the use of a S RCfor this study .
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 62of [ZIP_CODE].1.2 Schedule of Activities
Table9 Schedule of Activities: Module 1 (AZD4573 Monotherapy )
Procedure ScreeningaCycle 1,
Weeks 1 -5
(includes intra -
participant
Dose ramp -up)Cycle 2 to 12
(Cycle =21 Days)Cycles 13+ 
(Cycle = 
21days)Disease 
Assessment30-Day
FUeLTFU Details in 
Section
Cycle 1
Weeks 1 -5,
Day 1 VisitsDays Day
1 8 15 1
(±2 Days) (±2 Days) (±7 Days) (±7 Days) (±7 Days)
Informed consentbX Appendix A
Inclusion/exclusion X 5and 
10.4.3
Medical history and 
demographicsX 5and 
10.4.3
Physical examination X X X X X X X [IP_ADDRESS]
ECOG performance 
statusX X X X X X X [IP_ADDRESS]
B symptoms X X X X X X X [IP_ADDRESS]
Vital signs and weight X X X X X X X [IP_ADDRESS]
12-lead ECG X Refer to Section [IP_ADDRESS] for schedule X [IP_ADDRESS]
ECHO/MUGA X As clinically indicated X [IP_ADDRESS]
Cardiac troponin X X X X X [IP_ADDRESS]
T4, Cortisol, ACTH 
and TSHX X [IP_ADDRESS]
EBV Prior to receiving study 
treatment10.8.9.2
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 - D8231C00001
CONFIDENTIAL AND PROPRIETARY 63of 148Table9 Schedule of Activities: Module 1 (AZD4573 Monotherapy )
Procedure ScreeningaCycle 1,
Weeks 1 -5
(includes intra -
participant
Dose ramp -up)Cycle 2 to 12
(Cycle =21 Days)Cycles 13+ 
(Cycle = 
21days)Disease 
Assessment30-Day
FUeLTFU Details in 
Section
Cycle 1
Weeks 1 -5,
Day 1 VisitsDays Day
1 8 15 1
(±2 Days) (±2 Days) (±7 Days) (±7 Days) (±7 Days)
HaematologycX X X X X X X [IP_ADDRESS]
Coagulation X X X X X X X [IP_ADDRESS]
Clinical chemistrycX X X X X X X [IP_ADDRESS]
Urinaly sis X X X X X [IP_ADDRESS]
TLS monitoring 
(for at least [ADDRESS_137826] SOI )X X [IP_ADDRESS].2
Pregnancy testing 
(WOCBP )X Pre-dose Week 
1, Day  1 Prior to initiating a new cycle 
(once every 21 days )X [IP_ADDRESS]
Lipase/amy lase X X X X X X X [IP_ADDRESS]
Hepatitis serology X [IP_ADDRESS]
Liver chemistry test s X [IP_ADDRESS]
Whole blood samples 
for X Per Section [IP_ADDRESS] X X [IP_ADDRESS]
 sample for 
 Prior to receiving study 
treatment10.8.9.4
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 64of 148Table9 Schedule of Activities: Module 1 (AZD4573 Monotherapy )
Procedure ScreeningaCycle 1,
Weeks 1 -5
(includes intra -
participant
Dose ramp -up)Cycle 2 to 12
(Cycle =21 Days)Cycles 13+ 
(Cycle = 
21days)Disease 
Assessment30-Day
FUeLTFU Details in 
Section
Cycle 1
Weeks 1 -5,
Day 1 VisitsDays Day
1 8 15 1
(±2 Days) (±2 Days) (±7 Days) (±7 Days) (±7 Days)
Serum 
immunoglobulins 
(IgA, IgM, IgG)X Day 1 of Cy cles 3, 6and 9 
(pre-dose)Cycle 13 
(±7days) 
and every 
6months 
thereafterX [IP_ADDRESS]
Concomitant 
medicationX X X X X X X X 5.2, 6.5
Adverse event 
evaluationX X X X X X X 8.3
AZD4573 plasma PK Refer to Section 10.8.6 for schedule 10.8.6
 X 10.8.6
Pharmacodynamic 
samples (blood) for 
AZD4573Weeks 1 to 3 10.8.7
 X Weeks 1 to 3 If elevated liver chemistry tests /bilirubin [IP_ADDRESS]
Explo ratory  analy ses 
samplesX Refer to Section 10.8.8 for schedule 10.8.8
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 65of 148Table9 Schedule of Activities: Module 1 (AZD4573 Monotherapy )
Procedure ScreeningaCycle 1,
Weeks 1 -5
(includes intra -
participant
Dose ramp -up)Cycle 2 to 12
(Cycle =21 Days)Cycles 13+ 
(Cycle = 
21days)Disease 
Assessment30-Day
FUeLTFU Details in 
Section
Cycle 1
Weeks 1 -5,
Day 1 VisitsDays Day
1 8 15 1
(±2 Days) (±2 Days) (±7 Days) (±7 Days) (±7 Days)
Genomics Initiative 
sample ( optional )X 8.7
Bone marrow biopsy 
& aspi[INVESTIGATOR_337] 
(PTCL only)dX As 
clinically 
indicated 
and to 
confirm CR10.[IP_ADDRESS]
Fresh or archival 
tumour tissue sampleX [IP_ADDRESS].2
Additional tumour 
biopsy sample 
(optional )At disease 
progression(X) [IP_ADDRESS].2
Disease 
assessments/radiologic 
scansX After Cycle 2 (+/ -1 week), then Q9W 
until W26 (Cycle 8, Week 3), then Q12W 
(+/-1 week)X 10.8.1
AZD4573 (IV; once
weekly)cX X X X X 10.6
Disease progression 
follow -up (SoC)X 8.2.2
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 66of 148Table9 Schedule of Activities: Module 1 (AZD4573 Monotherapy )
Procedure ScreeningaCycle 1,
Weeks 1 -5
(includes intra -
participant
Dose ramp -up)Cycle 2 to 12
(Cycle =21 Days)Cycles 13+ 
(Cycle = 
21days)Disease 
Assessment30-Day
FUeLTFU Details in 
Section
Cycle 1
Weeks 1 -5,
Day 1 VisitsDays Day
1 8 15 1
(±2 Days) (±2 Days) (±7 Days) (±7 Days) (±7 Days)
Survival F UeX 8.2.[ADDRESS_137827] be obtained ≤ [ADDRESS_137828] be obtained before any protocol -defined screening tests are done.
cResults of safety laboratory testing (haematology and clinical chemistry at a minimum) must be available within [ADDRESS_137829] be 
reviewed by [CONTACT_122626]4573. To initiate Cycle 1 and subsequent cycles, haematology and chemistry criteria in 
inclusion criteria 10, 13, and 14shall be met. In addition, during AZD4573 treatment, dose modification and d iscontinuation guidelines are provided in 
Section 10.6.1.
dMandatory exploratory  analysis will be performed any time a bone marrow analysis is performed.
eThe follow -upvisit will be performed 30 days (± 7 day s) after the last dose of all study drug. Disease assessments will be repeated at this visit if they have 
not been performed within 9 weeks if the participant discontinued before Week 26,or 12 weeks if the participant discontinued after Week 26.
Abbreviations: ACTH, adrenocorticotropic hormone;ECG, electrocardiogram ; ECHO, e chocardiogram ; ECOG, Eastern Cooperative Oncology Group; FU, 
follow -up; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IV, intravenous; LTFU, long -term follow -up; MUGA , multigated 
acquisition ; PK, pharmacokinetic ; PTCL, peripheral T -cell lymphoma; SoC, standard of care ; SOI, start of infusion ; TLS, tumour lysis syndrome ; TSH, thyroid 
stimulating hormone; WOCBP, women of childbearing potential .
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 69of 148AZD4573 will be administered intravenously as a mo notherapy  to parti cipants wi th 
r/rPTCL or r/r cHL, including an intra -participant dose ramp -up. For d ose regimen, see 
Secti on 10.4.1  below .
For details on study  design applying to all modules, including information on the SRC 
and the definit ions for end of study , refer to the core protocol study  design (Secti on4.4).
10.4.1 Module 1 Design : AZD4573 monotherapy
Module [ADDRESS_137830] of 2 r/r PTCL  cohorts and 1 r/r cHL cohort; see 
Figure 5 and Table10 below for planned partici pant number s. 
Each cohort will include an intra -participant  dose ram p-up, starting at 6 mg AZD4573 
(Figure 6). The target dose fo llowing the ramp- up is [ADDRESS_137831] cy cle, parti cipants will receive a single dose of AZD4573 once weekly  
beginning with 6 mg W eek 1, 9 mg W eek 2, an d 12 m g for each of W eeks 3 to 5. 
Every  cycle bey ond Cycle 1 will be 3 weeks in length and participants will receive 12 mg 
infusio ns of AZD4573 once weekly unt il progression.
Figure 6 Module 1 AZD4573 Monotherapy Dosing Regimen in PTCL and cHL 
including Intra -Participant Dose Ramp -Up
Abbreviations: cHL, classical Hodgkin Lymphoma; D, day ; PTCL , peripheral T -cell lymphoma ; Q1W, once 
weekly.
A comprehensive initial review of all  safety  and PK/PD data will be conducted in 
approxim ately  the first 6 participant s of each cohort (safety run -in), with separate SRCs for 
each cohort executed independent ly. The safet y assessment will be undertaken by [CONTACT_122627] 10.4.[ADDRESS_137832] cy cle will  be as per the SoA  (Table9). Each cohort will have a separate dose 
confirmat ion, assessed independently by  [CONTACT_12217], to assess safety  and PK/PD data com pared 
to the known profiles in the first time in human  study  (Study  D8230C00001) lympho ma 
popul ation.

Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 71of [ZIP_CODE].4.2 Justification for Dose
Theplanned starting and target dose sof AZD4573 for Module 1 are as per the RP2D already 
determined for lympho ma in the ongoing Phase I mo notherapy  study  of AZD4573 
(D8230C00001). 
 
 
 
 
 
 
 
 
 
 
 These Grade [ADDRESS_137833] elevat ions metthe definit ion of DLT in 
versio ns 2 and 5 of the protocol (dated 7 July2017 and 18 April 2019), but were transient (less 
than 4 days duration) and were not accompanied by [CONTACT_122628]. Review of the data (December 2019) by  [CONTACT_38227] ’s Hepatic Safet y 
Knowl edge Group and external industry and academic experts concl uded that isolated 
asymptomat ic reversible Grade [ADDRESS_137834] oratory data from   samples collected from ongoing Phase I 
monotherapy  study  support target engagement  at all doses 
tested to date (ie, 6 mg and above), wi th a median  of  (range:  
) observed fo llowing the 12 m g weekly regimen (based on preliminary  PK/PD 
modelling). Corresponding bio logical  effects, eg,  
 have also been observed.
In addit ion, based on exposure versus safet y analysis conducted for the Phase I monotherapy  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 72of 148study ,  
 
Overall, these analyses support the evaluat ion of AZD4573 12 mg, once weekly , monotherapy  
regimen in the treatment of patients with r/r PTCL  or r/r cHL.
The clinical data will be used to refine a PK/pharmacodynamics/efficacy model, and future 
decisio ns on dose regimens and escalations will be based on the observed clinical data to date 
and this refined model.
10.4.[ADDRESS_137835] ill receiving study intervent ion atthe complet ion of the final analysis will 
be able to continue to receive the intervent ionat the sponsor ’s discret ionfor up to [ADDRESS_137836] 
6 participants of each cohort (safet y run-in), with separate SRCs for each cohort executed 
independ ently. Recrui tment will not be paused during this review . These participants will be 
CCI
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_137837] completed Cycle1,to ensure the treatment schedule is safe and 
tolerable. The SRC will review the totalit y of all relevant data (eg clinical, labo ratory , safety ) 
prior to provi dingdecisi ons on study  conduct. All decisio ns by [CONTACT_122629] h all participating sites.
If, on an ongoing basis, > 25% of participants experience any AEs related to study 
intervention that result in discont inuat ion of study  treatm ent, study  data will be evaluated by  
[CONTACT_12217]. Enrolment may  be paused unt il the safet y data review by [CONTACT_122609]. Following this SRC review , addi tional monitoring may  be implemented and/or
enrolment and dosing may resume at a lower dose level or on a modified schedule. The SRC 
will meet at least every  6 months to review the overall safety  and clinical  data f rom the study .
At any time point during the study , the occurrence of a fatal AEdeem ed rel ated to study  
therapy  (after full etiological work -up and in discussio n with the SRC) will result in study  
drug interruption and a comprehensive review of safet y.
10.5 Study Population –Module 1
Refer to Section 5.1and Section 5.2in core protocol for inclusion and exclusio n criteria, 
respectively .
10.6 Study Intervention –Module 1
AZD4573 is administered as an abso lute (flat) dose, 2 -hour (± 15 minutes) intravenous 
infusio n on a once weekly schedule.  
 
Arm name N/A
Intervention name [CONTACT_99213]4573
Type Drug
Dose formulation Concentrate for solution for infusion
Unit dose strength(s) 1.5 mg/ml
Dosage level(s) 6 mg AZD4573 (starting dose)
9 mg AZD4573
12 mg AZD4573 (target dose)
Route of administration IV infusion
Use Experimental
IP or NIP IP
Sourcing Provided centrally by [CONTACT_122630] a clear glass vial . Each vialwill be 
labelled as required per country requirement .
Former names AZ13810325
CCI
Clinical Study Protocol -2.[ADDRESS_137838]; IV ,intravenous; NIP ,non-investigational product.
10.6.1 Dose Modification
Dose m odificat ion and discont inuat ion gui delines for haematological and non -haematol ogical  
toxicities (excluding abnormal liver chemistry  test resul ts) are shown below in Table11. Dose 
modificati ons f or AZD4573 for abnormal liver chemistry  test results are described in Table12.
In general, if a part icipant experiences a Grade 1 or Grade 2 haematological or 
non-haematological toxicit y, no dose m odificat ion is required. If a participant experiences a 
Grade 3 or Grade 4 toxicit y, not attributable to the disease or disease -related processes under 
investigat ion, dosing will be interrupted and/or the dose reduced (see Table11for 
recommended dose modificat ionsfor AZD4573) and supportive therapy  administered as 
requi red. If the toxi city resolves or reverts in line with the dose modificat ion gui delines below
and the participant was showing clinical benefit, treatment with study  treatm ent(s) m ay be 
restarted.
If the toxicit y does not resolve in line wit h the dose modificat ion guidelines below ,then the 
participant shoul d be discont inued from the study  treatm ent and observed unt il reso lution of 
the toxicit y. Maximal  drug interrupti on all owed f or AZD4573 is 21 consecut ive days ; in cases 
where more than [ADDRESS_137839] igator 
and the Study  Physician.
Table11 Recommended Dose Modifications for  AZD4573
EventaOccurrence Action with AZD4573
Tumour Lysis Syndrome (TLS)
Changes in uric 
acid, potassium, 
phosphorus, 
creatinine or 
calcium, o r 
symptoms 
suggestive of TLSAny For any  abnormal changes present before dosing, initiate supportive 
therapy  and hold drug for up to [ADDRESS_137840] Grade 4 TLS, discontinue AZD4573.
Non-haematological toxicities (except liver dysfunction and TLS )
Clinical Study Protocol -2.[ADDRESS_137841] 
occurrenceDiscontinue AZD4573.
Haematological Toxicities
Grade 3 or 4 
neutropenia without 
fever or infection, 
lasting ˃ [ADDRESS_137842]
occurrenceWithhold dosing AZD4573 until Grade ≤2 or baseline level.
Restart at same dose level following resolution .
Second and 
subsequent 
occurrence sWithhold dosing AZD4573 until Grade ≤2 or baseline level.
Restart with 1dose level reduction following resolution .
In case of subsequent occurrences , dosing may be modified to skip 
weekly dose(s) (eg, 2 weeks on/1 week off or to 1 week on/1 to 2 
weeks off), after discussing with th e Study Physician.
Grade [ADDRESS_137843] 
occurrenceWithhold dosing AZD4573. 
To reduce the infection risks associated with neutropenia, G -CSF may 
be administered with AZD4573 if clinically indicated/required as per 
Instit utional practice. 
Consider secondary prophylaxis with G -CSF as per ASCO/ESMO 
guidelines. Once the toxicity has resolved to ≤Grade 2 or to baseline 
level, AZD4573 therapy may be resumed at the same dose.
Second
occurrenceWithhold dosing AZD4573.
Consider using G -CSF as clinically indicated/as per Institutional 
practice. Follow dose reduction guidelines when resuming treatment 
with AZD4573 after resolution.
Reduce dose by 1dose level. 
Clinical Study Protocol -2.[ADDRESS_137844]
occurrenceDiscontinue AZD4573.
Grade 3 
thrombocytopenia 
without bleedingAny Withhold AZD4573 until Grade ≤[ADDRESS_137845]
occurrenceWithhold AZD4573 until Grade ≤2 or baseline level.
Restart AZD4573 at the same dose level.
Second
occurrenceWithhold AZD4573 until Grade ≤2 or baseline level.
Restart AZD4573 with 1 level dose reduction.
If not recovered to Grade ≤[ADDRESS_137846]
occurrenceWithhold AZD4573 until Grade ≤2 or baseline level.
Restart AZD4573 with 1 level dose reduction.
If not recovered to Grade ≤2 or baseline level discontinue .
Second
occurrenceDiscontinue AZD4573.
aAdverse reactions are graded using N CICTCAE version 5.0.
bIn cases where more than 21 days are needed, a decision to continue, modify, or discontinue study treatment 
will be made on a case -by-case basis in consultation with the principal investigator [INVESTIGATOR_122554] .
Abbreviations: ANC ,absolute neutrophi l count; ASCO ,American Society of Clinical Oncology; ESMO ,
European Society for Medical Oncology; G -CSF ,granulocyte -colon y stimulating factor.
Dose m odificat ions for AZD4573 for abnormal liver chemistry test results are described in 
Table12.
Table12 Recommended Dose Modifications for AZD4573 for Abnormal Liver 
Chemistry T estResults
EventaAction
Isolatedbelevations in ALT, AST, or bilirubin
Grade 1
Isolated ALT/AST ≤3 × ULN 
or
Isolated Bilirubin ≤1.5 × ULNMaintain current dose level.
Monitor ALT, AST, ALP, and bilirubin at least 1x per 
week.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 77of 148EventaAction
Grade 2
Isolated ALT/AST > 3 to ≤ 5 × ULN
or
Isolated Bilirubin > 1.5to≤ 3 × ULNAfter 7 days if hepatic enzymes resolve to Grade ≤ 1, re-
challenge at same dose level.
Grade 3
Isolated ALT/AST > 5to 20 × ULNIf recovered to Grade ≤1 within 7 days, allow re -challenge 
at same dose level.
If not recovered to baseline level within 7 days, discontinue 
AZD4573.
Grade 3
Isolated Bilirubin > 3to 10 × ULNIf recovered to baseline level within 96 hours (- 2/+12 
hours) of start of dose allow re -challenge at same dose 
level.
If not, discontinue AZD4573 .
Grade 4
Isolated ALT > 20 × ULN
or
Isolated Bilirubin > 10 × ULNDiscontinue AZD4573.
Grade 4
Isolated elevation (≥ 20 × ULN) in
AST without concomitant elevation in ALT ≥ 
20 × ULN or concomitant elevation in TBL 
≥ 2 × ULN that fails to return to baseline level 
within [ADDRESS_137847] elevation ≥20×ULN without 
concomitant elevation in ALT ≥ 20 × ULN or 
TBL ≥ 2 × ULNFirst occurrence
If recovered to Grade ≤1 or baseline level within 7 days of 
start of dose allow re -challenge at same dose level .
Second occurrence
If recovered to Grade ≤[ADDRESS_137848], or bilirubin
(Please also refer to the H Lappendix in the CSP for actions to be taken in the event of PHL)
ALT or AST ≥ 3× ULN with TBL ≥ 2× ULN 
(PHL) AND INR ≥1.5× ULN (or ≥1.5× 
baseline if elevated at baseline) of any durationDiscontinue AZD 4573.
Clinical Study Protocol -2.[ADDRESS_137849] ≥ 3× ULN with the appearance of 
fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or 
eosinophilia > 5%Discontinue AZD4573.
ALT or AST ≥ 3 × ULN and TBL
≥ 2 × ULN where TBL does not return to 
baseline level within 96 hours (-2/+12 hours) 
from start of dose and/or AST or ALT do not 
return to baseline level within 7 days from start 
of doseDiscontinue AZD4573.
Grade 3 elevation ( ≥ 5 × ULN) in
ALT or AST with TBL elevation
above baseline level or ULN, but
< 2× ULN that do not return to baseline level 
within [ADDRESS_137850] ≥ 3× ULN with concomitant 
TBL ≥ 2× ULN, NO increase in INR ≥ 1.5 × 
ULN (or 1.5 × baseline), and NO fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or 
eosinophilia > 5%If recovered to Grade ≤1 or baseline level within 96 
(-2/+12) hours, re -challenge at same dose levelc.
aAdverse reactions are graded using N CICTCAE version 5.0.
bElevations in ALT or AST are considered isolated if bilirubin remains below Grade 1, and elevations in 
bilirubin are considered isolated if ALT and AST remain below Grade 1.
cParticipants who are considered for re -challenge in the event of Grade [ADDRESS_137851] discuss possib le risk of hepatotoxicity with the treating physician, who will document this discussion 
and participant agreement for continued treatment in the medical records.
Adequate supportive therapy as per Institutional guidelines should be given for all toxicitie s.
Abbreviations: ALP ,alkaline phosphatase; ALT ,alanine aminotransferase; AST ,aspartate aminotransferase; 
CTCAE ,Common Terminology Criteria for Adverse Events ; HL,Hy’s Law; INR,internatio nal no rmalised ratio; 
PHL,Potential Hy’s Law; TBL ,total bilir ubin; ULN, upper limit of normal.
10.6.[ADDRESS_137852] ion provi des recommendat ions for treatment of potential toxicit ies associated with 
AZD4573, and guidance about modifying the dose of AZD4573 due to those toxicit ies. For 
complete safet y informat ion refer to the IBfor AZD4573. 
Generally , Grade 1 or 2 non -haematological and/or haematological toxicit ies do not require 
AZD4573 dose reductions and should be managed as medically indicated (with or without 
short dose interruptions) by [CONTACT_1963]. Grade 3 and 4 toxicit ies require dose 
modificati ons, tem porary  treatm ent interruptions, or discontinuation of AZD4573. These are 
described in Table11and Table12in the Secti on 10.6.1 (Dose Modification –Modul e 1).
Clinical St udy Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 79of [ZIP_CODE].6.2.1 Tumour Lysis Syndrome (TLS)
Tumour lysis syndro me is an important ident ified risk for AZD4573 .TLS pr ophylaxis is 
mandatory for  all participants starting [ADDRESS_137853] dose of AZD4573, which 
shoul d be f ollowed in addit ion to institutional guidelines.
Tumour lysis syndro me is characterised by [CONTACT_122631]/or massive release of intracellular 
constituents (potassium, phosphorus and nucleic acids that can be metabo lised to uric acid) 
following tum our cell lysis, result ing in life-threatening complications in cluding acute kidney  
injury , arrhy thmias, and neurological co mplications. While TLS can be seen in so lid tumours, 
it is most prevalent in haematological malignancies. Prevent ion and m anagement of TLS is 
dependent on risk stratificat ion, and risk -based prop hylaxis and management ( Howard et al 
2016 ). Parti cipants i dentified with TLS potential per published risk guidelines ( Coiffier et al 
2008 ; Table13) shoul dbe provided with adequate hydrat ion, pharmaco logical pretreatm ent 
with allopurinol  or rasburi case, and be carefully monitored for development of TLS. The ri sk 
of TLS associated with AZD4573 is ant icipated to be lower for participants with PTCL  or cHL  
compared to parti cipants wi th DLBCL, as TLS is less often seen in these populat ions(Gopal  
et al 2015 ; Chen et al  2017 ; Coiffier et al 2014 ; O’Connor et al 2015 ; O’Connor et al  2011) .
The Howard modificat ion of the Cairo -Bishop definit ions of clinical and laboratory TLS are 
included in Appendix G.Laboratory  or clinical TLS may trigger dose modificat ion in 
accordance with guidelines provided in Table11.
[IP_ADDRESS].1 TLS Prophyla xis
Tumour lysis syndro me (TLS) prophylaxis is mandatory  for all participant s starting [ADDRESS_137854] itutional guidelines. In the event of a discrepancy between the protocol 
guidelines for the management of TLS and the Insti tutional guidelines of a given 
investi gator /centre, the invest igator should discuss wi th the Study  Physician .
In addit ion to the criteria outlined in Table13below, any participant with creatinine clearance 
(CrCL) < 80mL/min must be considered at higher risk o f developi[INVESTIGATOR_122555] .
TLS prophylaxis/management with rasburicase and IV fluid is permitted at any t ime during 
screening and treatm ent, however rasburicase and allopurino l must not be co- administered 
(Jones et al 2015).
It is strongly  recommended that for all participant s with elevated uric acid (hyperuricaemia) 
and intermediate/high risk of TLS, rasburicase (0.20 mg/kg/d IV over 30 minutes) should be 
administered as prophylaxis prior to AZD4573 and repeated as clinically indicated thereafter 
as per local standard. 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 80of 148NOTE: If hyp eruricaemia is pr esent at screening and/or  during ramp -up, SoC therapy 
should be administered (including IV fluid and rasburicase or  allopurinol) to r educe the 
uric acid levels to < ULN befor e each administration of AZD4573. Rasburicase and 
allopurinol mus t not be co -administer ed.
Table13 Mandatory TLS Prophylaxis Guidance (in Addition to Institutional 
Guidance)
Intermediate toHigh Risk
LDH > ULN OR any lymph node ≥5 cm
Prophylaxis
HydrationaOral (1.5 -2 L/day) plus additional IV fluid: Normal saline 500 mL over 2 to 4 hours
prior to AZD4573, then 100 to 175 mL/h as tolerated to maintain urine output .
Antihy peruricemics Allopurinol [ADDRESS_137855] d, 
LDH >2 ×ULN, or high tumour burden .
aAdminister more aggressive IV fluid hydration for any participant who cannot tolerate or maintain oral 
hydration.
bAfter the end of Week 1, or upon discussion and agreement with the Study Physician , the dose or frequency 
of allopurinol may be reduced. Note: The dose of allopurinol should be reduced for renal insufficiency.
cThe recommended dose for rasburicase is 0.20 m g/kg IV over 30 minutes. Rasburicase is contraindicated in 
participants with G6PD deficiency, so participants at higher risk for G6PD deficiency (eg, African or 
Mediterranean ancestry) should be screened for this condition prior to starting rasburicase. Ra sburicase and 
allopurinol must not be co -administered.
dUric acid levels should be < ULN before each dosing of AZD4573.
Adequate supportive therapy as per Institutional guidelines should be given for all toxicities. 
NOTE: TLS prophylaxis/management with ra sburicase and IV fluid is permitted at any time during screening 
and treatment. Rasburicase and allopurinol must not be co -administered.
Abbreviations: h ,hour; IV ,intravenous; LDH ,serum lactate dehydrogenase; ULN ,upper limit of normal.
Modified from Coiffier et al 2008.
[IP_ADDRESS].[ADDRESS_137856] start of infusio n during the intra -participant 
dose ram p-up (see Secti ons [IP_ADDRESS].1 and10.[IP_ADDRESS] ). If there are no signs of TLS at the 
[ADDRESS_137857] remain admitted for inpat ient TLS monitoring approximately every 6hours (or more 
frequently if cli nically  indicated) until  the [ADDRESS_137858] be reported as an SAE, per definit ion.
However, if it is purely for the purposes of extended observat ion then this does not qualify as 
an SAE and does not need to be reported.
For all participants, results of safet y laboratory  testing (haematology  and clinical  chemistry  at 
a minimum) must be a vailable within [ADDRESS_137859] be < ULN prior to the start of each AZD4573 infusio n.
It is strongly  recommended that for all participant s with elevated uric acid (hyperuricaemia) 
and intermediate/high risk of TLS, prophylaxis shoul d be administered prior to AZD4573 per 
Secti on [IP_ADDRESS] .1and repeated as clinically indicated thereafter as per local standard. 
Moni toring for TLS i ncludes checking potassium, calcium, phosphate, uric acid, and 
creatinine . Fluid balance must be monitored according to inst itutional standards.
Any participant developi[INVESTIGATOR_122556] m ust be treated prom ptly for el ectroly te 
abnorm alities (such as hyperkalaemia) to prevent arrhy thmias/seizures and for elevated uric 
acid (hyperuri caemia) wi th rasburicase (0.20 m g/kg/d IV over 30 minutes for up to 5 day s) to 
prevent acute renal failure and monitored closely for signs of progression to clinical TLS. 
If these measur es ar e inadequate, then haemodialysis repr esents definitive therapy and 
should be initiated pr omptly .
Any participant with hyperkalaemia should receive cardiac monitoring wit h continuous 
telemetry  for ECG changes associated with potentially  life-threatening arrhy thmias.
Parti cipants wi th TLS or suspi[INVESTIGATOR_122557].
[IP_ADDRESS].3 Management of Hydration
Adequate fluid intake for all participant s enrolled into the study  is mandatory , in parti cular, 
around the times of AZD4573 dosing.
All participant s are mandated to receive IVfluid hydrat ion with norm al saline (NaCl  0.9%). 
For participant s at intermediate or high risk for TLS (perTable13), normal saline 500 mL  
shoul d be administered over 2 to 4 hours prior to AZD4573 and then continued at a rate of 100 
to 175 mL/hr as tolerated to maintain urine output at leastuntil the 6 hourTLS m onitoring l ab 
assessment, and thereafter if medically indicated.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 82of 148In case of diarrhoea/nausea/vo miting, m ore aggressive IVfluid hydrat ion may be needed as 
clinically indicated. Participant s are al so encouraged to drink enough fluid before and after 
each dosing. Please use diuretics carefully; do not use them  prophylact ically, only if 
participant s have signs o f hyper -hydrat ion.
[IP_ADDRESS] Transaminases Increase With or Without Concomitant Bilirubin Increase
and the Risk of Liver Injury
Transaminase elevat ions are an important identified risk for participants treated with 
AZD4573. Evidence of abnormal liver function should be monitored as per the protocol 
guidelines. Increased levels of AST , ALT, or serum bilirubin should trigger an inves tigation of 
the cause, which may include viral infect ion or di sease progressi on wi th liver infiltrat ion. The 
investigator should consider whether the abnormal liver chemistry  test resul tsmeet the criteria 
for expedited reporting.
Bilirubin increase with t ransaminase increase (ALT or AST or both) is included as an 
important ident ified risk for AZD4573. Biochemical  changes of increased transaminases with 
concomitant increase in bilirubin fulfilling criteria for potenti al Hy's law have been observed 
in parti cipants treated with AZD4573. These events resolve drapi[INVESTIGATOR_122558]. Upon re -challenge wit h 
AZD4573, there is no consistent pattern of recurrence, nor is there any consi stent increase in 
severit y of the events. As such, whilst the events follow the biochemical definit ion of Hy's 
law, the clinical pattern is rapi[INVESTIGATOR_122559]-limit ing and does not seem to predict any  lasting liver 
damage.
Liver injury  is classified as an import ant potential risk for AZD4573. Parti cipant s who 
experience increases in transaminases or bilirubin levels after AZD4573 dosing must be 
monitored in line wit h Section [IP_ADDRESS] . Please refer to Section 10.6.1 (dose modificat ion and 
re-treatm ent) f or addi tional informat ion on how to manage a participant with increases in 
transaminases/bilirubin. 
Addit ional  will also be collected for central  analysis (see Section 
[IP_ADDRESS] ).
If bilirubin fails to resolve within 96 ( -2/+12) hours or transaminases fail to resolve within 
7days, or if the event is associated with significant clotting abnormalit y or clinical symptom s 
of liver disease, study  treatm ent m ust be perm anently  discontinu ed (the participant remains on 
study  for the 30 -day Fo llow-up and L TFU visits), and the event must be immediately 
communicated to [COMPANY_008].
For gui dance on treating liver toxicit y, please refer to Section 10.6.[ADDRESS_137860] igator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting AEs and SAEs according to the outcome of the review and assessment in line with 
standard safet y reporting processes.
Available transcriptomic and clinical patho logy data fro m the FIH study  of AZD4573 
monotherapy  suggests the presence of an acute phase response in part icipants showing signs 
of liver injury . Thu s, anti -inflammatory  prophylaxis wi th steroi ds (eg, de xamethasone) could 
be expected to have a beneficial effect on the incidence and severit y of adverse effects on the 
liver rel ated to AZD4573. While, in the absence of a suitably -sized control group witho ut 
prophylact ic steroid administration, there is no confirmatory  evidence for a posit ive effect of 
dexamethasone on liver safet y profiled fro m available FIH study  clinical  data as y et. 
Assessment of ALT changes fro m baseline versus cumulat ive dexamethasone dose suggests a 
possible trend towards a negative correlation, ie, high dexamethasone doses being associated 
with smaller increases in AL T post -baseline. 
[IP_ADDRESS] Diarrhoea
Diarrhoea is an important ident ified risk for AZD4573 ,based on monkey preclinical 
toxicology studi esandclinical data accumulated to date. 
Parti cipants wi th diarrhoea during therapy  shoul d be managed per Inst itutional guidelines wi th 
maximal supportive care and diagnost ic evaluat ions as clinically indicated. After excluding 
infect iousaetiologies, symptomat ic management should be considered. Participants 
experiencing prolonged or severe diarrhoea should be closely  monitored and m anaged as 
appropriate if dehydrat ion and/or electroly te abnormali ties are observed.
Prophylaxis for diarrh oea with atropi[INVESTIGATOR_122560] s enrolled 
into the study  as an anticholinergic drug, administered at 0.5 mg subcutaneously  15to 
30minutes prior to all scheduled AZD4573 infusio ns. In the event of multiple epi[INVESTIGATOR_122561], 1additional atropi[INVESTIGATOR_67910] m ay be considered and 
administered as outlined above. In addit ion, in the event of diarrhoea, participant s should 
remain fully  hydrated wi th addi tional intravenous fluids.
Clinical Study Protoco l -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 84of [ZIP_CODE].6.2.4 Nausea and Vomiting
Nausea and/or vomit ing are important ident ified risks for AZD4573. Participants with nausea 
and/or vomit ing during therapy  shoul d be m anaged per Inst itutional guidelines wit h maximal 
supportive care and diagnostic evaluat ions as clinically indicated. Participant s experiencing 
prolonged or severe vomit ing shoul d be cl osely  moni tored and m anaged as appropriate if 
dehydrat ion and/or electrolyte abnormalit ies are observed. 
Events of nausea and vo miting have been observed in approximately half o f all participant s 
dosed with AZD4573, and ha ve occurred at all dose levels tested to date (except 3 mg). 
Prophylaxis wit ha 5-HT3 antagonist (e.g. ondansetron +/ -dexamethasone )has been 
implemented in the Phase I study  (D8230C00001) to help alleviate this toxicit y. 
Theref ore, prophylaxis for nausea and vomit ing is recommended as fo llows:administer 
dexamethasone 8 mg (IV administration preferable but orally also permitted) plus a [ADDRESS_137861] (eg ,ondansetron init ially 8 m g to be taken before treatment, then 8 mg every 12 
hours for up to 3 day s) as ant i-emetics for all partici pants, approximately 30 to 60 min utes 
prior to all scheduled AZD4573 infusio ns. Addit ional doses of 8 mg dexamethasone may be 
administered if deemed clinically  warranted. In addi tion, in the event of vomiting, participant s 
should remain fully  hydrated wi th addi tional fluids. Participants experiencing prol onged or 
severe nausea and vo miting shoul d be closely  monitored and m anaged as appropriate if 
dehydrat ion and/or electrolyte abnormalit ies are obse rved.
[IP_ADDRESS] Neutropenia and Febrile Neutropenia
Neutropenia and febrile neutropenia are important ident ified risk sfor parti cipants treated wi th 
AZD4573. In the presence of CTCAE Grade 3/4 neutropenia, participant ’s blood counts 
shoul d be m onitored, using l ocal laboratori es, at l east every  48 hours until recovery .
In the clinical setting to date, Grade 3/Grade 4 neutropenia (~ 45% to 50%) has been observed 
in several participants with an onset around [ADDRESS_137862] igator site’s institutional guidelines. Anti-infective 
prophylaxis including ant i-fungal prophylaxis should be used according to institutional 
guidelines. Ant i-viral or cotrimo xazo le prophylaxis may not be used unless CD4 helper cell 
counts are l ess than 100 to 200 per micro litre.
Primary pr ophylaxis with G -CSF is not gen erally r ecommended. Anti -infective 
prophylaxis (antibiotics and antifungals) should be given in accordance with local hospi[INVESTIGATOR_122562]/European Societ y for 
Medical Oncology /American Soci ety of Clin ical Onco logy guidelines.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 85of [ZIP_CODE].6.2.6 Infection /Bone Marrow Toxicity with Peripheral Effect/Lymphoid Tissue 
Hypocellularity
Infection/Bone marrow toxicit y with peripheral  effect/lymphoi d tissue hypocellularit y is an 
important potential risk for AZD4573, based on findi ngs in preclinical toxicologystudi es. As 
observed in preclinical studies, this important potent ial risk refers to haematological changes 
(decreased platelets, red blood cell count/haematocrit, reticulocytes, neutrophils, lymphocy tes) 
that may  be/may not b e accom panied by  [CONTACT_122632]. AEs of thrombocy topeni a 
shoul d be managed as deemed appropriate by  [CONTACT_122633], management of thrombocy topenia may  require pl atelet 
transfusio ns;again ,these shoul d be done according to local hospi[INVESTIGATOR_48799].
Commo n treatable causes of anaemia (e.g., iron, vitamin B12, or folate deficiencies and 
hypothy roidism ) shoul d be excluded. In some cases, management of anaemia may  requi re 
blood transfusio ns whi ch shoul d be given as per l ocal Institutional guidelines.
[IP_ADDRESS] Pancreatic and Cortical Adrenal Injury (as well as Surveillance for Renal, 
Thymus, and Spleen Toxicity)
Pancreat ic injury and cortical adrenal injury are potential risks for AZD4573 based on 
preclin ical observat ions, however, to date, there areno clinical data suggestive of these risks, 
but safet y surveillance will continue. Regular complete blood counts, clinical chemistry ,and 
coagul ation tests will be performed throughout the conduct of the study to monitor for any  
abnorm al laboratory  param eters, for example :monitoring of lipase and amylase levels for 
potenti al pancreas toxi city, creatinine values and regular urinalysis testing for kidney  function, 
potassi um, sodi um, corti sol levels al ong with adrenocorti cotropi c horm one l evels for adrenal 
glands and TSH for any  thyroi d toxi city.
[IP_ADDRESS] Drug -Drug Interactions
Drug -drug i nteracti ons is a potenti al risk for AZD4573 and refers to interactions with potent 
CYP3A4 inhibitors. Specific drug- drug interaction stu dies have not y et been perform ed for 
AZD4573.
Given the proposed clinical dosing regimen of AZD4573, a short IV infusion over 2 hours 
(once weekly), and the observed short half -life of approximately [ADDRESS_137863] AZD4573 could reversibly inhibit cytochrome P450 (CYP)3A4/5, 
CYP2C8, CYP2C9, CYP2C19, organic anio n transporting polypept ide (OA TP)1B1, 
OATP1B3, organic anio n transporter (OA T)1, OA T3, organic cation transporter (OCT)[ADDRESS_137864] not yet been performed 
to access the drug- drug i nteracti on. Based on the static model reco mmended (FDA  2017 ),
exposure increase of CYP3A  sensi tive substrates caused by [CONTACT_99213]4573 will be 1.06, making it 
a weak inhibitor .
Clinical Study Protocol -2.[ADDRESS_137865] igator .
[IP_ADDRESS] Myocardial Ischaemia and Heart Rate In crease
Myocardial  ischaemia and heart rate increased are considered potential risk sfor AZD4573. 
There has been an iso lated case report of possible my ocardial  infarct ion in associat ion with 
AZD4573, but posit ive causalit y could not be establis hed. The same pat ient experienced heart 
rateincrease during the event of ST-segm ent el evati on my ocardi al infarct ion. A thorough 
evaluat ion of all participant s dosed to date has not revealed any  further cases suggest ive of 
myocardial  ischaemia or other car diovascular toxicit y causally rel ated to AZD4573 
administration.
Safety surveillance related to th ispotenti al toxicitywill include ECG and troponin 
measurements for all partici pants as described in Section 10.8.[ADDRESS_137866] ive of 
myocardial  ischaemia.
10.6.3 Criteria for Restarting Treatment
The criteria to be m et before aparticipant receives further study  drug infusio nsfollowing a 
pause in treatment , either wi thin 1cycle or between cycles , is as bel ow:
All participants:
1Parti cipant has recovered from all treatment -related non -haematological toxicit y to 
CTCAE Grade ≤ 2.
2Recovery  of neutrophils > 1000/μL and platelets > [ZIP_CODE]/μL or > [ZIP_CODE]/μL with bone 
marrow invo lvement.
3Parti cipant has recovered from all hepat ic toxicit y events within the timeframes described 
in Table 12above. If biochemical changes in transaminase(s) and total bilirubin are 
consistent with the definit ion of HL, the parti cipant m ay cont inue to receive study drug 
only if all abnorm alities have reso lved within the timeframes specified in Table 5above, 
there are no symptoms of liver injury  and INR has not increased above 1.5 × ULN (or 1.5 
× baseline). In these circumstances the participant must be made aware of the unknown 
potenti al for liver damage wi th cont inued exposure to AZD4573 prior to retreatment.
Docum entati on of  cont inued consent i s requi red.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 87of 1484Recovery  of uric acid to < ULN.
5Recovery  of changes in uric acid, potassium, phosphorus, creatinine or calcium, or 
symptoms suggest ive of TLS as defined in Table 11.
10.7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal –Module 1
SeetheSoA (Secti on 10.1.2 ) fordata tobecollected atthetime ofintervent iondiscont inuat ion
andfollow-up andanyfurther evaluat ionsthatneed tobecompleted.
Please refertoSecti on 7 (Core protocol) for informat ionon di scont inuat ionofstudy
intervent ionand participant discontinuat ion/wit hdrawal .
10.8 Study Assessments and Procedures –Module 1
Study  procedures and their timing are summarised or linked to in the SoA. Protocol
waivers or exempt ions are not allowed.
Immediate safet y concerns should be discussed wit h the sponsor immediately upon 
occurrence or awareness to determine if the participan t shoul d continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that pot ential 
participants m eet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilised for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the t ime frame defined in the SoA.
The m aximum  amount of blood collected fro m each participant over the duration of the 
study , including any  extra assessments that may be required, is not anticipated to exceed 
436.5mL in Cycle 1 (cy cle durati on of  5 weeks) and 124mLin each subsequent cy cle 
(cycle durati on of  3 weeks).
10.8.1 Efficacy Assess ments
[IP_ADDRESS] Disease Assessment Criteria
Disease assessments for PTCL  and HL  will be done by  [CONTACT_122634] ( Cheson et al 2014 ). 
Clinical Study Protocol -2.[ADDRESS_137867]-Based Response
Complete : Complete metabolic response : Complete radiologic response 
(all of the following):
Lymph nodes 
and extra -
lymphatic 
sitesScore 1, 2, 3awith or without a residual 
mass o n 5PSb
It is recogni sed that in Waldeyer’s ring or 
extra -nodal sites with physiologic uptake 
or with activation within spleen or marrow 
(eg, with chemotherapy or myeloid 
colony-stimulating factors), uptake may be 
greater than normal mediastinum and/or 
liver. In this circumstance, complete 
metabolic response may be inferred if 
uptake at sites of initial involvement i s no 
greater than surrounding normal tissue 
even if the tissue has high physiologic 
uptakeTarget nodes/nodal masses must regress to 
≤1.5cm in LDi
No extra -lymphatic sites of disease
Non-
measured 
lesionNot applicable Absent
Organ 
enlargementcNot applicable Regress to normal
New lesions None None
Bone marrow No evidence of FDG -avid disease in 
marrowNormal by [CONTACT_5293] ;if indeterminate, 
IHC negative
Partial : Partial metabolic response : Partial remission (all of the following):
Lymph nodes 
andextra -
lymphatic 
sitesScore 4 or 5bwith reduced uptake 
compared with baseline and residual 
mass(es) of any size
At interim, these findings suggest 
responding disease
At end of treatment, these findings indicate 
residual disease≥ 50% decrease in SPD of u p to [ADDRESS_137868], assign 5 mm x 5 mm as the default value
When no lo nger visible, 0 x 0 mm
For a node > 5 mm x 5 mm, but smaller than 
normal, use actual measurement for 
calculation
Non-
measured 
lesionsNot applicable Absent/no rmal, regressed, but no increase
Organ 
enlargementNot applicable Spleen must have regressed by > 50% in 
length beyond normal
New lesions None None
Clinical Study Protocol -2.[ADDRESS_137869]-Based Response
Bone marrow Residual uptake higher than uptake in 
normal marrow but reduced compared 
with baseline (diffuse uptake compatible 
with reactive changes from chemotherapy 
allowed). If there are persistent focal 
changes in the marrow in the context of a 
nodal response, consideration should be 
given to furthe r evaluation with MRI or 
biopsy or an interval scanNot applicable
No response or 
stable disease :No metabolic response : Stable disease :
Target 
nodes/nodal 
masses, extra -
nodal lesionsScore 4 or 5bwith no significant change in 
FDG uptake from baseline at interim or 
end of treatment< 50% decrease from baseline in SPD of up 
to 6 dominant, measurable nodes and extra -
nodal sites; no criteria for progressive 
disease are met
Non-
measured 
lesionsNot applicable No increase consistent w ith progression
Organ 
enlargementNot applicable No increase consistent with progression
New lesions None None
Bone marrow No change from baseline Not applicable
Progressive 
disease :Progressive metabolic disease : Progressive disease requires at least 1 of 
the following [COMPANY_003] progression:
Individual 
target 
nodes/nodal 
masses Extra -
nodal lesionsScore 4 or 5bwith an increase in intensity 
of uptake from baseline and/or 
New FDG -avid foci consistent with 
lymphoma at interim or end of treatment 
assessmentAn individual node/lesion must be abnormal 
with:
LDi > 1.5 cm and
Increase by  ≥ 50% from [COMPANY_003] nadir and
An increase in LDi or SDi from nadir
0.5 cm for lesions ≤ 2 cm
1.0 cm for lesions > [ADDRESS_137870] increas e by > 50% of the extent 
of its prior increase beyond baseline (eg, a 
15cm spleen must increase to > 16 cm). If 
no prior splenomegaly, must increase by [CONTACT_12697] [ADDRESS_137871]-Based Response
Non-
measured
lesionsNone New or clear progression of pre -existing 
non-measured lesions
New lesions New FDG -avid foci consistent with 
lymphoma rather than another aetiology 
(eg, infection, inflammation). If uncertain 
regarding aetiology of new lesions, biopsy 
or interval scan may be consideredRegrowth of previously resolved lesions ;
A new node > 1.5 cm in any axis ;
A new extra -nodal site > 1.0 cm in any axis; 
if <1.[ADDRESS_137872] be attributable to 
lymphoma ;
Assessable disease of any size unequivoc ally 
attributable to lymphoma
Bone marrow New or recurrent FDG -avid foci New or recurrent involvement
aA score [ADDRESS_137873] treatment, especially if at the time 
of an interim scan. However, in trials involving PET where de -escalation is investigated, it may be 
preferable to consider a score of 3 as inadequate response (to avoid under t reatment). Measured dominant 
lesions: Up to [ADDRESS_137874] dominant nodes, nodal masses, and extra -nodal lesions selected to be clearly 
measurable in 2 diameters. Nodes should preferably be from disparate regions of the body and should 
include, where app licable, mediastinal and retroperitoneal areas. Non -nodal lesions include those in solid 
organs (eg, liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. 
Non-measured lesions: Any disease not selected as measured, dominant disease and truly assessable disease 
should be considered not measured. These sites include any nodes, nodal masses, and extra -nodal sites not 
selected as dominant or measurable or that do not meet the requirements for measurability but are still
considered abnormal, as well as truly assessable disease, which is any site of suspected disease that would 
be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, 
leptomeningeal disease, abdominal masse s, and other lesions that cannot be confirmed and followed by 
[CONTACT_9661]. In Waldeyer’s ring or in extra -nodal sites (eg, GI tract, liver, bone marrow), FDG uptake may be 
greater than in the mediastinum with complete metabolic response, but should be no highe r than 
surrounding normal physiologic uptake (eg, with marrow activation as a result of chemotherapy or myeloid 
growth factors).
bPET 5 PS: 1 = no uptake above background ; 2 =uptake ≤ mediastinum ; 3 =uptake > mediastinum but 
≤liver; 4 = uptake moderately > liver ; 5 =uptake markedly higher than liver and/or new lesions ; X =new 
areas of uptake unlikely to be related to lymphoma .
Abbreviations: 5PS, 5 -point scale ;CT, compute dtomography; FDG, fluorodeoxyglucose ;IHC,
immunohistochemistry ; LDi, longest transverse diameter; MRI, magnetic resonance imaging; PET, 
positron -emission tomo graphy ;[COMPANY_003], crossproduct of the LDi and perpendicular diameter; SDi, shortest axis 
perpendicular to the LDi; SPD, sum of the product of t heperpendicular diameters for multiple lesions .
Cheson et al 2014
[IP_ADDRESS] Disease Assessment Schedule
Baseline tumour assessments will be performed using radio logic imaging by  [CONTACT_122635] -CT during the screening period. CT scans with contrast will cover neck, chest, 
abdo men, pelvis and any other di sease sites ; PET scans will cover the who le bo dy from base 
of skull to mid- thigh.
Radiologic scans (i e, contrast CT) and PET scans will be performed as specified in Table15
Clinical Study Protocol -2.[ADDRESS_137875] shoul d be assigned to read all the scans for a given partici pant
throughout the study .
Parti cipants who di scontinue study  interventi on for reasons other than PD will cont inue to be 
scanned for disease response fo llowing the same schedule unt il documented PD, regardless o f 
the start of new ant i-lympho ma treatment.
10.8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the Module 1 SoA (Secti on
10.1.2 ) and are detailed below .
[IP_ADDRESS] Physical Examinations
Baseline/screening:
A complete physical examinat ion, including a standard neurological examinat ion,shoul d be 
completed at screening and will include, at a minimum: the general appearance of the 
participant, hei ght, wei ght, and examinat ion of the skin, eyes, ears, nose, throat, lungs, heart, 
abdo men, extremit ies, musculoskeletal system, lymphat ic system , and nervous system . 
Invest igators should pay special attention to clinical signs related to previous serious illnesses 
and new or worsening abnormalit iesthat may qualify as AEs. 
Post first dose of AZD4573: 
From  the first dose of AZD4573 onwards , sympt om-directed physical examinat ionswill be 
perform edbefore each infusio nand at the 30- day follow -up visit as specified in the Modul e 1 
SoA (Section 10.1.2 ). 
ECOG performance status:
Perform ance status will be assessed at screening ,before eac h dose of AZD4573 and at the 
30-day follow-up according to ECOG criteria as follows :
0 = Fully  active, a ble to carry  out all pre -disease activit ies without restrict ions.
1 = Restri cted in physically strenuous activit y but ambulatory  and able to carry  out work of a 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 93of 148light or sedentary  nature eg, light housework, office work .
2 = Ambulatory  and capable of self -care, but unable to carry  out any  work activit ies. Up and 
about m ore than 50% of waking hours .
3 = Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours .
4 = Com pletely disabled, cannot carry  on self -care, totally confin ed to bed or chair .
[IP_ADDRESS] B symptoms 
Inform ation on B symptoms (e.g., unintent ional wei ght loss, f evers and ni ght sweats) willbe 
collected at each visit. 
[IP_ADDRESS] Vital Signs
Vital signs (body  temperature, blood pressure [BP], heart [pulse] rate and body  weight) will be 
perform ed at timelines specified below .
Blood pressure and pulse/heart rate measurements will be assessed in supi[INVESTIGATOR_122563] a com pletely autom ated device. Manual techniques will be used only  if an 
autom ated device is not available.
Blood pres sure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_137876] for the participant in a quiet setting.
Vital signs are to be taken before any blood collectio n.
Body  temperature willbe taken prior to all infusio ns (within 2 hours before sta rt of 
the infusion). 
Weight will be measured at screening, prior to infusions on Day 1 of each cycle, and 
at the 30 -day follow-up v isit.
Blood pressure and pulse rate will be measured at the fo llowing timepo ints:
Screening
On Day  1 of each AZD4573 dose inCycle 1
Cycle 2 Day  1 at the following t imepo ints: 
Pre-dose (up to 2 hours prior to infusio n)
1 hour after the start of the infusion (± 10 min utes) 
At end of infusio n (up to [ADDRESS_137877] -dose)
4 hours (± 30 minute s)after end of infusio n
6 hours (± 30 min utes) after end of infusio n
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 94of 148For all subsequent infusio ns:
Pre-dose ( up to 30 min utes prior to infusio n)
At the end of infusio n (up to [ADDRESS_137878] -dose)
At the 30- day follow-up visit.
[IP_ADDRESS] Electrocardiograms
ECG will be performed at time points specified below .
Twelve-lead digital ECGs will be obtained after the participant has been rest ing semi -supi[INVESTIGATOR_31146] [ADDRESS_137879] the Study  Physician .
Single ECGs will be c ollected for central analysis at the timepo intsbelow:
Screening 
During Cycle 1, all weeks : 
Pre-dose (up to 2 hours prior to infusio n) 
End of infusio n (wi thin 30 minutes of the end of infusio n)
Cycle 2 Day  1 
Pre-dose (up to 2 hours prior to infusio n)
End of infusio n (within 30 minutes of the end of infusio n)
Cycle 3+: End of infusio n (within 30 minutes ofthe end of infusio n)
30-dayfollow-up visit
The ECG parameters to be determined will include (but will not be limited to) the fo llowing:
Heart rate
RR interval: duration in msec between 2 R peaks of 2 consecutive QRS complexes
PR interval: duration in msec fro m the beginning of wave P to onset of ventricular
depol arisat ion (Q and R)
QRS interval: duration in msec of the QRS complex
QT interval: du ration in msec fro m the beginning of Q wave to the end of the T -wave
QTcF: QT interval corrected for heart rate using Fridericia ’s formula
(QT[m sec]/RR[sec]1/3)
Clinical Study Protocol -2.[ADDRESS_137880] ing finding in the ECGs (parameters or abnormal
findings in the tracing) must be considered an AE and must be recorded in the AE eCRF form.
If an unscheduled ECG is done at any  time, then an electrolyte panel (ie, calcium, magnesium, 
potassi um,and troponin) m ust be done to coincide with the ECG testing (see Section 
[IP_ADDRESS] ).
Echocardi ograms: In addit ion to screening, an ECHO should be done within 14 days after an 
abnorm al ECG finding (T wave inversion/flattening) or as soon as possible when clinically  
indicated. If an ECHO cannot be taken, a MUGA  scan to assess L VEF will  be done. In case of 
any T wave abnormalit y, the ECHO (or MUGA) should be repeated at the 30- day follow-up
visit to address the question o f recovery , during the off -treatm ent peri od.
[IP_ADDRESS] Clinical Safe ty Laboratory Assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, coagul ation,
and urinalysis will be taken at the timepo ints indicated below .
Addit ional safet y samples may  be collected if clinically indicated at the d iscret ion of the 
investigator . The date, time of collection and result s (values, unit s and reference ranges) will 
be recorded on the appropriate eCRF .
The clinical chemistry , haematol ogy and urinalysis will be performed at a local laboratory  at 
or near to the invest igator site. Sample tubes and sample sizes may vary depending on 
laboratory  method used and routine practice at the site.
For all participants, results of safet y laboratory  testing (haematology  and clinical  chemistry  at 
a minimum) must be availab le within [ADDRESS_137881] ion 10.6.1 . For each TLS monitoring timepo int, a TLS Monitoring page in the 
eCRF is to be filled out. If clinically indicated, addit ional clinical laboratory  tests and 
evaluat ions m ay be performed by [CONTACT_122636]. 
The laboratory  variables to be measured for haematology /haemostasis, clinical chemistry , 
urinalysis , coagul ation, and pregnancy testing are listed in Table 16. 
Haematology: shoul d be measured at screening, during Cycles [ADDRESS_137882] start of infusio n, before dosing for Cy cles 4+, and at the 30 -day 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 96of 148follow-up. From  Cycle 4 onwards, a 24 -hour sample is only required where clinically 
indicated.
Clinical chemistry: blood sam ples shoul d be taken during Cycles [ADDRESS_137883] start of infusio n, before dosing for Cy cles 4+, and at the 30 -day 
follow-up. From  Cycle 4 onwards, a 24 -hour sample is only required where clinica lly 
indicated .
In addit ion, GLDH and CPK will be measured at screening for all participants. For 
any participant on study  who experiences elevated ALT or AST ≥ 3 × ULN and/or 
total bilirubin ≥ 2 × ULN after dosing, repeated measurements of liver chemistry 
tests arerequired at least every  48 hours ( -2/+12 hours) post start of infusio n unt il 
resol ution ofthe event to baseline level.
Note that addit ional samples are required for TLS mo nitoring at baseline and prior to 
infusio n, 6 hours after start of infusio n,and 24 hours after start of infusio n during the 
intra-participant ram p-up; see TLS m onitoring below for further details.  
If an unscheduled ECG is done at any  time, then an electrolyte panel (ie, calcium, 
magnesium, potassium ,and troponin) must be done to coincide wit h the ECG testing. 
Coagulation: shoul d be measured at screening, during Cycles [ADDRESS_137884] start of infusio n, before dosing for Cy cles 4+, and at the 30 -day 
follow-up. From  Cycle 4 onwards, a 24-hour sample is only required where clinically 
indicated . 
INR/PT and fibrinogen (and D -dimer where available at local inst itution) shoul d be 
measured at 96 ( -2/+12) hours and [ADDRESS_137885] elevat ions ≥ 3 × ULN wi th concomi tant el evation in total 
bilirubi n ≥ 2 × ULN, then as clinically indicated unt il reso lution of the liver 
chemistry  test abnormalit y to baseline level.
Urinalysis: shoul d be done at screening, up to 30 minutes prior to infusio n on Day 1 of 
each cy cle, and at the 30 -day follow-up . 
Supra -renal glands: T4, cortisol, adrenocorticotropic hormone and TSH shoul d be 
measured at screening andat the 30 -Day FU.
Pancr eas: Lipase and amylase measurements are required at screening, pre-dose on each 
AZD4573 dosing day ,andat the 30-Day FU. 
Hepatitis serology: will be conducted at screening. Hepatit is serology must include 
hepat itis B surface antigen (HbsAg), hepat itis B surface antibody (anti -HBs), ant i-HBc, 
and hepat itis C (HCV) ant ibody . Parti cipants who are anti -HBc posi tive, or have a known 
histor y of HBV infect ion, shoul d be m onitored every  [ADDRESS_137886] 
PCR testing for verificat ion purposes.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 97of 148Pregnancy: a urine or serum sample for a pregnanc y test will be co llected fro m all 
female participants of childbearing potential at the following t imepo ints:
Screening
Pre-dose on Cy cle 1, Day  1
Prior to init iating a new cycle (once every 21 days)
At the [ADDRESS_137887] igator discretion for example in the event of 
suspected contraception failure.
Cardiac: Cardiac troponin measurements are required at:
Screening .
Cycle 1: pre -dose (up to 2 hours prior to infusio n) and at 24 hours after start of 
infusio n.
Cycle 2+ : pre-dose (up to 2 hours prior to infusio n).
30-Day follow-up visit.
TLS monitoring : potassi um, calcium, phosphate, uri c acid,and creatinine at baseline , 
then at the fo llowing timepo ints for each infusio n: prior to infusio n, [ADDRESS_137888] be admitted 
for inpat ient TLS m onitoring for 24 hours and monitored every 4 to6hours during this 
time (or m ore frequent ly if clinically ind icated); see Section [IP_ADDRESS].2 .
Liver chemistry test s:GLDH and CPK, will be measured at screening for all 
participants.
For any participant on study who experiences elevated ALT/AST (≥ 3 × ULN) and/or  
elevated total bilirubin (≥ 2 × ULN), r epeated liver chemistry test s are requir ed 
including: total and di rect/indi rect bili rubin, AL T, AST , ALP, C-reactive protein, CPK, 
GLDH, INR/PT , fibrinogen, D -dimer (where available at local inst itution). L iver chemistry 
tests should be measured at least every 48 hours ( -2/+12 hours) post start of infusio n until 
resol ution of the event to baseline (or Grade 1) levels.
If liver chemistry  tests are still elevated after [ADDRESS_137889] until resolut ion for each incidence of the elevated 
ALT and/or AST. During the course of the study  the invest igator will remain vigilan t for 
increases in liver biochemistry . The invest igator participates in review and assessment of these 
cases together wi th the sponsor . HL criteria are m et if there is no alternat ive explanat ion for 
the elevations in transaminases and total bilirubin levels. Ifa parti cipant is assessed as meeting 
PHL criteria, please refer to Appendix E‘Actions required in cases of increases in liver 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 98of 148biochemistr y and eval uation of  HL’, for further instructi ons. 
The fo llowing laboratory  variables for haematol ogy/haemo stasis, clinical  chemistry , 
urinalysis, and pregnancy testing will be measured.
Table 16 Laboratory Safety V ariables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma )
B-Full blood count with differential S/P-Creatinine S/P-Chloride
B-Hb S/P-Bilirubin total S/P-Magnesium
B-White blood cell count with differential S/P-Direct and indirect bilirubin 
(where required)S/P-Phosphorus
B-Platelet count S/P-Alkaline phosphatise S/P-Cholesterol
B-Haemocrit S/P-Aspartate transaminase S/P-Amylase
B-Absolute neutrophil countS/P-Alanine transaminaseS/P-Lactate 
dehy drogenase
B-Absolute ly mphocy te count S/P-Albumin S/P-Lipase
B-Blast Cells S/P-Potassium S/P-Bicarbonate
Urinalysis (dipstick)S/P-CarbonateS/P-glutamate 
dehy drogenase
U-Hb/Ery throcy tes/Blood U-pH S/P-Calcium, total S/P-Blood urea nitrogen
U-Protein/Albumin U-Bilirubin S/P-Sodium S/P-Glucose (fasting 
preferred)
U-Glucose U-Ketones S/P-Creatine phosphokinase S/P-Total protein
U-Specific gravity U-Drug 
screeningaS/P-Uric acid S/P-GGT
U-Microscopy including white blood cells 
/high -power field, red blood cells /high -power 
fieldS/P-Trigly cerides S/P-Ferritin
Coagulation S/P-C-reactive protein S/P-Urea
International normali sed ratio S/P-Trigly cerides S/P-Phosphate
Activated partial thromboplastin time, 
absolute or relativeS/P-Troponin
Prothrombin time S/P-Ammo nia (where available at local institution; to be 
tested ever y 2 weeks)Fibrinogen
D-Dimer (where available at local institution)
Pregnancy Test (women of childbearing potential only)
U-hCG S-beta hCG (at screening only)
aMandated at screening visit only; for all other urinalysis tests, drug screening may be performed at 
investigator discretion.
Abbreviations: B, blood; GGT, gamma -glutamyl transferase; Hb, haemoglobin; hCG, human chorionic 
gonadotropin; P, plasma; S, serum; U, urinalysis .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 99of [ZIP_CODE].8.2.6 Other Safety Assessme nts
Moni toring for TLS per the SoA  (Secti on 10.1.2 ) and prophylaxis for TLS are outlined in 
detail in Section [IP_ADDRESS].2 .
Blood sam ples f or  will be collected per the SoA  (Secti on 10 ) and as 
outlined in Sect ion [IP_ADDRESS] .
Addit ional test ing requirements (refer to the SoA  [Secti on 10 ] for timing ) include:
Echocardi ograms: In addit ion to screening, an ECHO should be done within 14 days after 
an abnormal ECG finding (T wave inversio n/flattening) or as soon as possible when
clinically indicated. If an ECHO cannot be taken, a MUGA scan to assess LVEF will be 
done. In case of any T wave abnormalit y, the ECHO (or MUGA) should be repeated at 
the 30-day follow-up visit to address the question of recovery, during the off -treatm ent
period.
Serum  immunogl obulins (IgA, IgM, IgG): Screening, pre -dose on Day  [ADDRESS_137890] ivefor Modul e 1.Plasma samples will be used to 
analyse the PK of AZD4573 (and metabo lites, if applicable) . Sam ples co llected for analyses of 
AZD4573 concentration may also be used to evaluate safet y or efficacy aspects related to 
concerns ari sing during or after the study .
[IP_ADDRESS] Pharmacokinetics Sampling Schedule
Plasma samples will be collected for measurement of plasma concentrations of AZD4573 at 
the following timepo ints on Cycle 1, Day  1 of Weeks 1 through 3 and Cy cle 2, Day  1: 
Pre-dose (up to 2 hours prior to AZD4573 administration)
Following the start of infusio n at the following t imepoints :
CCI
Clinic al Study  Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 100of 1481 hour (± 15 minutes)
2 hours (± 15 minutes)
4 hours (± 30 minutes)
7hours (± 1 hour)
24 hours (± 1 hour) (ie , Cycle 1 Day  2).
Samples may  be collected at addi tional time points during the study  if warranted and agreed 
upon between the investigator and the sponsor, eg, for safet y reasons. The timing of sampling 
may be altered during the course of the study  based on newly available data (eg, to ob tain data 
closer to the time of peak or trough matrix concentrations) to ensure appropriate monitoring. 
 





Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  Manual.
[IP_ADDRESS] Determination of Drug Concentration
Samples for determination of drug concentration in plasma will be assayed by 
[CONTACT_122637] o f Ast raZeneca, usin g an appropri ately 
validated bioanaly tical method. Full  details of the analy tical method used will be described in 
a separate Bioanalyt ical Report.
Incurred sample reproducibilit y analysis, if any , will  be perform ed al ongside the bioanalysis 
of the test sa mples. The results from the evaluat ion, if performed, will be reported in a 
separate Bioanaly tical Report.
10.8.7 Pharmacodynamics
Who le blood sam ples will be co llected and immediately processed (within 30 minutes) on-site 
for . The object ive of these studies is to evaluate whether AZD4573 is  
 as expected, and to gain an 
understanding of kinet ics and dose response.  
 
[IP_ADDRESS] Collection of Samples
Mandatory  pharmacodynamic (who le blood) samples will be c ollected at the fo llowing 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 101of 148timepo ints:
Screening
Week 1 (6 mg AZD4573; starting dose)
C1D1 predose ( up to 2 hours prior to dosing)
C1D1 2 hour s (± 15 minutes) after start of infusio n
C1D1 4 hours (± 30 minutes) after start of infusio n
C1D1 7hours (± 1 hour) after start of infusio n 
C1D2 24 hours (± 2 hours) after start of infusio n 
Week 2 (9 mg AZD4573)
C1D8 predose (up to 2 hours prior to dosing )
C1D 82 hour s (± 15 minutes) after start of infusio n
C1D 8 4 hours (± 30 minutes) after start of infusio n
C1D8 7hours (± 1 hour) after start of infusio n 
C1D9 24 hours (± 2 hours) after start of infusio n 
Week 3 (12 m g AZD4573; target dose)
C1D15 predose (up to 2 hours prior to dosing)
C1D15 2 hours (± 15 minutes) after start of infusio n
C1D15 4 hours (± 30 minutes ) after start of infusio n
C1D15 7hours (± 1 hour) after start of infusio n 
C1D16 24 hours (± 2 hours) after start of infusio n 
Note: The timing o f these samples may be adjusted dependent upon ongoing PK and 
pharmacodynamic analysis and interpretation.
 must be collected at each pharmacodynamic timepoint once 
participants have reached the target dose.
Further details on sample processing, handling and shipment will be provided in the 
Laboratory  Manual.
For storage, re -use and destruction of pharmacodynamic samples see Section 8.5and 
Appendix C. 
10.8.[ADDRESS_137891] ions below .
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 103of [ZIP_CODE].8.8.1 Whole blood for Exploratory (all 
participants)
Mandatory  whol e blood sam ples to enable exploratory  analysis will be co llected as 
specified below . Note: Collect ion time begins with the start of infusio n.
Screening
C1D1 predose ( up to 2 hours prior to dosing )
C1D15 predose ( up to 2 hours prior to dosing )
C1D29 predose ( up to 2 hours prior to dosing )
C2D1 predose (up to 2 hours prior to dosing)
C2D15 predose ( up to 2 hours prior to dosing)
C3D1 predose (up to 2 hours prior to dosing)
C5D1 predose ( up to 2 hours prior to dosing)
C6D1 predose ( up to 2 hours prior to dosing)
C7D1 predose ( up to 2 hours prior to dosing)
Every  scheduled or unscheduled tumour assessment scan (if onday of infusio n,collect 
pre-infusio n)
Disease progressi on/End of treatm ent
[IP_ADDRESS] Whole Blood for  Analysis (All Participants )
Mandatory  whol e blood sam ples to i solate plasma for  and 
 analysis will be collected to  
 
Note: Collect ion time begins wit h the start of infusion.
Screening
C1D1 predose ( up to 2 hours prior to dosing )
C1D15 predose ( up to 2 hours prior to dosing )
C1D29 predose ( up to 2 hours prior to dosing )
C2D1 predose ( up to 2 hours prior to dosing)
C2D15 predose ( up to 2 hours prior to dosing)
C3D1 predose ( up to 2 hours prior to dosing)
C5D1 predose ( up to 2 hours prior to dosing)
C6D1 predose ( up to 2 hours prior to dosing)
C7D1 predose ( up to 2 hours prior to dosing)
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 104of 148Every  scheduled or unscheduled tumour assessment scan (if on day of infusio n, collect 
pre-infusio n)
Disease progressi on/End of treatm ent
[IP_ADDRESS] Whole Blood Samples for  (All Participants )
Mandatory  whol e blood sam ples will be collected fro m all parti cipants at the timepo ints 
indicated below .  
 Note: Collect ion time 
begins wit h the start of infusio n.
Screening
C1D1 predose ( up to 2 hours p rior to dosing)
C1D15 predose ( up to 2 hours prior to dosing )
C1D16 24 hours (± 2 hours) after start of infusio n 
C2D1 predose (up to 2 hours prior to dosing)
C3D1 predose (up to 2 hours prior to dosing)
C5D1 predose ( up to 2 hours prior to dosing)
C7D1 predose ( up to 2 hours prior to dosing)
Every scheduled or unscheduled tumour assessment scan (if on day of infusio n,collect 
pre-infusio n)
Disease progressi on/End of treatm ent
[IP_ADDRESS] Whole Blood Samples for  (All Participants)
Mandatory  whol e blood sam ples will be collected fro m all parti cipants at the timepo ints 
indicated below .  
 Note: Collect ion time begins with the start of 
infusio n.
Screening
C1D1 predose ( up to 2 hours prior to dosing )
C1D15 predose ( up to 2 hours prior to dosing )
C1D16 24 hours (± 2 hours) after start of infusio n 
C2D1 predose ( up to 2 hours prior to dosing )
C3D1 predose (up to 2 hours prior to dosing)
C5D1 predose ( up to 2 hours prior to dosing)
C7D1 predose ( up to 2 hours prior to dosing)
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Stu dy Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 105of 148Every  scheduled or unscheduled tumour assessment scan (if on day of infusio n, collect 
pre-infusio n)
Disease progressi on/End of treatm ent
[IP_ADDRESS] Whole Blood for  Exploratory Analysis (All Participants)
Mandatory  whol e blood sam ples will be collected fro m all parti cipants in 
 at the timepo ints indicated below to 
 Note: 
Collect ion time begins wit h the start of infusio n.
Screening
C1D1 predose ( up to 2 hours prior to dosing )
C2D1 predose ( up to 2 hours prior to dosing )
C3D1 predose ( up to 2 hours prior to dosing)
C5D1 predose (up to 2 hours prior to dosing)
C7D1 predose ( up to 2 hours prior to dosing)
Every  scheduled or unscheduled tumour assessment scan (if on day of infusio n, collect 
pre-infusio n)
Disease progressi on/End of treatm ent
[IP_ADDRESS] Whole Blood for  Exploratory An alysis (All Participants)
Mandatory  whol e blood sam ples will be collected in  from all 
participants at the timepo ints indicated below .  
 
 Note: Collect ion time begins wit h the start of 
infusio n.
Screening
Week 1 (6 m g AZD4573; starting dose)
C1D1 predose (up to 2 hours prior to dosing )
C1D1 2 hours (± 15 minutes) after start of infusio n
C1D2 24hours (± 2 hours )after start of infusio n
Week 2 (9 m g AZD4573)
C1D8 predose (up to 2 hours prior to dosing )
C1D8 2 hours (± 15 minutes) after start of infusio n
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 106of 148C1D9 24 hours (± 2 hours) after start of infusio n
Week 3(12 m g AZD4573; target dose)
C1D15 predose (up to 2 hours prior to dosing )
C1D15 2 hours (± 15 minutes) after start of infusio n
C1D16 24 hours (± 2 hours) after start of infusio n
C2D1 predose (up to 2 hours prior to dosing)
C3D1 predose (up to 2 hours prior to dosing)
C5D1 predose (up to 2 hours prior to dosing)
C7D1 predose (up to 2 hours prior to dosing)
Every  scheduled or unscheduled tumour assessment scan (if on the day of infusio n,
collect pre -infusio n)
Disease progressi on/End of treatm ent
10.8.9
[IP_ADDRESS] Tissue Samples
[IP_ADDRESS].[ADDRESS_137892] be willing and able to provide mandatory  baseline bone marrow 
aspi[INVESTIGATOR_122564]/or biopsy  no older than [ADDRESS_137893]-infusio n.
For all participants, a ny time a bone marrow analysis is performed, mandatory exploratory 
 analysis will be performed.  
[IP_ADDRESS].[ADDRESS_137894] be confirmed to be available at screening.
This should be provi ded as afresh biopsy (preferable) where available and clinically feasible ,
orwhere a fresh biopsy is unavailable, an archival tumour biopsy sample FFPE tumour block 
may be provided. Where an archival tumour biopsy FFPE tumour block is unavailable, 
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_137895] been obtained as a core biopsy or excisi onal node b iopsy and meet 
the specified criteria detailed in the Laboratory  Manual. Associated pathology  report(s) for 
archival t issue samples must be obtained at screening for all participants enrolled into the 
study .
Where clinically  feasible, participants may also consent to provide an addit ional optional 
biopsy at end of treatment/disease progression for analysis of candidate resistance 
mechanisms. Informed consent must be obtained from any part icipant who agrees to provide 
tissue for opti onal tum our tissue sample testing. This opti onal sample m ay be taken at the 
30-day follow-up visit if not collected previously.
The tum our bi opsy  procedure will be performed by  [CONTACT_122638] e, under radi ologi cal guidance, 
or surgically if the site of disease is superficial and palpable or visible (eg , palpable lymph 
node). Tu mour biopsies shoul d be preferent ially obtained from  tumour ti ssues that are safely 
accessible, as determined by [CONTACT_093], and are not obtained fro m sites that requi re 
significant risk procedures. Participants will undergo [ADDRESS_137896] possible qualit y of the bi opsy, as 
the blood/nutrient supply  to the tum our is not disrupt ed prior to biopsy co llection. Fine -needle 
aspi[INVESTIGATOR_122565]. Failure to obtain sufficient tumour sample after making 
best efforts to biopsy the tumour will not be considered a protocol deviat ion.
Sites shoul d confirm  adequacy of tum ourbiopsy material at the time o f the procedure. The 
exact time that the biopsy  was taken shoul d be clearly  noted i n the associ ated docum entati on. 
For m andatory  and opti onal biopsy  parti cipants, the associated pathology  report(s) for fresh 
tumour sam ples will be required at screening and requested on -treatm ent for all parti cipants 
enrolled into the study .
Instructi ons on tum our bi opsies processing, storage, and shippi[INVESTIGATOR_122566].
[IP_ADDRESS] Blood samples
EBV serology  will be conducted at screening. EBV serology  must include IgM and IgG. Any 
participants testing posit ive for EBV must also have EBV viral load (PCR) performed at 
screening. For participants with positive EBV serology at baseline , sites shoul d enter 
histori cal EBV -encoded RNA  in situ hybridisat ion and/or latent m embrane protein 1 
immunohistochemical data where available.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 108of [ZIP_CODE].8.9.3
Plasma sam ples will be collected from all participants to assess exploratory  .
These samples will be collected as per the timepo ints in Table18below .
Table18 Sampling Schedule (All Participants)
Day Timing for blood samples Window
Screening At any  screening visit Not applicable
Cycle 1, Weeks [ADDRESS_137897] start of infusion ± [ADDRESS_137898] start of infusion ± [ADDRESS_137899] start of Day 1 infusion ± 1 hour
In cases of increased liver 
chemistry  tests/bilirubin at 24h 
post start of infusion96 hours post start of infusion -2/+12 hours
Pre-dose the following infusion Within 4 hours before start of 
infusion
Each timepoint where chemistry 
panel testing is performedN/A
Any visit from Cy cle 1, Week 4 
onwards w here increased liver 
chemistry  tests/bilirubin is 
observed (post dose chemistry 
panel test)Same schedule as Cycle 1, 
Weeks 1-3N/A
For all participants, pl asma samples will be collected during Cycle 1, Weeks 1to3. In 
addition, if a participant has increases in liver chemistry  tests/bilirubin (defined as any 
elevated transaminases of Grade 3 or above or fulfilling PHL  criteria), samplesshou ldalso be 
taken at [ADDRESS_137900] start of infusio n (-2/+12 hours) ,pre-dose the following infusio n (wi thin 
4 hours) and whenever chemistry  panel testing is being performed, unt il reso lution of the 
event .
For any  elevated liver chemistry test s/bilirubin th at is observed with subsequent dosing with 
AZD4573,  should be performed using the timepo ints outlined 
above ( excluding screening sample).
[IP_ADDRESS] Other Study Related  Research
 Sample for  
Per local regulati ons, a mandatory   sample for will be collected 
from participant s in this module. It is important to assess  
 will be used to discriminate th is. The sample 
shoul d be collected from  participant s before receiving study  treatm ent.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 109of 148Details on sample processing, handling, and shipment are provided in the Laboratory Manual. 
For storage, re -use and destruction of  samples see Section 8.5. 
10.8.10 Optional Genomics Initiative Sample
See core protocol Section 8.7.
10.9 Statistical Considerations –Module 1
10.9.1 Statistical Hypotheses
Not applicable.
10.9.2 Sample Size Determination
Table19 Sample Size: Module 1
Indication Primary Analysis Sample Size
PTCL Cohort 1: Non -NK PTCL, 
N =21 response -evaluable
Cohort 2: NKTCL, 
N =21 response -evaluable
cHL Cohort 3: cHL, 
N =21 response -evaluable
Abbreviations: cHL, classical Hodgkins lymphoma; NKTCL, natural killer T -cell lymphoma; non -NK PTCL; 
non-natural killer peripheral T -cell lymphoma; PTCL, peripheral T -cell lymphoma;  
 
Module [ADDRESS_137901] ion of posit ive benefit -risk for participants with r/r PTCL  treated with AZD4573 
monotherapy . 
 
 
 This 
may enab le the sponsor to conti nue enro lling partici pants , bey ond the ini tial 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Pro tocol -2.[ADDRESS_137902] ion of posit ive benefit -risk for participants with r/rcHL treated wi th 
AZD4573 monotherapy .
 
 
In Module [ADDRESS_137903] ive is to evaluate efficacy of AZD4573 monotherapy in 
non-NK PTCL  (excluding NKTCL), NKTCL  and cHL. For primary ORR endpo int analyses 
approximately  21 RP2D -treated response -evaluable participants will be incorporated per 
cohort. These sample sizes are large enough to give a reasonable chance of detecting an 
efficacy signal.
Historical response rates for drugs approved for r/r PTCL  2L are in the range of 25 % to 30% 
(Zain 2019 ). 
The fo llowing examples give an indicat ion of the level of precisio n that will be achieved at the 
primary  analysis for PTCL  within and across Module 1 Cohorts 1 and 2 of this study :
Table20
In addit ion to ORR, the criteria for success will take into accoun t the observed safet y and 
tolerabilit y data, and the other efficacy endpo ints, in particular the DoR.
The DCO for the primary analysis for each Module [ADDRESS_137904] init iated other anticancer 
therapy , or when 75% of participants have progressed or died, whichever occurs first. If one 
cohort reaches its planned primary  analysis DCO ahead o f the other, then the slower enro lling 
cohort m ay be evaluated for efficacy responses at the same t ime. The purpose of evaluat ing 
the slower cohort early  woul d be f or internal planning and to review cont inued development 
of the AZD4573 in one or both r/r PTCL  groups. When both cohorts have reached thei r 
primary  analysis DCOs the efficacy and safet y data m ay be pool ed for analysis. Addit ional 
data cuts m ay also be performed, if required.
Historical response rates in r/r cHL  3L (excluding BV and ant i-PD1) have been in the range of 
10% to 50% ( Vassilakopoulos et al 2020 ).
The fo llowing examples give an indicat ion of the level of precisio n that will be achieved for 
cHL in Modul e 1 Cohort 3 of this study :
Table21
In addit ion to ORR, the criteria for success will take into accoun t the observed safet y and 
tolerabilit y data, and the other efficacy endpo ints, in particular the DoR.
The DCO for primary  analysis o f Modul e [ADDRESS_137905] init iated other ant icancer therapy , or when 75% of 
participants have progressed or died, whichever occurs first. Addit ional data cuts m ay also be 
perform ed, if required.
In Module 1 cohorts a secondary  objective is to confirm if the lympho ma RP2D is safe and 
tolerable or if addit ional dose optimi sation at a revised dose is indicated. Up to a maximum o f 
approximately  60 r/r PTCL  parti cipants and30r/rcHL participants will be treated with 
AZD4573 monotherapy  in Modul e 1. The data from these approximately 90 new lympho ma 
participants woul d supplement safet y data collected for participants treated at this dose level 
in D8230C00001. Module 1 will also provide further data for PK/PD modelling.
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 112of 148At the end of the module a final analysis will be conducted to incorporate all data (up to and 
beyo nd the primary  analysis) from  all participant s.
10.9.3 Populations for Analyses
For purposes of analysis, the study popul ations are defined as provided inTable22.For the 
safet yand PK analyses, participant s will be classified according to the dose schedule they  
actually received. For all efficacy analyses, and for baseline and demography , parti cipants will 
be classified according to the dose they  were assigned to (ie, the planned dose schedule).
Table22 Populations for  Analyses
Population/Analysis set Description
Enrolled All participants who sign the ICF.
Safety All participants who receive at least 1 dose of any study intervention.
Full analysis set/ITT All participants who receive any amount of any study intervention. 
This is for efficacy, baseline and demography . 
Response evaluable All dosed participants who have measurable disease at baseline.
PK All participants who receive any amount of study intervention with at 
least 1 reportable concentration.
Abbreviations: ICF, informed consent form ; ITT, intent ion-to-treat; PK, pharmacokinetics.
10.9.[ADDRESS_137906] important endpoints including primary 
and key  secondary endpo ints.Any deviat ions from this plan will be reported in the CSR.
[IP_ADDRESS] General Considerations
Refer to Sec tion 9.4.[ADDRESS_137907] ical analyses.
The primary  endpoint for Modul e 1is ORR; other efficacy endpo ints are secondary .
[IP_ADDRESS] Efficacy Analyses 
The efficacy endpo ints of ORR , CR rate andDoR will be summarised on the response 
evaluable set. The efficacy endpoints of PFS and OS will be summarised on the full analysis 
set(ITT).
Addit ional subgroup analysis of efficacy may be performed as specified in the SAP .
The response criteria for mali gnant lymphom a(Cheson et al 2014 ) will be used , as assessed 
by [CONTACT_122639], to derive the endpoints (ORR, CR rate, DoR and PFS ).
[IP_ADDRESS].1 Primary Efficacy Endpoint (s)
The primary  efficacy endpo int is ORR, defined as the proportion of parti cipants who have a 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 113of 148tumour response (CR and PR) .
Overall Response Rate and Co mplete Response Rate
Overall response rate (and CR rate) will be presented with corresponding 80% and 95% 
2-sided C Is.
[IP_ADDRESS].2 Secondary Efficacy Endpoint(s)
The secondary  efficacy endpo ints areCR rate, DoR ,PFS and OS.
Duration of  Response
Durati on of  response is defined as the time from the first object ive response o f CR or PR to 
the time o f docum ented di sease progressi on or death (in the absence of disease progressi on).It 
will be summarised using descript ive statist ics and KM plotswhere there are sufficient 
numbers of responders.
Progression FreeSurvival
PFS i s defined as the time from first dose date to documented disease progression, or death 
(by [CONTACT_31617] c ause in the absence of progression), regardless of whether the pa rticipant withdraws 
from study  treatm ent or receives another ant i-cancer therapy  prior to progressi on. Parti cipants 
who have not progressed or died at the time of analysis will be censored at the time of the 
latest date of assessment fro m their last evaluable asses sment. 
The PFS time will always be derived, based on scan/assessment dates, not visit dates.
Assessments/scans contributing towards a particular visit may be performed on different 
dates. The fo llowing rules will be applied:
Date of progression will be de termined, based on the earliest of the dates of the 
component that tri ggered the progression.
When censoring a participant for PFS, the participant will be censored at the latest of the 
dates contribut ing to a particular overall visit assessment.
KM pl ots and estimates will be provided.
Overall Survival
Overall survival is defined as the time from first dose until the date of death fro m any cause. 
Any p articipant not known to have died by  [CONTACT_122640]. KM plotsand estimates
willbe pr ovided.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 114of [ZIP_CODE].9.4.3 Safety Analyses
See core protocol Section 9.4.3 for safet y analyses.
[IP_ADDRESS] Pharmacokinetic Analyses
The secondary  endpoints for PK are plasma concentrations and derived PK parameters for 
AZD4573. Addit ional details on PK analyses will be provided in the SAP .
[IP_ADDRESS] Pharmacodynamics analyse s
Deta il on exploratory  endpo intswill be contained in the SAP .
 status will be assessed for participants in each cohort according to pre -specified 
criteria that may  be detailed in the SAP .  assessments may  include, but are not 
limited to, pharmacodynamic analysis o f  
 
 
 exploratory  analyses m ay be described in a separate analysis plan and may be 
reported outside the CSR in a separate report or publicat ion. The results of this  
assessment m ay be pool ed wi th  data from other studies wit h the study  interventi on 
to generate hy potheses to be tested in future research.
10.9.5 Interim Analyses
No interim analyses are planned for this module. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol - 2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 115of [ZIP_CODE] SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 116of 148Appendix ARegulatory, Ethical, and Study Oversight Considerations
A 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Orga nizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
docum ents ( eg,advertisements) must be submitted to an IRB/IEC by  [CONTACT_122641]/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori tyapproval  before implementat ion of changes made to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
[COMPANY_008] will be responsible for obtaining the required authorisations to conduct the 
study  from the concerned Regulatory  Authority. This responsibilit y may be delegated to a 
CRO but the accountabilit y remains wi th [COMPANY_008].
The invest igator will be responsible for providing oversi ght of  the conduct of the study  at 
the site and adherence to requirements of 21 CFR, ICH guideline s, the IRB/IEC, 
European Regulati on 536/2014 for clinical studies (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), and all other 
applicable local regulat ions.
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The spo nsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, Institutional Review Boards 
(IRB)/Independent Ethics Co mmittees (IEC), and investigators.
For all studies except those utili sing m edical devices investigator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and sponsor policy and forwarded to invest igators as necessary.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 117of 148European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other a pplicable local regulat ions
An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (eg,summary or list ing of SAEs) fro m the sponsor will review 
and then file it along with the [ IBor state other documents] and will notify the IRB/IEC, 
if appropriate according to local requirements.
A [ADDRESS_137908] igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion o f the study .
A 3 Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant or his/her legally  author ised representative and answer all quest ions regarding 
the study .
Participants m ust be inform ed that thei r parti cipat ion is vo luntaryand they are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason 
during the study . Partici pants or thei r legally  author ised representative will be requi red to 
sign a statem ent of  inform ed consent that meets the requirements of [ADDRESS_137909] 
(HIPAA) requirements, where applicable, and the I RB/IEC or study  centre .
The m edica l record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The author ised person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
author ised representati ve.
A participant who i s rescreened is not required to sign another ICF if the rescreening occurs 
within 30days fro m the previous ICF signature [CONTACT_568].
The ICF will contain a separate section that addresses and documents the collect ion and use of 
any mandatory  and/or opti onal human bio logical  sam ples. The invest igator or author ised 
designee will explain to each participant the objectives of the analysis to be done on the 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 118of 148samples and any potential future use. Participants will be told that they are free to refuse to 
participate in any optional samples or the future us e and may wit hdraw their consent at any  
time and for any  reason during the retenti on period.
A 4 Data Protection
Parti cipants will be assigned a uniq ue identifier by [CONTACT_456]. Any part icipant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
The parti cipant m ust be inform ed that hi s/her personal  study -related data will  be used by  
[CONTACT_456] i n accordance with local data protection law. The level of disclo sure and use 
of their data must also b e explained to the participant in the informed consent .
The pa rticipant must be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other author ised personnel appointed by  [CONTACT_103], by  [CONTACT_6667]/IEC members, and by [CONTACT_32857].
A 5 Committees Structure
Not applicable.
A 6 Dissemination of Clinical Study Data
A descri ption of this clinical study will be available on http://astrazenecaclinicaltrials.com and 
http://www .clinicaltrials.gov as will the summary of the main study  resul ts when they  are 
available. The clinical study and/or summary  of main study  resul ts may also be available on 
other websites accor ding to the regulat ions of the countries in which the study  is conducted.
A 7 Data Quality Assurance
All participant data relat ing to the study  will be recorded on eCRF unless transmitted to 
the sponsor or designee electronically ( eg,laboratory  data). The inv estigator i s 
responsible for verifying that data entries are accurate and correct by  [CONTACT_122642].
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator mu st permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect a ccess to source data documents.
Moni toring details describing strategy  (eg,risk-based init iatives in operations and qualit y 
such as Risk Mana gement and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Moni toring Plan.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 119of 148The sponsor or designee is responsible for the data management of this study  includin g 
qualit y checking of the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals ( eg,
Contract Research Organi sations).
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_122643], com plete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
thestudy  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regu latory requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by  [CONTACT_41176] 15years after study  com pletion unless local 
regul ations or inst itutional policies requi re a l onger retenti onperiod. No records m ay be 
destroy ed during the retention period without the written approval of the sponsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor .
A 8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documen ts are filed at the invest igator’s site.
Data reported on the eCRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The invest igator may need to request previous medical records or transfer 
records, depending on the study . Also, current m edical records must be available.
All information in original records and certified copi[INVESTIGATOR_122567], observat ions, or other activit ies in aclinical  study  necessary  for the 
reconstruction and evaluation o f the study  are defined as source documents. Source data 
are contained in source documents (original records or certified copi[INVESTIGATOR_014]). 
A digital copy  of all imaging scans shoul d be stored as sou rce documents.
A [ADDRESS_137910] igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 120of 148Reasons for the early closure of a study  site by [CONTACT_17095]:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP gui delines .
Inadequate recruit ment of parti cipants by  [CONTACT_17062] .
Discontinuati on of  further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investigator s, the IECs/IR Bs, the regulatory  authorit ies, and any contract research 
organi sation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
[CONTACT_122644]. The invest igator shall pro mptly inform the participant 
and shou ld assure appropriate participant therapy  and/or foll ow-up.
Parti cipants from terminated sites will have the opportunit y to be transferred to another site to 
continue the study .
A 10 Publication Policy
The results of this study  may be published or presented at scientific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provi de comments.
The sponsor will co mply wit h the requi rements for publication of study  resul ts. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publicat ion of multicentre studi es only  in thei r entirety  and not as individual site data. In 
this case, a coordin ating invest igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 121of 148Appendix BAdverse Events: Definitions and Procedures for Record ing, 
Evaluating, Follow -up, and Reporting
B [ADDRESS_137911] a causal  relati onship wi th this treatm ent. An AE can therefore be any unfavourable and 
unintended sign ( eg, an abnorm al laboratory  finding), symptom (for example nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, w hether or not 
considered related to the medicinal product . 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence . An AE may occur at any  time, including 
run-in or washout perio ds, even if no Study  treatment has been administered.
B 2 Definitions of Serious Adverse Event
A serious adverse event i s an AE occurring during any study phase ( ie,run-in, treatment, 
washout, follow -up), that fulfils one or more of the fo llowing cri teria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hospi[INVESTIGATOR_122568] n of exist ing hospi[INVESTIGATOR_72913] 
Results in persistent or significant disabilit y or incapaci ty. 
Is a congenital anomalyor birth defect
Is an important medical event that may jeopardise the participant or may requi re medical  
treatm ent to prevent one of the outcomes listed above.
Adverse Events (AEs) for malignant tumours reported during a study  shoul d generally  be 
assessed as Serious AEs. If no other seriousness criteria apply , the ‘Important Medical Event ’ 
criterion shoul d be used. In certain situat ions, however, medical judgement on an individual 
event basis should be applied to clarify that the malignant tumour event should be assessed 
and reported as a non-s erious AE. For example, if the tumour is included as medical history  
and progression occurs during the study , but the progressi on does not change treatment and/or 
prognosi s of the m alignant tum our, the AE m ay not fulfilthe attribute s for being assessed as 
serious, al though reporti ng of the progression of the malignant tumouras an AE is valid and 
shoul d occur .Also, some t ypes of malignant tumours, which do not spread remotely after a 
routi ne treatm ent that does not require hospi[INVESTIGATOR_73256], may be assessed as non-serious; 
examples in adults include Stage [ADDRESS_137912] ion is a new 
malignant tumour (ie, it is notthe tum our f or whi ch entry  into the study  is a cri terion and that 
is being treated by  [CONTACT_122645] ). Malignant tum ours that –as part of norm al, if 
rare, progression –undergo transformat ion (eg, Richter ’s transform ation of B -cell chronic 
lymphocy tic leukaemia into diffuse large B -cell lymphom a) shoul d not be considered a new 
malignant tumour .
Life-threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred or it is suspected that use or continued use of the product would result in the 
participant ’s death . ‘Life-threatening ’ does not m ean that had an AE occurred in a more severe 
form itmight have caused death ( eg,hepatit is that resolved wit hout hepatic failure).
Hospi[INVESTIGATOR_72917] a serious AE, although the reasons 
for it may be ( eg,bronchospasm, laryngeal oedema) . Hospi[INVESTIGATOR_122569]/or surgi cal 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the participant was enrolled in the study , provi ded that i t did not deteriorate in 
an unexpected way  during the study .
Importa nt Medical Event or Medical Treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_72913], disability or incapaci ty but may jeopard isethe participant or may  
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgement must be used.
Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent.
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylc ysteine .
Intensive treatment in an emergency room or at home for allergic bronchospasm .
Blood dy scrasias ( eg,neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_72913].
Development of drug dependency or drug abuse .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 123of 148Intensity Rating Scale :
mild (awareness of sign or symptom, but easily tolerated)
moderate (di scomf ort sufficient to cause interference with normal act ivities)
severe (incapacitat ing, with inabilit y to perform norm al activities)
It is important to dist inguish between serious and severe AEs . Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_73010] B 2. An AE of severe 
intensity need not necessarily be considered serious . For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in App endix B 2.
The grading scales found in the revised National Cancer Inst itute CTCAE versio n 5.0 will be 
utilised for all events with an assigned CTCAE grading . For those events without assigned 
CTCAE gr ades, the recommendation in the CTCAE criteria that converts mild, moderate and 
severe events into CTCAE grades should be used . A copy  of the CTCAE can be downloaded 
from the Cancer Therapy Evaluat ion Program websi te (http://ctep.cancer .gov). The applicabl e 
versio n of CTCAE should be described clearly .
B 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_33641].
Time Course . Exposure to suspect drug . Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile . Was the AE consiste nt with the previ ous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience . Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause . The AE cannot be reasonably explained by [CONTACT_73011], other drugs, other host or environmental factors.
Re-challenge experi ence. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challenge .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 124of 148Laboratory  tests . A specific laboratory invest igation (if performed) has confirmed the 
relationship .
In difficult cases, oth er factors could be considered such as:
Is this a recogn isedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related ’ is made if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case . The expression 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perf ormed based on the available data including enough 
inform ation to m ake an informed judgment . With no available facts or arguments to suggest a 
causal relat ionship, the event(s) will be assessed as ‘not rel ated’.
Causal relat ionship in cases where the di sease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
B 4 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study drug that either causes harm to the participant 
or has the potential to cause harm to the participant . 
A medicat ion error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error . 
Occurred
Was identified and intercepted before the participant received the drug
Did not occur, but circumstances were recognised that coul d have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error eg, medication prepared incorrectly , even if i t was not actually  given to 
the participant
Clinical Study Protocol -2.0 [COMPANY_008]
AZD457 3 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 125of 148Drug not administered as indicated, for example, wron g route or wrong site of 
administration
Drug not taken as indicated eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed eg, kept in the fridge when it should be at room temperature 
Wrong participant recei ved the medicat ion (excluding IRT/RTSM errors)
Wrong drug administered to participant (excluding IRT/RTMS errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTMS -including those which lead to one of the 
above listed events that would otherwise have been a medication error 
Parti cipant acci dentally  missed drug dose(s) eg, forgot to take medication
Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an [COMPANY_008] product 
Medicat ion errors are not regarded as AEs but AEs may occur as a consequence of the 
medicat ion error .
Clinical Study Protocol -2.[ADDRESS_137913] igator at each centre keeps full traceability of collected bi ological sam ples f rom the 
participants while in storage at the centre until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
[COMPANY_008] or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders.
Samples retained for further use will be stored in the [COMPANY_008] -assigned bi obanks or other 
sample archive facilit ies and wi ll be tracked by  [CONTACT_122646] T eam during for 
the rem ainder of the sam ple life cycle.
If required, [COMPANY_008] will ensure that remaining bio logical samples are returned to the site 
according to local regulations or at the end of the retenti on peri od, whi chever i s the sooner .
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
[COMPANY_008] ensures that bio logical samples are returned to the source or destroyed at the end 
of a specified period as described in the informed consent.
Ifa parti cipant wi thdraws consent to the use of donated bio logical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analysed ,[COMPANY_008] is not obliged to destroy  the resul ts of this research .
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The invest igator:
Ensures participant ’s withdrawal of informed consent to t he use of donated samples is 
highlighted immediately to [COMPANY_008] or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 127of 148Ensures that the participant and [COMPANY_008] are informed about the sample disposal.
[COMPANY_008] ensures the organis ation(s) hol ding the sam ples is/are inform ed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action documented and study  site notified.
C [ADDRESS_137914] SAMPLES
International Airline Transportation Associat ion (IA TA) 
(https://www .iata .org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt .
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal disease in 
otherwi se healt hy humans or animals. 
Category A pathogens are,eg, Ebola, Lassa fever virus. Infectious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900:
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are ,eg, Hepatitis A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]
UN 3373 –Biological Substance, Category  B
are to be packed in accordance with UN [ADDRESS_137915] to these Regulations unless they  
meet the criteria for inc lusio n in another class.
Clinical study samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo /cargo/dgr/Documents/DGR -60-EN-PI650.pdf).
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry -ice content
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 128of 148Appendix DOptional Genomics Initiative Sample
D 1 Use/Analysis of DNA
[COMPANY_008] intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response 
to medicat ions. This g enetic research may lead to better understanding of diseases, better 
diagnosis of diseases or other improvements in healt h care and to the discovery o f new 
diagnosti cs, treatm ents or m edicat ions. Therefore, where local regulat ions and IRB/IEC 
allow, a sample will be collected for DNA analysis from co nsent ing participants .
This optional genet ic research may consist of the analysis o f the structure of the 
participant ´s DNA, ie,the entire geno me. 
The results of genet ic analyses may be reported in a separate study summary.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confident iality.
D 2 Genetic Research Plan and Procedures
Selection of Genetic Resear ch Population
All participant s will be asked to participate in this genet ic research . Parti cipat ion is 
voluntary and if a participant declines to participate there will be no penalt y or loss of 
benefit . The participant will not be excluded fro m any aspect of the main study .
Inclusion Criteria
For inclusio n in this genet ic research, participant s must fulfil a ll of the inclusio n criteria 
described in the main body  of the Clinical Study  Protocol  and: Provi de informed consent for 
the Geno mics Init iative sampling and analyses.
Exclusion Criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in 
the main study  or any  of the f ollowing:
Previous allogeneic bone marrow transplant
Healthy Vol unteers and paediatric participant sampl es will  not be collected for th e 
Geno mics Init iative .
Withdrawal of Consent f or Genetic Research
Parti cipants may wit hdraw fro m this genet ic research at any t ime, independent of any 
decisio n concerning participation in other aspects of the main study . Vol untary  
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 129of 148withdrawal  will not pre judice further treatment . Procedures for withdrawal are outlined in 
section 7.2of the m ain Clinical Study  Protocol .
Collection of Samples for Geneti c Research
The sample for this genetic research will be obtained fro m the participant s after 
rando misat ionat the visit specified in the relevant module SoA . Although DNA is stable, 
early  sample collect ion is preferred to avoid introducing bias through excluding 
participant s who may wit hdraw due to an AE . If for any  reason the sample is not drawn at 
the planned visit , it may be taken at any  visit until the last study  visit. Only one sample 
shoul d be collected per participant for genetics during the study .
Coding and Storage of DNA Samples
The processes adopted for the coding and storage of samples for genet ic analysis are 
important to maintain participant confident iality. Sam ples will  be stored for a m aximum  
of 15years, from the date of last participant last visit, after which they will be destroy ed. 
DNA is a finite resource that is used up during analyses . Sam ples will  be stored and used 
until no further analyses are possible or the maximum storage time has been reached.
An addit ional second code will be assigned to the sample eit her before or at the time of 
DNA extraction replacing the informat ion on the sample tube. Thereafter, the sample will 
be ident ifiable only by [CONTACT_33160], unique number . 
This number i s used to i dentify  the 
sample and corresponding data at the [COMPANY_008] genet ics laboratori es, or at the 
designated organisation . No personal details ident ifying the individual will be available to 
anyperson ([COMPANY_008] emplo yee or desi gnated organi sations working with the DNA).
The link between the participant enrolment/randomisat ion code and the second number 
will be maintained and stored in a secure environment, with restricted access at 
AstraZenec a or desi gnated organisat ions. The link will be used to identify  the rel evant 
DNA samples for analysis, facilitate correlat ion of genoty pic resul ts wi th clinical data, 
allow regulatory  audi t, and permi t tracing of samples for destruction in the case of 
withdrawal o f consent.
Ethical and Regulatory Requirements
The principles for ethical and regulatory  requi rements for the study , incl uding this genet ics 
research component, are outlined in Appendix A.
Informed Consent
The genetic component of this study  is opti onal and the participant may part icipate in 
other components of the main study  without parti cipating in this genet ic component . To 
CCI
Clinical Study Protocol -2.[ADDRESS_137916] be give n to 
the participant and the original filed at the study  centre . The principal investigator (s) is 
responsible for ensuring that consent is given freely and that the participant understands 
that they  may freely wi thdrawal  from the genetic aspect of the stud y at any  time.
Participant Data Protection
[COMPANY_008] will not provide individual genoty pe resul ts to participant s, any  insurance 
company, any emplo yer, thei r family members, general physician unless required to do so 
by [CONTACT_2371].
Extra precautions are taken to preserve confident iality and prevent genetic data being 
linked to the ident ity of the participant . In except ional circumstances, however, certain 
individuals might see both the genet ic data and the personal ident ifiers of a participant . 
For example, in the case of a medical emergency , an [COMPANY_008] Physician or an 
investigator might know a participant ’s ident ity and al so have access to his or her genetic 
data. Regul atory  authori ties may requi re access to the rel evant files, though the 
participant ’s medical information and the genet ic files would remain physically separate.
Data Management
Any genet ic data generated in this study will be stored at a secure system at [COMPANY_008] 
and/or designated organi sations to analyse the samples.
[COMPANY_008] and its d esignated organisat ions may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with 
other researchers, such as hospi[INVESTIGATOR_600], academic organisations or healt h insurance 
companies . This can b e done by [CONTACT_103472], where they  can 
be co mbined with the results of similar studies to learn even more about health and 
disease . The researchers can only  use thi s inform ation for health -related research 
purposes . Researchers may see summary result s but they  will not be able to see individual 
participant data or any personal ident ifiers . 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic 
data in a suitable secure environment sep arate from the clinical database.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 131of 148Appendix EActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E 1 Introduction
This Appendix describes the process to be fo llowed in order to i dentify and appropriately 
report Potential Hy ’s Law (PHL) cases and Hy ’s Law (HL) cases . It is not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries. 
Specific guidance on managing liver anomalies can be found in the Dose Modificat ion sect ion 
of each m oduleinthe Clini cal Study  Protocol .
During the course of the study  the invest igator will remain vigilant for increases in liver 
biochemistry . The investigator is responsible for determining whether a participant meets PHL  
criteria at any  point during the study .
All source s of laboratory  data are appropri ate for the determinat ion of PHL  and HL  events; 
this includes samples taken at scheduled study  visits and other vi sits including central  and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for example, PHL  
criteria coul d be m et by  [CONTACT_96724] a central  laboratory  and/or elevated TBL  from 
a local laboratory . 
The invest igator will also review Adverse Event data (for example, for AEs that may indicate 
elevations in liver biochemistry ) for possible PHL  events.
The Investigator participates, together with [COMPANY_008], in review and assessment of cases 
meet ing PHL  criteria to agree whether Hy ’s Law (HL) cri teria are m et. HL criteria are m et if 
there is no alternat ive explanation for the elevat ions in liver bio chemistry . 
The invest igator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting SAEs and AEs according to the outcome of the review and as sessment in line with 
standard safet y reporting processes.
E 2 Definitions
Potential Hy’s Law
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (AL T) ≥ 3×Upper Limit of 
Norm al (ULN) together  with Total Bilirubin (TBL) ≥ 2× ULN at any point during the study  
following the start of study  medicat ionirrespect ive of an increase in Alkaline Phosphatase 
(ALP).
Hy’s Law
AST or ALT ≥ 3×ULN together  with TBL ≥ 2× ULN, where no other reason, other than the 
IMP, can be found to explain the co mbinat ion of increases, eg,elevated ALP indicat ing
Clinical Study Protocol -2.[ADDRESS_137917] precede or be coincident with ( ie,on the 
same day ) the el evati on in TBL, but there is no specified timeframe within whic h the 
elevations in transaminases and TBL  must occur .
E 3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL  it is important to perform a comprehensive review of 
laboratory  data for any  participant who meets any of the fo llowing ident ificat ion criteria in 
isolation or in combinat ion:
ALT ≥ 3× ULN
AST ≥ 3× ULN
TBL ≥ 2× ULN
Central Laboratories Being Used :
When a participant meets any of the PHL  identification criteria, in iso lation or in co mbinat ion, 
the central  laboratory  will imme diately send an alert to the investigator (also sent to 
[COMPANY_008] representative). 
The invest igator will also remain vigilant for any local laboratory reports where the PHL  
ident ificat ion criteria are met, where this is the case the invest igator will:
Notify  the [COMPANY_008] representative .
Request a repeat of the test (new blood draw) by  [CONTACT_122647] .
Com plete the appropri ate unscheduled laboratory  eCRF module(s) wi th the ori ginal  local 
laboratory  test resul t.
When the identificat ion criteria are m et from central  or local laboratory  resul ts the invest igator
will wit hout del ay:
Determine whether the participant meets PHL criteria (see Section E 2for definit ion) by 
[CONTACT_33156] (incl uding both central  and l ocal 
laboratory  resul ts).
Local Laboratories Being Used:
The invest igator will wit hout delay  review each new labo ratory  report and if the ident ificat ion 
criteria are met will:
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 133of 148Notify  the [COMPANY_008] representative .
Determine whether the participant meets PHL criteria (see Section E 2for definit ion) by 
[CONTACT_33156] .
Prom ptly enter the laboratory  data into the l aboratory  eCRF .
E 4 Follow -up
E4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL  criteria the investigator will:
Inform  the [COMPANY_008] representative that the participant has not m et PHL cri teria. 
Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the Clinical Study  Protocol .
E4.2 Potential Hy’s Law Criteria met
If the participant does m eet PHL cri teria the investigator will:
Determine whether PHL criteria were met at any  study  visit prior to starting study  
treatm ent (s eeSection E 6).
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within [ADDRESS_137918] igator will report the case as an SAE of 
Potenti al Hy’s Law; seri ous cri teria ‘Im portant m edical event’ and causalit y assessment 
‘yes/related’ according to CSP process for SAE reporting.
The Study  Physician contacts the investigator , to provide guidance, discuss and agree an 
approach for the study  participant s’follow-up (including any further laboratory  testing) 
and the continuous review of data.
Subsequent to this contact [CONTACT_33157]:
Moni tor the participant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the aetiology o f the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. 
Com plete Liver /PHL eCRF Modules /formsas info rmation beco mes available .
E 5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this section shoul d be fo llowed for all cases where PHL  criteria are met.
Clinical Study Protocol -2.[ADDRESS_137919] and TBL elevat ions, a 
determinat ion of whether the alternat ive ex planat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF.
If the alternat ive explanat ion is an AE/SAE: update the p reviously submitted Potential 
Hy’s Law SAE eCRFs accordingly  with the new inform ation (reassessing event term; 
causalit y and seri ousness cri teria) fo llowing the [COMPANY_008] standard processes.
If it is agreed that there is no alternative explanation for the ALT or AST and TBL elevations:
Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes.
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria apply .
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If there is an unavo idable delay  in obtaining the information necessary  to assess whether or 
not the case meets the criteria for HL, then it is assumed that there is no alternat ive 
explanat ion:
Continue fo llow-up and review according to agreed plan . Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met . Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 135of 148E 6 Actions Required When Potential Hy’s Law Criteria are Met 
Before and After Starting Study Treatment 
This sect ion is applicable to participant s with liver metastases who m eet PHL cri teria on study  
treatm ent, having previously met PHL  criteria at a study  visit prior to starting study treatment.
At the first on -study  treatm ent occurrence of PHL criteria being met the invest igator will 
determine if there has been a significant change in the participant s’ condi tion com pared wi th 
the last visit where PHL  criteria were met .
If there is no significant change ,no action is requi red.
If there is a significant change, notify the [COMPANY_008] representative, who will inform the 
central  Study  Team , then foll ow the subsequent process described in Section E4.2.
E 7 Actions Required for Repeat Epi[INVESTIGATOR_33099]’s Law
This sect ion is applicable when a participant meets PHL  criteria on study  treatm ent and has 
already met PHL  criteria at a previous on study  treatm ent visi t (Secti on E 6 ).
The requi rement to conduct fo llow-up, revi ew and assessment of a repeat occurrence(s) of 
PHL is based on th e nature of the alternative cause identified for the previous occurrence . 
The invest igator should determine the cause for the previous occurrence of PHL  criteria being 
met and answer the fo llowing quest ion:
Was the al ternat ive cause for the previous occur rence of PHL  criteria being met found 
to be the di sease under study  eg,chronic or progressing malignant disease, severe 
infect ion or liver disease ?
If No: follow the process described in Section E4.2for reporting PHL  as an SAE .
If Yes: Determine if there has been a significant change in the participant ’s condi tion 
compared wi th when PHL  criteria were previously met .
If there is no significant change ,no action is required .
If there is a significant change fo llow the process described in Section E4.2for reporting 
PHL as an SAE .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 136of 148E 8 Laborato ry Tests
Hy’s Law Lab Kit for Central Laboratories 
Additional standard chemistry and coagulation 
testsGGT
LDH
Prothrombin time
INR
Viral hepatitis IgM anti -HAV 
HBsAg
IgM and IgG anti -HBc 
HBV DNAa
IgG anti -HCV
HCV RNAb
IgM anti-HEV
HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin ( CD-
transferrin)c
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha -1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrinc
Transferrin saturation
aHBV DNA is only recommended when IgG anti -HBc is positive
bHCV RNA is only recommended when IgG anti -HCV is positive or inconclusive 
cCD-transferrin and Transferrin are not available in China. Study teams should amend this list accordingly
E 9 References
Aithal et al, 2011 Aithal et al 2011, Clinical Pharmacol ogy and Therapeut ics 89(6):806 -815.
FDA Guidance for Industry, July 2009
FDA  Guidance for Industry  (issued July 2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available fro m; https://www .fda.gov/regulatory -informat ion/search -fda-
guidance -docum ents/drug -induced -liver-injury -premarket ing-clinical -evaluati on
Clinical Study Protocol -2.[ADDRESS_137920] computed tomography
CTCAE Common Terminology Criteria for Adverse Events
DCO data cut -off 
DLBCL diffuse large B -cell ly mphoma
DLT dose limiting toxicity
DoR duration of response
DUS disease under study
EBV Epstein –Barr virus
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_137921] disease
HBV hepatitis B virus
HCP Health Care Professional
HIV human immunodeficiency virus
HL Hy’s Law
HSCT haematopoietic stem cell transplantation
IATA International Airline Transportation Association
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IgA immunoglobulin A
IgG immunoglobulin G
IgM immunoglobulin M
IMP investigational medicinal product
INR International Normalised Ratio
IP investigational product
IRB Institutio nal Review Board
IRT/RTSM Interactive Response Technology System/Randomisation and Trial 
Supply Management
ITT intention -to-treat
IV intravenous
KM Kaplan -Meier
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 139of 148Abbreviation or special term Explanation
LDH serum lactate dehydrogenase
LTFU long-term follow -up
LVEF left ventricular ejection fraction
MCL1 myeloid cell leukaemia 1
MedDRA Medical Dictionary for Regulatory Activities 
MM multiple myeloma
MTD maximum tolerated dose
MUGA multigated acquisition
NCI Natio nal Cancer Institute
NK natural killer
NKTCL natural killer/T -cell lymphoma
OAE other significant adverse event
ORR overall response rate
OS overall survival
PCR polymerase chain reaction
PD progressive disease
PET positron emission tomography
PFS progression free survival
PHL potential Hy's Law
PK pharmacokinetic
PK/PD pharmacokinetic/pharmacodynamic
PR partial response
PTCL peripheral T -cell lymphoma
RECIST Response Evaluation Criteria in Solid Tumors
RP2D recommended phase IIdose
r/r relapsed /refractory
SAE serious adverse event 
SAP Statistical Analysis Plan
SCT stem cell transplantation
SD stable disease
SoA schedule of activities
SoC standard of care
SOI start of infusion
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_137922] upper limit of normal
US Unites States
WOCBP women of childbearing potential
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 141of 148Appendix GCairo -Bishop Tumour Lysis Syndrome Definition and 
Grading Criteria (Howard Modification)
Laboratory  tumour lysis syndrom e (TLS) i s defined as alevel above or bel ow norm al, as 
defined below , for any  2 or m ore serum  values of  uric acid, potassi um, phosphate, and calcium 
within 3 day  before or 7 day  after the ini tiation of ant i-cancer therapy . This assessment 
assumes that a participant has or will receive adequate hy dration and a hypouri caemic 
agent(s).
Cairo -Bishop Definition of Laboratory T umour  Lysis Syndr ome (Howard Modification)
Element Value
Uric Acid ≥476 µmol/L (8 mg/dL)
Potassium ≥6.0 mmol/L (6 mg/L)
Inorganic phosphorus ≥1.45 mmol/L (4.5 mg/dL)
Calcium ≤1.75 mmol/L (7.0 mg/dL)
Howard et al [ADDRESS_137923] ome
Clinical tum our lysis syndro me assumes the laboratory  evidence of metabo lic changes and 
significant clinical toxicit y that requi res clinical int ervent ion. Clinical tumour lysis syndro me 
is defined as the presence of laboratory  tumour lysis syndrom e and any 1 or more of the 
below -ment ioned criteria. Maximal clinical tumour lysis syndrome manifestation (renal, 
cardi ac, neuro) defines the grade.
(1) Creatinine ≥1.5× ULN (age > 12years or age adjusted)
(2) Cardi ac arrhy thmia/sudden death
(3) Sei zure
Cairo -Bishop Clinical Tumour Lysis Syndrome Grading Criteria
Grade
Complication 0 1 2 3 4 5
Creatinine*,†≤1.5 × 
ULN1.5 × ULN 1.5 –3.0× ULN >3.0 –6.0 × 
ULN>6.0 × ULN Death
Cardiac 
Arrhy thmia*None Intervention 
not indicatedNonurgent 
medical 
interventio n 
indicatedSymptomatic 
and 
incompletely 
controlled Life-
threatening 
(eg, 
arrhy thmia Death
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 142of 148medically or 
controlled with 
devise (eg, 
defibrillator) associated 
with CHF, 
hypotension, 
syncope, 
shock)
Seizure* None None One brief, 
generalised 
seizure; 
seizure(s) well 
controlled by 
[CONTACT_122648]; 
poorly  
controlled 
seizure 
disorder; with 
breakthrough 
generalised 
seizures 
despi[INVESTIGATOR_122571] n Seizure of 
any kind 
which are 
prolonged, 
repetitive or 
difficult to 
control (eg, 
status 
epi[INVESTIGATOR_7397], 
intractable 
epi[INVESTIGATOR_002] )Death
ADL = ac tivities of daily living; CHF = congestive heart failure; CTLS = clinical tumour lysis syndrome; 
LTLS = laborato ry tumour ly sis sy ndrome; ULN = upper limit of normal
Clinical tumour lysis syndrome (CTLS) requires one or more clinical manifestations along with criteria for 
LTLS. Maximal CTLS manifestation (renal, cardiac, neuro) defines the grade.
*Not directly or probably attributable to therapeutic agent (eg, rise in creatinine after amphotericin 
administration).
†If no institutional ULN is specified, age /sex ULN creatinine may be defined as 105.6 μmol/L for female 
participant s ≥16 years of age and 114.4 μmol/L for male participant s ≥16 years of age. 
Modified from Cairo and Bishop 2004 .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 143of 148Appendix HChanges Related to Mitigation of Study Disruptions Due to 
Cases of Civil Crisis, Natural Disaster, or Public Health 
Crisis
Note: Changes below should be implemented only during study disruptions due to any of or a 
combinat ion of civil crisis, natural disaster, or public healt h crisis (eg, during quarant ines and 
resul ting site closures, regional travel restrictions and considerat ionsif site personnel or study  
participants beco me infected with SARS -CoV-2or similar pandemic infection) during which 
participants may not wi sh to or m ay be unable to visit the study  site for study visits. These 
changes should only be implemented if allowab le by [CONTACT_5737]/regi onal guidelines and following 
notification from the sponsor and instructions on how to perform these procedures will be 
provi ded at the time of implementation.
Please note that during civil crisis, natural disaster, or public healt h crisis, some study  
assessment sand procedures may  not be conducted due to internat ional or local po licies or 
guidelines, hospi[INVESTIGATOR_122572] ’s safety . If in doubt, please contact [CONTACT_122649].
H 1 Reconsent of Study Participants During Study Interruptions
During study  interrupti ons, i t may not be possible for the participants to com plete study  visits 
and assessments on site and alternat ive means for carrying out the visit s and assessments m ay 
be necessary , eg, rem ote visits. Reconsent should be obtained for the al ternative m eans of 
carrying out visits and assessments and should be obtained prior to performing the procedures 
described in Sections H 2to H 6. Local and regional regulat ions and/or guidelines regarding 
reconsent of study participants shoul d be checked and fo llowed. Reconsent m ay be verbal if 
allowed by  [CONTACT_96728] (note, i n the case of verbal reconsent the ICF should 
be signed at the participant ’snext contact [CONTACT_72953]). V isiting the study  sites for the 
sole purpose of obtaining reconsent should be avo ided. 
H [ADDRESS_137924] On -site Visit (where applicable)
A qualified HCP from the study site or TPV servi ce will visit the participant ’shome / or other 
remote locati on as per l ocal SOPs, as applicable. Supplies will be provided for a safe and 
efficient visit. The qualified HCP will be expected to collect informat ion per the clinical study 
protocol  (CSP).
H [ADDRESS_137925] On -site Visit (where applicable)
In thi s appendix, the term  telemedicine visit refers to remote contact [CONTACT_122650], virtual or video visit s, and 
mobile health devices.
During a civil crisis, natural disaster, or public health crisis, on -site visi ts may  be replaced by  
a telemedicine visit if allowed by  [CONTACT_5737]/regional guidelines. Having a telemedicine contact 
[CONTACT_122651].
H 5 At-home or Remote Location IP Administration Instructions
If a site visit is not possible, at -home or remote location administration of IP may be 
perform ed by  a qualified HCP , provi ded this is acceptable w ithin local regulati on/guidance. 
The opti on of  at-home or remote location IP administration ensures partici pants safet y in cases 
of a pandemic where participants may be at increased risk by [CONTACT_122652]/clinic. This 
will also minimi se interrupti on of  IP administration during other study  disrupti ons, eg, si te 
closures due to natural disaster . 
H5.1 At-home or Remote Location IP Administration by [CONTACT_122653]/Her Caregiver
Prior to at -home or remote location IP administration the investigator mu st assess the 
participant or his/her caregiver to determine whether they  are appropri ate for at -home or 
remote locati on administrati on of  IP. Once the participant or his/her caregiver i s deemed 
appropriate for at -home or remote location administration, he/she must receive appropriate 
training. All necessary  supplies and instructions for administration and documentation of IP 
administration will be provided. More informat ion related to the visit can be obtained via a 
telemedicine or hom e / rem ote visit.
H 6 Data Capture During Telemedicine or Home / Remote Visits
Data collected during telemedicine or home / remote visits will be captured by [CONTACT_122654] .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 145of [ZIP_CODE] REFERENCES
Armitage et al 2004
Armitage JO, V ose JM, W eisenburger DD. Towards understanding the peripheral T -cell 
lympho mas. Ann Onco l. 2004;15(10):1447-1449. doi : 10.1093/annonc/mdh409. PMID: 
15367401.
Boiko et al 2020
Boiko S, Proi a TA, San Mart in M, Gregory G, Wu MM, Aryal NK et al. Targeting Bfl -1 via 
acute CDK9 inhibit ion overcom es intrinsic BH3 mimet ic resistance in lympho mas. Blood. 
2021;137(21):2947 -2957 . doi: 10.1182/blood.[PHONE_2779].
Cairo and Bishop 2004
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classificat ion. 
Br J Haem atol 2004;127(1):3 -11.
Cancer Stat Facts: Hodgkin Lymphoma.
Cancer Stat Facts: Hodgkin Lymphoma. SEER NCI. Available at: 
https://seer.cancer.gov/statfacts/ht ml/hodg.html. Accessed on 05 May  2021 .
Cancer Stat Facts: Non -Hodgkin Lymphoma
Cancer Stat Facts: Non -Hodgkin Lympho ma. SEER NCI. Available at: 
https://seer.cancer.gov/statfacts/ht ml/nhl.ht ml. Accessed on: 05 May  2021 .
Chen et al 2016
Chen R, Gopal AK, Smit h SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five -year survival 
and durab ility results of brentuximab vedotin in patients with relapsed or refractory  Hodgkin 
lympho ma. Blood. 2016;128(12):1562 -1566. doi: 10.1182/blood-2016-02-699850.
Chen et al [ADDRESS_137926] J, et al . 
Pembrolizumab in relapsed or refractory  Hodgkin lymphom a: 2-year follow-up of  
KEYNOTE -087. Blood. 2019;134(14):1 144-1153. doi: 10.1182/blood.[PHONE_2780].
Chen et al [ADDRESS_137927], Fanale MA, Armand P , Johnson NA, Bri ce P, et al . Phase II Study  of the 
Efficacy and Safet y of Pembro lizumab for Relapsed/Refractory  Classic Hodgkin L ympho ma. 
J Clin Onco l. 2017;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316.
Cheson et al 2014
Cheson BD, Fisher RI, Barrington SF , Cavalli F , Schwartz LH, Zucca E, et al. 
Reco mmendat ions for init ial evaluat ion, staging, and response assessment of Hodgkin and 
non-Hodgkin lympho ma: the Lugano classificat ion. J Clin Onco l. 2014;32(27):3059-3068. 
doi: 10.1200/JCO.2013.54.8800.
Clinic al Study  Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 146of 148Cidado et al 2020
Cidado J, Boi ko S, Proi a T, Ferguson D, Criscio ne SW, San Martin M, et al . AZD4573 Is a 
Highly Selective CDK9 Inhibitor That Suppresses MCL -1 and Induces Apoptosi s in 
Hem atologic Cancer Cells. Clin Cancer Res. 2020;26(4):922- 934. doi: 10.1158/1078 -
0432.CCR -19-1853.
Coiffier et al 2014
Coiffier B, Pro B, Prince HM, Foss F , Sokol  L, Greenwood M, et al. Romidepsin for the 
treatm ent of rel apsed/refractory  peripheral T -cell lympho ma: pi[INVESTIGATOR_122573] e responses. J Hematol Oncol. 2014;7:1 1. doi: 10.1 186/1756-8722-7- 11.
Coiffier et al 2008
Coiffier B, Altman A, Pui CH, Y ounes A, Cairo MS. Guidelines for the management of 
pediatric and adul t tum or lysis syndrom e: an evidence -based review . J Clin Oncol . 
2008;26(16):2767 -2778.
Connors et al 202 0
Connors JM, Cozen W , Stei dl C, Carbone A, Hoppe R T, Flechtner HH, et al. Hodgkin 
lympho ma. Nat Rev Dis Primers. 2020;6(1):61. doi: 10.1038/s41572 -020-0189 -6.
EMA -CTFG -EC 2021
European Medicines Agency (EMA), Clinical Trials Facilitat ion and Coordinat ion Group 
(CTFG), European Commissio n (EC). Gui dance on the Management of Clinical Trials During 
the COVID -19 (Coronavirus) Pandemic, V ersion 4, 04 February 2021. Available fro m: 
https://ec.europa.eu/healt h/sites/health/files/files/eudralex/vo l-
10/gui danceclin icaltrials_covi d19_en.pdf ( Accessed on 14 May  2021 ).
FDA 2020
US Food and Drug Administration (FDA). FDA  Guidance on Conduct of Clinical Trials of 
Medical Products During the COVID -19 Public Health Emergency , March 2020 (updated 
January 27, 202 1). Available fro m: https://www .fda.gov/media/136238/download (Accessed 
on 14 May  2021 ).
FDA 2017 
FDA  Guidance for Industry  (Draf t, 2017) ‘In Vit ro Metabolism and Transporter Mediated 
Drug -Drug Interaction Studies ’. Available fro m: 
https://www .fda.gov/med ia/108130/download (Accessed on 17 June 2021).
Fiore et al [ADDRESS_137928], Chan WC, Inghirami G. Peri pheral  T cell 
lympho mas: from the bench to the clinic. Nat Rev Cancer . 2020;20(6):323 -342. 
doi:10.1038/s41568 -020-0247 -0.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 147of 148GLOBOCAN 2020
Ferlay  J, Ervi k M, Lam  F, Col ombet M, Mery  L, Piñeros M, Znaor A, Soerjo mataram  I, 
Bray F.2020. Gl obal Cancer Observatory : Cancer T oday. Lyon, [LOCATION_009]: International Agency 
for Research on Cancer . Available fro m: https://gco.iarc.fr/today ,accessed [ 08 June 2021 ].
Gopal et al 2015
Gopal  AK, Chen R, Smit h SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable 
remissions in a pi[INVESTIGATOR_30338] 2 study  of brentuximab vedotin in relapsed or refractory  
Hodgkin lympho ma. Blood. 2015;125(8):1236 -1243 . doi: 10.1 182/blood -[ADDRESS_137929] SC, T rifilio S, Gregory  TK, Baxter N, McBride A. Tumor lysis syndro me in the era of 
novel and targeted agents in patients with hematologic malignancies: a systemat ic review . Ann 
Hem atol. 2016;95(4):[ADDRESS_137930] SC, Jones DP , Pui CH. The tumor lysis syndro me. N Engl J Med. 2011 . 
12;364(19):1844 -1854. doi : 10.1056/NEJMra0904569. Erratum in: N Engl J Med. 2018 Sep 
13;379(11):1094.
Jones et al 2015
Jones GL, W ill A, Jackson GH, Webb NJ, Rul e S.Guidelines for the management of tumour 
lysis syndrome in adult s and children with haematological malignancies on behalf of the 
British Committee for Standards in Haematology .Br J Haem atol.2015;169(5):661 -671.
Kumar et al 2019
Kumar A, S ha F, Toure A, Dogan A, Ni  A, Batlevi CL, et al. Patterns of survival in pat ients 
with recurrent m antle cell lympho ma in the modern era: progressive shortening in response 
durati on and survival after each relapse. Blood Cancer J. 2019;9(6):50. doi: 10.1038 /s41408 -
019-0209 -5
Kuruvilla et al 2021
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz -Kozik E, Gasi orowski  R, Johnson NA, 
et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory  classical  Hodgkin 
lympho ma (KEYNOTE -204): an interim an alysis of a m ulticentre, randomised, open -label, 
phase 3 study . Lancet Oncol . 2021;22(4):512 -524. doi: 10.1016/S1470- 2045(21)[ZIP_CODE]- X. 
Epub 2021 Mar 12. Erratum in: Lancet Onco l. 2021 May;22(5):e184.
O’Connor et al 2015
O'Connor OA, Horwitz S, Masszi T , VanHoof A, Brown P , Doorduijn J, et al. Belino stat in 
Patients W ith Relapsed or Refractory  Peripheral T -Cell L ympho ma: Results of the Pi[INVESTIGATOR_122574] (CLN -19) Study . J Clin Oncol. 2015;33(23):2492 -2499. doi : 
10.1200/JCO.2014.59.2782.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD4573 -D8231C00001
CONFIDENTIAL AND PROPRIETARY 148of 148O’Connor et al 2 011
O'Connor OA, Pro B, Pi[INVESTIGATOR_61813]- Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate 
in patients with relapsed or refractory  peripheral T -cell lympho ma: results fro m the pi[INVESTIGATOR_122575] . J Clin Oncol . 201 1;29(9):1182 -1189. doi : 10.1200/JC O.2010.29.9024.
Park and Ko 2014
Park S, Ko YH. Peripheral T cell lympho ma in Asia. Int J Hematol. 2014;99(3):227 -239. doi : 
10.1007/s12185 -014-1520 -3. Epub 2014 Jan 31. PMID: 24481942.
Swedlow et al 2017
Swedl ow SH, Cam po E, Harri s NL, Jaffe ES, Pi[INVESTIGATOR_27604], Stein H, Thiele J, editors. WHO 
Classificat ion of Tumours of Haematopoietic and L ympho id Tissues. WHO Classificat ion of 
Tumours, Revised 4th Edit ion, Volume 2. IARC, 2017.
Vassilakopoulos et al 2020
Vassilakopoul os TP , Asimakopoulos JV , Konstantopoulos K, Angelopoulou MK. Optimizing 
outcom es in rel apsed/refractory  Hodgkin lymphoma: a review of current and forthcoming 
therapeuti c strategi es. Ther Adv Hematol. 2020;11:2040620720902911. doi: 
10.1177/204062072090291 1.
Xia et al 2020
Xia Y, Jin R, Zhao J, Li W ,Shen H. Ri sk of COVID -19 for patients with cancer . Lancet Oncol  
2020;21(4):e180.
Yu et al 2020
Yu J, Ouy ang W , Chua MLK, Xi e C. SARS -CoV-2 Transmissio n in Pat ients with Cancer at a 
Tertiary Care Hospi [INVESTIGATOR_122576], China. JAMA  Oncol  2020;6(7):1 108-1110.
Zain 2019
Zain JM. Aggressive T -cell lymphom as: 2019 updates on diagnosis, risk stratificat ion, and 
management. Am J Hem atol. 2019;94(8):929 -946. doi : 10.1002/ajh.[ZIP_CODE].
Zhang et al [ADDRESS_137931] ics of COVID-19-
infected cancer patients: A retrospective case study in three hospi[INVESTIGATOR_122577] W uhan, China. 
Ann Onco l. 2020;31(7):[ADDRESS_137932] that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d8231c00001-csp-v2
Document Title: D8231C00001 Clinical Study Protocol version 2
Document ID: Doc ID-004539955
Version Label: 2.[ADDRESS_137933] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
14-Sep-2021 12:53 UTC Content Approval
14-Sep-2021 12:52 UTC Author Approval
14-Sep-2021 13:17 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Signature [CONTACT_11032]-TMF-984997 v1.0
Signature [CONTACT_11032]-TMF-984997 v1.0Reason for signing: Approved Name: 
[CONTACT_1221]: Medical Writing
Date of signature: 22-Sep-2021 12:15:31 GMT[PHONE_006]
[COMPANY_003]